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General Introduction 
Classification and treatment 
Disorders of keratinization comprise a large and heterogeneous group of skin diseases, 
which can be subdivided into hereditary and acquired forms. The majority of hereditary 
disorders of keratinization are monogenic with a mendelian inheritance. Classification can 
be made on clinical grounds, histological and biochemical characteristics and by 
molecular genetic analyses. Clinical description of skin manifestations has to be detailed. 
History and general examination will reveal whether a defined disorder of keratinization 
can be regarded as "isolated entity" or alternatively whether the disorder is part of a 
"syndrome". Histological examination of skin biopsies will reveal whether the 
abnormality of keratinization can be designated as orthokeratotic, parakeratotic or can be 
identified as acantholytic or epidermolytic hyperkeratosis. Accompanying inflammation 
in dermis or epidermis may provide an additional key to the diagnosis of a disorder of 
keratinization. More recently, molecular genetics has been developed to the extent that 
some disorders of keratinization, now can be diagnosed at the gene level. Using above 
mentioned distinct modes of classification, many new disorders of keratinization have 
been described in recent years. On the other hand, forms which were previously 
considered to be distinct entities now have been shown to be variants of the same 
disorder. In the near future, the diagnosis of disorders of keratinization will be confirmed 
by modem molecular genetics. 
The treatment of monogenic disorders of keratinization has not received the broad 
attention which has been dedicated to frequently occurring polygenic disorders of 
keratinization such as psoriasis and acne. Although each entity within the group of 
monogenic disorders of keratinization has a relatively low occurrence in itself, the total 
group is large. So large, that the general dermatologist is often faced with the need to 
provide his patient suffering from a monogenic disorder of keratinization the most 
optimal treatment. An important "point de départ" is the adequate diagnosis. Based on 
the diagnosis, the natural course of the disease, the individual impairment of quality of 
life of a patient and the risk/benefit ratio of the available treatments, the dermatologist 
will select a treatment strategy. Either a long-term treatment or crisis intervention may be 
undertaken. In many disorders of keratinization systemic retinoids are effective. As 
serious side effects may be associated with systemic retinoid treatment, the use of this 
drug is limited. Systemic retinoids are indicated exclusively in those patients who are 
retinoid responders and in those patients with a very severe involvement. The optimum 
retinoid dosage is disease-dependent. For reason of side effects of systemic retinoids, 
development of new therapeutic approaches is of major importance. 
This thesis will be focused on three monogenic disorders of keratinization: ichthyosis, 
Darier's disease and palmoplanar keratoderma. Recently, major advances have been 
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made in the understanding of ichthyosis and Darier's disease, whereas progress on insight 
of various représentants of palmoplanar keratoderma is more modest. Whereas 
classification of ichthyosis has been the objective of modem genodermatology, such an 
integrated approach has not updated the nosology of palmoplantar keratoderma. 
Therefore, in this thesis the following major objectives were outlined: 
(i) Development of new therapeutic approaches for patients with ichthyosis 
and Darter's disease with special reference to the disease specificity of 
therapeutic intervention. 
(ii) Development of an updated integrated nosology of palmoplantar 
keratoderma and exploration of new treatments. 
Ichthyosis and Darter's disease 
Ichthyosis is a general designation for both acquired and hereditary disorders of 
cornification, clinically characterized by excessive scaling, covering a substantial part of 
the body. An updated classification of the hereditary ichthyoses has recently been 
described by H Traupe, who distinguishes four major groups according to their their 
clinical and biochemical characteristics: isolated vulgar, associated vulgar, isolated 
congenital and associated congenital ichthyoses. This classification now is developed 
further in the "époque" of molecular genetics. In Table I the main groups without 
associated features (isolated ichthyoses) have been listed. For a detailed account on these 
various diseases the reader is referred to the monography of Traupe (1) and the thesis of 
Steijlen (2). 
In part I of this thesis new therapeutical approaches for disorders of keratinization are 
presented. We have restricted these studies to the isolated vulgar ichthyoses autosomal 
dominant ichthyosis vulgaris and x-linked recessive ichthyosis, the isolated congenital 
ichthyoses bullous ichthyotic erythroderma of Brocq, erythrodermic lamellar ichthyosis 
and non-erythrodermic lamellar ichthyosis, the associated congenital ichthyoses Sjögren-
Larsson syndrome and Comèl-Netherton syndrome and Darier's disease. The reader is 
introduced briefly into the main features of these disorders. For a more detailed account, 
the reader is referred to the monography of Traupe (1), various textbooks (3,4) and 
reviews (5). 
Figure 1 illustrates clinical appearance. Histological features are expressed in Figure 2. 
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Table I. belated ichtbyoses (adapted from Traupe et aL) 
ichthyosis, 
vulgar 
ichthyosis, 
congenital 
inheritance 
AD 
X-linked 
AD 
AR 
AR/AD 
no associated features 
• autosomal dominant 
ichthyosis vulgaris 
- x-linked recessive 
ichthyosis 
- autosomal dominant 
lamellar ichthyosis 
- bullous ichthyotic 
erythroderma of Brocq 
- ichthyosis bullosa of 
Siemens 
- ichthyosis hystrix of Curth 
and 
Macklin 
- erythrodermic lamellar 
ichthyosis 
• non-erythrodermic lamellar 
ichthyosis 
• harlequin fetus 
gene defect 
- steroid sulfatase 
(6) 
- keratin 1 or 
keratin 10 (7) 
- keratin 2e (8-10) 
- transglutaminase 
(11) 
- transglutaminase 
(") 
(i) Autosomal dominant ichthyosis vulgaris (ADIV) is the most frequent and 
mildest subtype with an estimated prevalence of 1%. It usually starts during the 
first year of life, and is characterized by small white to light gray scales covering 
mainly the trunk and extensor surfaces of the extremities. The flexures are spared. 
The palmoplantar skin folds usually are pronounced. Keratosis pilaris may be 
present on the extensor sides of the extremities. In ADIV filaggrin, a structural 
protein of the corneocyt causing aggregation of keratin filaments into larger 
filaments, and its precursor profilaggrin, synthesized in the upper granular cell 
layer and stored in the keratohyalin granules, are both reduced. The reduction 
correlates with the severity of the disease. Histologically, these biochemical defects 
are reflected by reduction of the granular cell layer. The course of ADIV is 
chronic. Bland emollients usually are sufficient to control the condition. 
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Fig. 1. Clinical appearance of the ichthyoses examined in this this thesis and Darier's disease, a. 
ADIV. Small white coloured scales on the extensor surface of the upper extremities; b. XRI. Small 
brown coloured scales covering the arms, with exception of the elbow folds; с BCIE. Extensive 
hyperkeratosis with prominent keratotic ridges; d. IBS. Keratotic lichenification of the flexural skin 
covering the ankle joints with superficially eroded area's, the so-called "mauserung" 
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Fig. 1. Clinical appearance of the ichthyoses examined in this this thesis and Darier's disease. 
e. Lamellar ichthyosis. Prominent large brown coloured scales with some erythema in between: f. 
SLS. Yellow-brown hyperkeratosis with a verrucous aspect. The muscular hypertonus is visualized by 
the scoliosis; g. CNS. Classical ichthyosis linearis circumflexa variant, exhibiting gyrate, serpiginous, 
double-edged hyperkeratoses. Furthermore, coexisting generalized erythema is visible as observed in 
the congenital ichthyosiform erythroderma, usually the presenting sign in CNS; h. Darier's disease. 
Red-brownish papules focally confluencing into plaques on the chest. 
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Fig. 2. Histological features of these ichthyoses and Darier's disease, a. AD1V. Mild orthokeratotic 
hyperkeratosis with absence of the granular cell layer; b. BCIE. Epidermolytic hyperkeratosis is 
expressed in the keratinocytes of the suprabasal compartment which show cytoplasmic edema and 
perinuclear vacuolization, giving the boundaries between the keratinocytes a blurred appearance, 
whereas the basal keratinocytes appear normal. Orthokeratotic hyperkeratosis, hypergranulosis and 
acanthosis reflect the reactive hyperproliferation; c. BCIE. Electron micrograph of the spinous cell 
layer. Aggragated tonofilaments are aranged around the nucleus in a shell-like formation. Clumps of 
irregular tonofilaments are localized in the cell periphery. These changes result in disruption of the 
normal tonofilament insertion in the desmosomal plates; d. IBS. The same features are observed as in 
BCIE, though the epidermolytic hyperkeratosis is confined to the upper spinous and granular cell 
layer. The epidermis shows plump, confluent rete ridges 
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Fig. 2. Histological features of these ichthyoses and Darier's disease. 
e. Lamellar ichthyosis. Massive orthohyperkeratosis and papillomatosis of the epidermis. The upper 
dermis shows a mononuclear perivascular cell infiltrate; f. CNS. Parakeratotic cornified cell layer 
containing masses of pyknotic granulocytes, intracorneal cleft formation, papillomatosis and 
perivascular inflammatory infiltrates focally invading the epidermis; g. SLS. Moderately increased, 
predominantly orthokeratotic cornified cell layer, acanthosis and some papillomatosis, resembling the 
features of lamellar ichthyosis; h. Darier's disease. Characteristic is the disruption of the cell 
interconnections with widening of the intercellular space (acantholysis). Massive orthohyperkeratosis, 
focal parakeratosis, and acanthosis reflect the reactive hyperproliferation. 
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X-linked recessive ichthyosis (XRI) has an estimated prevalence of 1:2000 -
1:6000 males. XRI has its onset, like ADIV, in the first year of life. Brown-
coloured scales are found, covering the extremities. The skin folds of elbows and 
knees are spared. The trunk may be affected to a variable extent. The underlying 
defect is a deficiency of the enzyme steroid sulfatase, katalyzing the breakdown of 
cholesterol sulphate (6). Accumulation of cholesterol sulphate in the comified cell 
layer, causes increased cohesion between the comeocytes, and therefore retention 
hyperkeratosis. Two other features of steroid sulfatase deficiency are 
cryptorchidism and insufficient cervical dilatation, causing prolonged delivery. The 
steroid sulfatase locus does not fully escape X inactivation. Consequently, steroid 
sulfatase activity in most female carriers is below that in normal males. When 
enzyme activity is rather low, this is visible as a fine scaling especially on the 
lower legs, occurring in about 25% of female carriers. Although patients may 
respond sufficiently to topical emollients, many patients require a more effective 
treatment. Sometimes, systemic retinoids might be indicated. 
Congenital bullous ichthyotic erythroderma of Brocq (CBIE). This is a 
sporadically occurring disease. Immediately after birth a substantial part of the skin 
is covered with erythema and large blisters. During the first year of life, both 
erythema and blisters improve gradually. At the same time, hyperkeratosis appears, 
especially in the skin folds. After removal of these hyperkeratoses, some erythema 
is visible. Blisters may appear after localized traumata, pressure or friction. The 
histological hallmark is epidermolytic hyperkeratosis, showing clumping of keratin 
filaments, present in the entire suprabasal compartment. The underlying genetic 
defect has been found in the genes coding for keratin 1 or keratin 10 (7). 
Mutations in keratin 1 cause CBIE with palmoplantar keratoderma, whereas 
mutations in keratin 10 lead to the phenotype of CBIE without palmoplantar 
keratoderma. The epidermolytic epidermal nevus probably represents a mosaic of 
CBIE, due to a somatic mutation of the CBIE gene during embryogenesis. 
Systemic retinoids are indicated and may cause a dramatic improvement (Figure 
3). However, the dosage should not be to high in order to prevent blister 
formation. 
Ichthyosis bullosa of Siemens (IBS). Patients suffer from birth from blistering 
and dark-gray hyperkeratoses. In contrast to BCIE, erythroderma is absent and 
hyperkeratoses are more localized. As in BCIE the flexural surfaces of the 
extremities are involved, while the palmoplantar skin is spared. Hyperkeratoses 
display a lichenified appearance on the extensor sides of the joints. Characteristic 
are the superficially eroded areas on the lower aspects of the legs and the backs of 
hands and feet (mauserung). Blisters may develop after minor mechanical 
traumaespecially when combined with profuse sweating. With increasing age, the 
degree of blister formation and the extent of keratotic involvement tend to 
improve. IBS is histologically characterized by epidermolytic hyperkeratosis, 
though less marked as in BCIE and confined to the upper epidermal cell layers. 
The underlying genetic defect has been found in the keratin 2e gene (8-10). 
Systemic retinoids are indicated. The maintanace dose is lower than required in 
BCIE. 
Fig. 3. Congenital Bullous Ichthyotic Erythroderma of Brocq: a. Before treatment; b. After 10 
weeks of treatment with etretinate (50 mg/day). 
(v) Erythroderma· lamellar ichthyosis (ELI), again a relatively rare condition, 
appears immediately after birth. The most outstanding feature is erythroderma. 
Sometimes, the babies are encased in a thick cornified shell, covering the entire 
skin surface. This so-called collodion membrane is shed off in the first days after 
birth and replaced by relatively small translucent, white-greyish scales on an 
erythematous underground. In a few patients the erythroderma fades and is no 
longer visible in later life. Most patients express marked palmoplantar 
keratoderma. Systemic retinoids are indicated in this condition. 
(vi) Non-erythrodermic lamellar ichthyosis (NELI) has its onset, like ELI, 
immediately after birth. The disorder has a sporadic occurrence. Large brown-
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coloured scales are covering the entire skin. Except for some erythematous stripes 
between the scales, no erythema is present. Palmoplantar keratoderma is only 
minimal in contrast to the marked palmoplantar keratoderma in the erythrodermic 
subtype. NELI patients may also be bom as collodion-baby. Recently, mutations of 
keratinocyte transglutaminase have been established to cause lamellar ichthyosis 
(11). Disturbed membrane anchorage of transglutaminase could alter loricrin and 
involucrin cross-linkage and as a result the formation of the comified envelope. In 
the literature dealing with the genetic background of lamellar ichthyosis, the 
clinical distinction between an erythematous and non-erythematous variant is not 
made, though lamellar ichthyosis is rather regarded as a congenital skin disorder 
characterized by generalized scaling and variable redness. Systemic retinoids are 
indicated in this condition, however, the dosage has to be low. 
(vii) The SjSgren-Larsson syndrome (SLS) is a rare, severe, neurodegenerative skin 
disorder, characterized by congenital ichthyosis and neurologic manifestations. The 
disease is inherited as an autosomal recessive trait. Ichthyosis manifests at birth as 
a generalized fine scaling only, whereas the typical clinical features develop during 
the first year of life. During childhood a typical yellow- brown verrucous 
hyperkeratosis appears especially covering the flexures, the lower abdomen and the 
neck, whereas thin adherent scales may be seen on the legs. The hyperkeratosis is 
considered hyperproliferative. Neurologic manifestations consist of mental 
retardation and spastic bi- or tetraparesis and have their onset between 4 and 30 
months of age. Ophthalmologic^ examination may reveal small glistening dots in 
the macular region of the retina, representing fatty degeneration of retinal 
microglia. Recently, mutations in the fatty aldehyde dehydrogenase (FALDH) gene 
localised on chromosome 17, have been found in SLS, leading to diminished 
enzyme activity (12). Although the deficiency of FALDH activity is the cause of 
SLS, the pathogenetic mechanism responsible for neurologic and cutaneous 
symptoms is still unclear. Owing to the involvement of FALDH in fatty alcohol 
oxidation, it is thought that the symptoms arise from accumulation of fatty 
alcohols, which subsequently are incorporated in lipids in keratinocytes and 
neurons. This might cause derangement of normal lipid composition of the stratum 
comeum and nerve sheats, and therefore explain both dermatological and 
neurological symptoms. 
(viii) The Comèl-Netherton syndrome is inherited as an autosomal recessive trait and 
characterized by a distinctive type of ichthyosis in combination with specific hair 
anomalies, associated with a number of non-dermatological symptoms. Ichthyosis 
may start with congenital ichthyosiform erythroderma (CIE) which in classical 
cases évoluâtes into ichthyosis linearis circumflexa (ILC). ILC is characterized by 
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erythematous, gyrate, serpiginous patches surrounded by double-edged fine 
hyperkeratotic margin on the trunk and extremities. CIE, however, may persist in 
later life, strongly resembling the clinical picture of erythrodermic lamellar 
ichthyosis. Immune deficiency, leading to infections of the skin and internal 
organs, is an important non-cutaneous manifestation. According to Traupe, 
immune defects are more severe in those patients exhibiting the CIE phenotype. 
Enteropathy, growth retardation, failure to thrive and dehydration are other non-
cutaneous manifestations reported especially in the CIE phenotype, whereas these 
features are absent or mild in the ILC phenotype. Trichorrhexis invaginata is the 
characteristic hair shan abnormality, resulting in brittle hair, breaking easily. 
Histologically, deposition of eosinophilic material in the stratum comeum, a 
reduced to absent granular cell layer, and subcorneal cleft formation, are the most 
important epidermal changes, whereas the dermis shows a marked inflammatory 
infiltrate, invading the epidermis. On electron microscopy, a marked decrease of 
the tonofilament- desmosome complex, lack of lamellar bodies and keratohyalin 
granules are observed. 
(ix) Darier's disease (13) is inherited as an autosomal dominant trait. The estimated 
prevalence ranges from 1 : 55.000 in England to 1 : 100.000 in Denmark. Skin-
coloured to red-brownish papules are found on the predilection sites such as the 
chest, back, hairline, neck, scalp, and ears. Usually, the body folds such as arm 
pits, inguinal folds, and the skin below the breasts, are affected mildly. Lesions on 
hands and feet consist of small pits, spiky hyperkeratoses, verruca plana-like 
papules, and nail-changes (longitudinal white and/or red discolorations with a V-
shaped splitting at the free margin). Small white papules may be found at the oral 
mucosa, and cause swelling of the salivary gland when these obstruct the salivary 
duct. The disease usually starts between the age of 6 and 10 years. Exacerbations 
occur after exposition to heat, sunlight, stress, and the use of lithium (14). A great 
interindividual variation exists in severity, varying from only minimal nail-changes 
to widespread forms covering a substantial part of the body surface. On 
histological examination acantholysis is found, due to disruption of the 
desmosome-keratin-filament complexes, as observed by electronmicroscopy. The 
underlying genetic defect has recently been localized on chromosome 12 (15,16). 
The acantholytic epidermal nevus probably represents a mosaic of Darier's disease, 
due to a somatic mutation of the Darier gene during embryogenesis. The classical 
treatment is systemic retinoids. However, the dosage has to be individualised. 
In general the genetically determined dermatoses require lifelong care. Topical treatment 
remains the first line of maintenance therapy and aims at keratolysis and rehydration of 
the stratum comeum. Nevertheless, these classical topical treatments are insufficient as 
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monotherapy in the treatment of severe ichthyosis subtypes other than ADIV and 
Darier's disease. In these conditions, acitretin has been a major tool to improve various 
représentants of ichthyosis and Darier's disease. The nosological independency of these 
conditions is reflected, at least to some extent, in the therapeutic response partem to 
acitretin (thesis R. ν Dooren (17)). In brief, the clinical responses to acitretin for NELI, 
ELI, CBIE, and Darier's disease, were respectively mild-excellent, excellent, excellent 
and moderate-excellent The optimal daily dosage range (mg/day) fluctuated from 
respectively 10-55, 10-25, 40-60 to 10-60 respectively. 
However, the toxicity potential of acitretin and the selective therapeutic action spectrum 
in these disorders require a further drug development programm. There is an urgent need 
to develop new treatments and to establish guidelines for these new approaches within 
the field of indications as heterogeneous as the spectrum of ichthyoses and Darier's 
disease. New therapeutical principles will be provided in part I of this thesis. 
Palmoplantar keratodermas 
The hereditary palmoplantar keratodermas (HPPK's) comprise a heterogeneous group of 
different clinical entities. HPPK may invalidate patients considerably (Figure 4). 
The total group of HPPK is substantial although various entities may have a relatively 
rare occurrence. HPPK's may be restricted primarily to the hands and feet, or be 
associated with more generalized skin disorders, such as ADIV, CBIE, ELI, NELI, and 
erythrokeratoderma. Classification of the HPPK's restricted primarily to the hands and 
feet, is rather difficult, because of inter-and intraindividual variations and differences in 
nomenclature. Many authors have attempted to classify the HPPK's. Most classifications 
have been based on the morphology, distribution, associated symptoms and mode of 
inheritance. Despite the fact that these criteria are useful in making an attempt to classify 
the individual patient, previous classifications are of limited value, because they are 
rather dated. The most recent classification has appeared in 1986 in the literature (18). In 
recent years, a number of new entities have been defined (19-22). On the other hand, 
HPPK's which previously were considered to be distinct types, have been shown to be 
variants of the same type of HPPK (23,24). Furthermore, the underlying genetical defects 
have been localized in several types of HPPK. In HPPK of Vomer mutations were found 
in the gene coding for keratin 9 (25). In pachyonychia congenita mutations were detected 
in the keratin 6 or 16 gene (Jadassohn-Lewandowski type) (26) and in the keratin 17 
gene (Jackson-Lawler type) (27). Three other HPPK's have been mapped: the Huriez 
syndrome to 4q28-31, focal aerai hyperkeratosis of Costa to 2p and HPPK of Unna-Thost 
to 12q (28). 
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Fig. 4. The Omsted syndrome. Warty hyperkeratoses diffusely cover the palmoplanar skin 
leading to painful flexion contractures. 
As classification is a prerequisite for choosing appropriate treatment and providing 
adequate genetic information, it is definitely warranted to develop an updated 
classification. It should be realised that the diagnosis of HPPK's is not an academic 
exercise but born out of practical relevance. In this respect the clinical appearance, 
histopathological hallmarks of a skin biopsy and a complete history and general 
examination of the patient are indispensable for a precise diagnosis. The diagnosis will 
inform on the natural course and most adequate therapeutical intervention. 
In part 2 a description of previously recognized HPPK's will be given. These casuistical 
presentations are of interest because they highlight previously unrecognized presentations, 
and new therapeutical options for these forms of HPPK. Based on this information and a 
thorough study of the worlds literature, an integrated nosology for the HPPK's will be 
proposed. 
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Objectives of the thesis 
(i) The development of a treatment program for patients with ichthyosis and 
Darier's disease. 
target 1 Establishment of the efficacy of new treatment modalities for 
ichthyoses and Darier's disease and the determination of disease 
specificity of new therapies, 
target 2 Cytometric characterization of ichthyosis and Darier's disease 
before and after treatment, 
target 3 An update of the therapeutic approach. 
(ii) The development of a nosology for palmoplantar keratodermas. 
target 1 Description of the expression of palmoplantar keratodermas and 
the construction of an integrated nosology for palmoplantar 
keratodermas. 
target 2 Proposition for new therapeutical approaches. 
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Ichthyosis and Darier's disease 
Parti 

Introduction 
As has been highlighted in the general introduction, the classical treatment for disorders 
of keratinization have their limitation with respect to efficacy and or side effects. 
Therefore, further development of new treatments is of importance. However, as each of 
these diseases are relatively seldom, new treatment development in the more frequently 
occurring polygenic disorders of keratinization (psoriasis spectrum) and inflammatory 
skin disorders such as acne, is an important source for new developments for ichthyosis 
and Darier's disease. In these frequently occurring diseases, major therapeutical progress 
has been made during the last decade. These developments were based on new leads in 
the pharmacological intervention with growth regulation of benign cell lines or neoplasias 
and interference with inflammation control. 
A summary of the origin of new treatments with a potential impact for ichthyoses and 
Darier's disease is provided below. In the chapters of part I, an evaluation is provided 
whether a selection of these treatments might be of relevance for ichthyosis and Darier's 
disease. 
Retinoids interfere with various aspects of epidermal growth and differentiation, as well 
as cutaneous inflammation. Epithelial tissues including epidermis, require a critical 
concentration of vitamin A for normal proliferation and differentiation. A deficiency or 
excess of vitamin A alter the normal pathways and lead to basal cell hyperproliferation 
and metaplasia. Retinoids can be considered both as growth promotors and as growth 
inhibitors, depending on the cell type and the experimental conditions. In quiescent 
epidermal cells, addition of retinoids induces increased proliferation. Such in contrast to 
the growth inhibition induced by retinoids in hyperproliferating (benign or malignant) 
cell lines, a feature that makes retinoids of interest in the treatment of hyperproliferative 
epidermal skin diseases and as antitumour drugs. As there is an inverse relationship in 
most tissues between proliferation and differentiation, retinoids inhibit differentiation of 
normal epidermal cells, whereas a stimulation of differentiation is observed in 
hyperproliferative tissues (1). These effects are believed to be primarily mediated by 
nuclear retinoic acid receptors, which are members of the steroid receptor superfamily 
(2). In addition to interference with epidermal behaviour, retinoids demonstrate 
immunomodulatory and anti-inflammatory effects (3). 
As systemic treatment with acitretin has various side effects, the question arises whether 
a localized retinoid effect restricted to the target tissue can be reached by alternative 
principles. Theoretically, topical application and manipulation of retinoid metabolism are 
possible approaches to reach such. Many years ago, topical tretinoin, effective in the 
treatment of acne, has been shown to be effective to some extent in the treatment of 
ichthyosis (4) and Darier's disease (5). However, severe irritation of the skin prevented 
the routine use in these disorders of keratinization. Recently, topical 13-cis-retinoic acid 
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became available and has become a well established treatment for acne, either as 
systemical (6) or topical drug (7). As this new formulation has an ultra low irritancy 
potential, the question arose to what extent this new formulation might be beneficial in 
disorders of keratinization. 
Imidazole derivatives have been found in recent years to inhibit several cytochrome P-
450-dependent steps in the biosynthetic pathway of testicular, ovarian and adrenal 
steroids. Imidazole derivatives were originally used as antimycotic agents exerting their 
activity by inhibition of the fungal cytochrome P-450 enzyme dependent synthesis of 
ergosterol (8). After gynecomastia developed in two patients treated with high doses for 
systemic mycotic disease, antiandrogenic effects of these drugs were detected (9). 
Thereafter, inhibition of testicular, ovarian and adrenal steroid metabolism by 
interference with the cytochrome P-450-dependent steps in their biosynthetic pathway 
was demonstrated (10-12). As a result, the therapeutic potential of imidazole derivatives 
was expanded with the treatment of androgen-dependent diseases such as prostatic cancer 
(13). One of the most recent imidazole derivatives is liarozole. Unlike first line imidazole 
derivatives, liarozole treatment of advanced prostatic cancer was not mediated via 
modulation of androgen metabolism. Remarkably, coexisting mucocutaneous side effects 
similar to those found in hypervitaminosis A could be attributed to increased plasma 
retinole acid levels, which suggested an alternative pathway for liarozole to exert its 
cytotoxic effects (14). Furthermore, liarozole was found to inhibit the metabolism of 
endogeneously produced (15,16) or exogeneously applied (17,18) all-trans retinole acid, 
resulting in increased levels of this vitamin in the skin. This was achieved by inhibition 
of the cytochrome P-450-mediated enzyme 4-hydroxylase, one of the main enzymes in 
the catabolic pathway of all-trans retinoic acid (19,20). Therefore, it was suggested that 
inhibitors of the all-trans-retinoic acid metabolism, might be useful in the treatment of 
skin conditions improving on retinoids, such as psoriasis and acne. Clinical improvement 
was obtained with oral liarozole in the treatment of psoriasis, whereas plasma 
testosterone and Cortisol levels remained in the normal range (21). Consequently, the 
question arose, whether this new imidazole compound could be effective in monogenic 
disorders of keratinization. As retinoids are effective in both systemic and topical 
formulations, an additional question was whether liarozole might be effective as topical 
treatment for monogenic disorders of keratinization. 
Calcipotriol is a synthetic vitamin D3 analogue with a high binding affinity to the 
cellular receptor for the biologically active form of vitamin D3: 1,25 dihydroxyvitamin 
D3 (calcitriol) (22). Like retinoids, vitamin D3 analogues mediate their biological 
response by binding to its nuclear receptor, also being a member of the steroid receptor 
superfamily (23). A wide variety of cells posess nuclear receptors for vitamin D3, 
including keratinocytes and fibroblasts (24,25). Calcipotriol and calcitriol, the naturally 
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occuring active form of vitamin D3 produce an equivalent dose-dependent inhibition o f 
proliferation, and stimulation o f terminal differentiation in cultured human keratinocytes 
(24-30). Calcipotriol was found effective in the treatment of the polygenic disorders o f 
keratinization, psoriasis (25,31,32) and pityriasis rubra pilaris (33). The question was 
addressed whether calcipotriol might be of benefit in the treatment of monogenic 
disorders of keratinization. 
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SUMMARY 
In a prospective, double blind, bilaterally paired comparative study, a cream containing 
13-cis-retinoic acid (13-cis-RA) 0.1% and the cream base only were applied during a 
period varying between 4 and 10 weeks in 12 ichthyosis patients (1 patient with 
autosomal dominant ichthyosis vulgaris (ADIV), 7 patients with X-linked recessive 
ichthyosis (XRI), 2 patients with bullous congenital ichthyotic erythroderma of Brocq 
(BCIE), and 2 patients with erythrodermic lamellar ichthyosis (ELI)). A significant 
unilateral improvement was found for the clinical parameters scaling and induration. 
Clinical improvement was observed in all ichthyosis groups, except for ADIV. 
Continuation of the treatment beyond the first month, caused a further reduction of skin 
lesions. Side effects due to the study medication were only minimal and easily controlled 
by adjusting the application frequency. Biopsies for immunohistochemical examination 
were taken from representative skin lesions from 9 patients, one before and one from 
each side after treatment. The keratins 4, 13, and 8, were induced by treatment with 
topical 13-cis-RA. These keratins could not be detected in the biopsies taken before 
treatment nor in the biopsies derived from the cream-base treated side. Keratin 4 was 
induced in 6 of the 9 patients. Induction of keratin 13, visualized with mab 1C7 and 
2D7, was found in 1 and 3 patients respectively. Keratin 8, visualized with mab LE4.1 
and M20, was induced in respectively 1 and 3 patients. No clear correlation could be 
established between expression of keratins and clinical efficacy. Cellular proliferation 
tended to be increased at the 13-cis-RA treated side. No changes were found for the 
investigated parameters of inflammation. 
INTRODUCTION 
Oral retinoids have proven to be very effective in the treatment of ichthyosis (1-3). 
Because of side effects, caused by systemic long term therapy with retinoids, topical 
preparations have regained much of their former importance. Common topical treatment 
modalities are based on keratolysis and hydration of the epidermis. Although some 
improvement may be achieved, severe ichthyosis subtypes do not improve sufficiently 
using these topical treatments. 
Topical retinoids affect epidermal proliferentiation and differentiation (4). Good 
responses have been reported in patients with lamellar ichthyosis, ichthyosis vulgaris and 
to a lesser extent in patients with X-linked ichthyosis and epidermolytic hyperkeratosis, 
treated with topical tretinoin 0.1% cream. Adverse reactions were erythema, pruritus and 
irritation and occured in 26 of the 30 patients (87%) (5). Because of these irritative side 
effects, the use of topical retinoids has been limited (6). 
Recently, Steijlen et al. treated one patient with autosomal dominant ichthyosis vulgaris, 
and seven patients with non erythrodermic lamellar ichthyosis (NELI), for four weeks 
using a double-blind, bilaterally paired approach with topical 13-cis-retinoic acid (13-cis-
RA) 0.1% and cream base only. A good clinical improvement, in favour of the verum 
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treated side, was observed in two patients with NELL Immunohistochemical examination 
revealed induction of keratin 4 in two NELI patients (7). It was suggested that the 
selective modulation of the cytokeratin pattern might provide an immunohistochemical 
tool to investigate the mode of action of retinoids. 
The aim of the present study was an investigation of the clinical efficacy and tolerability 
of prolonged topical treatment with 13-cis-RA in one patient with autosomal dominant 
ichthyosis vulgaris (ADIV), seven patients with X-linked recessive ichthyosis (XRI), 2 
patients with bullous congenital ichthyotic erythroderma of Brocq (BCIE) and 2 patients 
with erythroderma lamellar ichthyosis (ELI). Furthermore, immunohistochemical 
assessment was made of parameters of proliferation, keratinization and inflammation, 
using monoclonal antibodies, to examine whether a selective modulation of the 
cytokeratin pattern could be established. 
PATIENTS AND METHODS 
Patients 
One patient with autosomal dominant ichthyosis vulgaris (ADIV), seven with X-linked 
recessive ichthyosis (XRI), two with bullous congenital ichthyotic erythroderma of Brocq 
(BCIE) and two patients with erythrodermic lamellar ichthyosis (ELI) were treated with 
13-cis-RA after informed consent was obtained. The XRI-patients had a documented 
steroidsulphatase deficiency. NELI- and BCIE-patients had characteristic changes on 
light- and electronmicroscopic examination. Further details regarding ichthyosis subtype, 
sex, age, duration of treatment, reason for discontinuation and previous treatments are 
summarized in Table I. 
Topical as well as systemic treatment was stopped respectively 2 and 4 weeks before the 
trial was started. Using a prospective, bilaterally paired comparative, double-blind 
approach, 13-cis-RA 0.1% in cream base and cream base only (Hoffmann-la Roche, 
Basel, Switzerland) were applied twice daily, without occlusion, on a rectangular area of 
10 by 10 cm on 2 symmetrical and representative lesions. The creams were applied 
thinly and evenly during a test period varying between 4 and 10 weeks. In the event of 
intolerable irritation, patients were instructed to reduce the treatment frequency. In order 
to establish clinical efficacy, scaling, erythema, and induration were scored using a 4 
point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe). Statistical analysis was 
carried out using the Wilcoxon signed-rank test for paired data. 
Analytical procedures 
Biopsies from representative skin lesions within the test areas were taken from 9 patients, 
one at the start and one from each area at the end of treatment The keratin antibodies 
used were the same as used previously (7). In addition the monoclonal antibody Ki-67 
was used to assess proliferation, whereas Leul4, OKT6, WT14, Ti l , and anti-elastase 
were used to assess B-lymphocytes, Langerhans cells, macrophages and monocytes, T-
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lymphocytes, and polymorphonuclear leucocytes respectively. Biopsy procedures and 
immunohistochemical staining methods were used as described before (7). An indirect 
alkalic phosphatase technique was used for staining with the antibodies Ki-67 and anti-
elastase. 
Ki-67 positive nuclei were counted per millimetre length of section. Presence in the 
epidermis and dermis of the remaining stained structures were assessed using a semi-
quantitative scale: 
Epidermis: 0= no staining; 1= sporadic staining; 2= minimal staining; 3= moderate 
staining; 4= moderate-pronounced staining; 5= pronounced staining; 6= whole epidermis 
stained. 
Dermis: 0= absence; 1= sporadically present; 2= 1-25% of infiltrate cells stained; 3= 26-
50% of infiltrate cells stained; 4= 51-75% of infiltrate cells stained; 5= 76-99% of 
infiltrate cells stained; 6= 100% of infiltrate stained. 
Table L Patient details 
patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
diagnosis 
AD1V 
XRI 
XR1 
XRI 
XRI 
XRI 
XRI 
XRI 
BCIE 
BCIE 
ELI 
ELI 
sex 
V 
m 
m 
m 
m 
m 
m 
m 
m 
f 
f 
f 
age 
26 
53 
17 
30 
32 
45 
17 
62 
25 
39 
51 
37 
duration of 
treatment 
(weeks) 
10 
6 
10 
4 
6 
10 
10 
10 
10 
9 
8 
7 
reason for 
discontinuation 
end of study 
end of study* 
end of study 
clearance 
clearance 
end of study 
end of study 
end of study 
end of study 
end of study* 
end of study* 
holidays 
previous treatments 
urea 
propylaenglycol 
salicylic acid, urea, ac. 
lacticum, 
propylaenglycol 
urea 
urea 
salicylic acid, urea, 
petrolatum 
none 
salicylic acid, petrolatum 
unknown 
etretinate, petrolatum 
ac. lacticum, urea. 
petrolatum 
etretinate, urea, 
ac.lacticum 
* Patients used up all the trial medication 
RESULTS 
Clinical response 
Patient details and side effects of the treatment with 13-cis-RA, are summarized in Table 
I. Table II overviews the clinical efficacy of both verum and cream base. 
At the end of the study, 6 of the 12 treated patients showed a half side reduction of 
scaling in favour of the 13-cis-RA treated side (patient no. 2,7,8,9,11,12)(Figs. 1 and 2). 
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Fig. 1 a. XRI-patient with the characteristic phenotype consisting of small brown scales covering the 
arms with sparing of the flexures, before treatment, lb. After treatment, the 13-cis-RA 
treated left side has improved markedly, whereas only slight improvement is observed on 
the cream base treated right side. 
Fig. 2 After treatment, substantial improvement is seen on the 13-cis-RA treated right side. Scaling is 
almost completely absent, whereas minimal erythema persists. The scaling on the cream base treated 
left side, is comparable with the pretreatment state. Erythema is clearly visible, due to absence of 
reflections in this close-up view. 
U 
Table IL Clinical effects of topical 13-cis-RA 
patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
scaling 
vehicle 
start 
2 
3 
2 
2 
1 
3 
3 
2 
3 
3 
3 
3 
end 
2 
3 
1 
0 
0 
1 
3 
1 
2 
1 
3 
3 
13-cis 
start 
2 
3 
2 
2 
1 
3 
3 
2 
3 
3 
3 
3 
-RA 
end 
2 
1 
2 
0 
0 
1 
0 
0 
0 
2 
0 
1 
induration 
vehicle 
start 
2 
end 
1 
3 
0 
0 
0 
0 
1 
1 
2 
2 
3 
3 
13-cis-RA 
start 
2 
3 
1 
1 
1 
2 
1 
1 
3 
3 
2 
3 
end 
1 
1 
0 
0 
0 
0 
1 
0 
0 
2 
0 
I 
In the subgroup with ELI, all patients showed unilateral improvement, whereas in the 
XRI and BCIE subgroups a half side reduction was achieved in respectively 3 out of 7 
and 1 out of 2 patients. No clinical improvement was achieved in the patient with ADIV. 
Five of these responders also showed improvement of induration (patient 2,8,9,11,12). 
The reduction of scaling at the 13-cis-RA side, compared to the cream base side, was 
statistically significant (p<0.05), as was the reduction of induration (p<0.05). No 
significant alterations were observed in erythema. 
An interindividual variation was observed with regard to duration of treatment needed to 
achieve a half side reduction. The earliest response was noticed within one week of 
treatment, while the latest response was not observed before eight weeks of treatment. 
Within the first month of treatment, a half side reduction was achieved in 5 patients 
(patient no. 2,7,9,11,12). In all of them further improvement was obtained by continuing 
the treatment beyond the first month. 
Itching and irritation of the skin (burning), were reported as side effects in four patients 
(33%) at the verum treated side only. These side effects, though, were only minimal and 
could be easily controlled by adjusting the application frequency. Irritation did not 
necessitate discontinuation of the treatment in any patient. 
Histological findings 
Before treatment RKSE60, recognizing keratin 10, marker for cornifying epithelia, 
reacted with the suprabasal compartment in a homogeneous pattern. Treatment with 
topical 13-cis-RA did not change the reaction pattern. The basal cell markers RCK102 
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and RCK107, stained the basal cell layers in all biopsies taken before and after treatment. 
No consistent change in staining patterns was observed after treatment with 13-cis-RA. 
The markers for non-cornifying epithelia, i.e. antibodies 6B10 to keratin 4, and 1C7 and 
2D7 to keratin 13, showed no reaction in the biopsies taken before treatment. After 
treatment with 13-cis-RA a significant increase of keratin 4 expression (Mab 6B10) was 
observed (p<0.05). Staining for keratin 4 was absent at baseline, but was present in 6 out 
of the 9 patients after treatment: staining was moderate in 1 BCIE (Fig. 3) and 1 ELI, 
minimal in 1 ELI, and sporadic in 3 XRI patients (Table III). Staining for keratin 13 was 
sporadic in 1 BCIE patient, using mab 1C7, and sporadic in 1 ADIV, 1 BCIE, and 1 ELI 
patient, using mab 2D7. Induction of keratin 4 and 13, was only found at the 13-cis-RA 
treated side. The markers for simple epithelial cells, i.e. antibodies to keratin 7, 18, and 
19, showed no epidermal staining in the biopsies taken either before or after treatment. 
Staining for keratin 8, using the Mab CAM5.2, M20, and LE4.1, was absent at baseline. 
After treatment, minimal staining of Mab M20 was found in 1 ADIV, 1 XRI, and 1 ELI 
patient (Fig. 4), whereas Mab LE4.1 stained sporadic in 1 ELI patient (Fig. 5), at the 13-
cis-RA treated side only. No staining was found with CAM5.2. For Mab KS8.12, 
staining keratin 13 and proliferation-associated keratin 16, no consistent change in 
staining pattern was observed after treatment with 13-cis-RA. The average number of 
cycling cells per millimetre epidermis was 103 before treatment. After treatment, this 
number was 120 at the 13-cis-RA treated side, and 90 at the cream-base treated side. No 
changes were found for the investigated parameters of inflammation. 
Fig 3. Induction of keratin 4 visualized with mab 6B10 in a patient with BCIE at the 13-cis-RA 
treated side. Keratin 4 expression is only found in the upper epidermal cell layers. 
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Fig. 4. Minimal staining with mab M20, indicating keratin 8, in the ELI patient at the 13-cis-RA 
treated side. Induction of keratin 8 is confined to the upper granular cell and comified cell layers. 
Fig. 5. Same patient as Figure 4, showing expression of mab LE4.1, staining keratin 8. Induction of 
keratin 8 is restricted to the upper parakeratotic layers of the stratum corneum. 
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Table HI. Immunohistochemical effects of topical I3-cis-RA 
patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
keratin 4 
6 В 10 
0 
1 
not done 
not done 
1 
0 
0 
1 
3 
not done 
2 
3 
keratins and monoclonal antibodies 
keratin 8 
M 20 
2 
0 
not done 
not done 
0 
0 
0 
2 
0 
not done 
0 
2 
LE 4.1 
0 
0 
not done 
not done 
0 
0 
0 
0 
0 
not done 
0 
1 
keratin 13 
1 C 7 
0 
0 
not done 
not done 
0 
0 
0 
0 
1 
not done 
0 
0 
2 D 7 
1 
0 
not done 
not done 
0 
0 
0 
0 
1 
not done 
0 
1 
DISCUSSION 
Twelve ichthyosis patients were treated in a prospective, double-blind, bilaterally paired 
study, with a cream containing 13-cis-retinoic acid 0.1% and its cream-base only, for a 
period varying between 4 and 10 weeks. A statistically significant improvement of 
scaling and induration was observed. Clinical improvement was observed in all ichthyosis 
groups, except for ADIV. Irritation was minimal and could be controlled easily by 
adjustment of the application frequency. Immunohistochemical assessment of biopsies, 
revealed a statistically significant induction of keratin 4 in 6/9 patients. Keratin 13 was 
induced in 3/9 patients. Induction of keratin 8 was found in 3/9 patients. These keratins 
were only detected at the 13-cis-RA treated side. No induction was observed at baseline. 
Mab Ki-67, taken as a parameter for proliferation was elevated after treatment at the 13-
cis-RA treated side. 
The good results with respect to efficacy and tolerability of topical 13-cis-RA in 
ichthyosis patients, are in accordance with a previous case report on 2 patients with 
NELI (7), and demonstrates that other ichthyosis subgroups as XRI, BCIE, and ELI, may 
also improve on 13-cis-RA. Additional improvement was observed by extending the 
treatment period beyond the first month. Further improvement may be achieved by 
adapting the concentration (8,9), the mode of application (10) and the cream basis (II). 
It is attractive to hypothesize that other retinoids, such as the arotinoids, may be even 
more effective as a topical treatment for ichthyosis (12). 
Keratin 4 and 13, are foetal keratins absent in normal adult skin. Induction has been 
described after treatment with topical retinoids (7,13,14). This selective modulation of 
the keratin pattern has been proposed as an immunohistochemical tool to investigate the 
mode of action of retinoids (7). Our immunohistochemical results are in conjunction with 
these previous observations. Furthermore, we found selective induction of keratin 8 at the 
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13-cis-RA treated skin, which to our knowledge, has not been described previously. In 
adult skin, keratin 8 is normally expressed in apocrine and eccrine sweat glands (15). In 
fetal skin it is expressed in the basal cell layer (16). It is possible that keratin 8 
represents another keratin, selectively modulated by retinoids. As fetal keratins are 
normally not expressed during epidermal differentiation, one could argue about the 
relevance of their induction. No clear correlation could be established between the extent 
of expression and the clinical efficacy to 13-cis-RA. 
In conclusion, topical treatment of ichthyoses with 13-cis-RA 0.1% was followed by a 
clinical improvement in XRI, BCIE and ELI. Irritation of the skin was minimal and 
could be controlled easily. In addition to keratin 4 and 13, keratin 8 might represent 
another keratin induced by retinoids, and thus provide a new immunohistochemical tool 
to investigate the mode of action of retinoids. The clinical relevance of this keratin 
expression remains to be established. 
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SUMMARY 
We investigated the clinical efficacy of topically applied calcipotriol in 6 patients with 
congenital ichthyosis, using a double-blind, bilaterally paired, comparative approach. 
Unilateral improvement, in favour of the calcipotriol-treated side, was observed in 3 
patients with lamellar ichthyosis. A beneficial response was also observed in a patient 
with bullous ichthyotic erythroderma of Brocq. No clinical side-effects or laboratory 
anomalies were observed. This study indicates that calcipotriol constitutes a new and 
promising approach in alleviating disorders of keratinization characterized by 
hyperproliferation, other than psoriasis. 
INTRODUCTION 
Lamellar as well as epidermolytic ichthyoses, comprise congenital ichthyosis subgroups, 
not associated with other diseases. The lamellar ichthyoses are a heterogeneous group of 
at least five types inherited as autosomal recessive traits, and an autosomal dominant 
type. Among the autosomal recessive types, erythrodermic and non-erythrodermic 
subtypes can be distinguished, i.e. erythrodermic autosomal recessive lamellar ichthyosis 
(EARLI) and non-erythrodermic autosomal recessive lamellar ichthyosis (NEARLI). The 
group of epidermolytic ichthyoses comprises at least three different autosomal dominant 
diseases: bullous ichthyotic erythroderma of Brocq, ichthyosis bullosa of Siemens, and 
ichthyosis hystrix of Curth-Macklin. The Brocq and Siemens types comprise the bullous 
ichthyoses, in which the occurrence of blisters enables differentiation from the Curth-
Macklin type. The Comèl-Netherton syndrome is a rare syndrome of congenital 
ichthyosis linearis circumflexa associated with trichorrhexis invaginata [1]. 
Common treatment modalities, based on keratolysis and (re)hydration of the epidermis, 
are useful in the treatment of autosomal dominant ichthyosis vulgaris (ADIV), but 
severely affected X-linked recessive (XRI), lamellar, and bullous ichthyosis patients can 
only be improved by the use of oral retinoids. Because of the potential toxicity of 
systemic retinoids, it would be an advantage if an effective topical agent was available. 
Calcipotriol is a vitamin D3 analogue which has a high binding affinity to the cellular 
receptor for the biologically active form of vitamin D3: 1,25 dihydroxyvitamin D3 
(calcitriol) [2]. Receptors for calcitriol have been demonstrated in various cells, including 
keratinocytes and fibroblasts [3,4]. Calcitriol and calcipotriol produce equivalent dose-
dependent inhibition of proliferation [5-7], and stimulation of terminal differentiation 
[3,4,7,8], in cultured human keratinocytes [9]. 
Favourable results in the treatment of psoriasis have been obtained with calcitriol [10], 
and calcipotriol [4,11,12], and a beneficial effect was also noted in a case of pityriasis 
rubra pilaris treated with calcipotriol [13]. Extensive clinical research on topical 
calcipotriol has not revealed any significant rise in serum calcium, or increase in urine 
calcium excretion, in patients using less than 100 g per week [14]. The present study was 
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performed to assess the clinical efficacy of topical calcipotriol in the treatment of 
lamellar and epidermolytic ichthyoses, and a case of Comèl-Netherton syndrome. 
PATIENTS AND METHODS 
In a prospective, double-blind, bilaterally paired comparative study, six patients with 
congenital ichthyosis were treated with calcipotriol ointment (SO μg/g) and the ointment 
vehicle. Details of ichthyosis subgroup, sex, age, duration of treatment and previous 
treatment are summarized in Table I. AH affected body areas with the exception of the 
face, scalp and genital region, were treated with the study medication. Other topical and 
systemic treatments were stopped 2 and 10 weeks, respectively, before the start of the 
study. Patients were allowed to apply the emollient cream Locobase (Gist-brocades nv 
Delft, the Netherlands), to the affected body areas during the wash-out phase, and to the 
face and genital region throughout the study period. The ointments were applied thinly 
and evenly, twice daily, for a period of 12 weeks. A maximum amount of 120 g/week 
was dispensed for each side of the body. To avoid inadvertent spread to other body 
areas, patients were instructed to wash their hands after application of the ointments. 
Blood samples for haematological and biochemical analysis were taken 2 weeks before 
the start of the study, and at weeks 2 and 12 of the treatment phase. Serum calcium 
levels were monitored, but urinary calcium excretion was not assessed in this study. The 
clinical assessment was performed using a four-point scale for scaling, roughness and 
erythema. 
Table I. Patient details 
patient diagnose sex age duration of previous treatment 
NEARLI 
NEARLI 
EARLI 
Siemens 
Brocq 
Netherton 
M 
M 
F 
M 
F 
F 
25 
21 
45 
56 
39 
18 
treatment 
12 weeks 
12 weeks 
12 weeks 
12 weeks 
12 weeks 
12 weeks 
Acitretin, urea, sal. acid 
Acitretin, urea, sal.acid, 
lactic acid 
Acitretin, retinoic acid, 
sal.acid 
Acitretin 
Acitretin, sal.acid, urea, 
13-cis-retinoic acid 
Urea, sal.acid 
RESULTS 
The clinical effects of calcipotriol ointment and the ointment vehicle are summarized in 
Table II. At the end of the study, there was a reduction of scaling and roughness on the 
calcipotriol-treated side in all three patients with lamellar ichthyosis (Figs 1-3), and in 
the patient with bullous ichthyotic erythroderma of Brocq. The Comèl-Netherton patient 
showed unilateral improvement with regard to roughness. The degree of erythema 
remained constant during the study in all patients, except for the patient with the Comèl-
Netherton syndrome, who showed worsening on the ointment base-treated side at the end 
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of the study. The patient with ichthyosis bullosa of Siemens did not show any change in 
severity on either side of the body. 
Improvement on the ointment base-treated side was seen in one responder, but to a lesser 
extent than the calcipotriol-treated side, and one patient showed equal improvement on 
both sides. 
Apart from some discomfort on both sides, attributable to the fatty ointment base, no 
unilateral side-effects were reported. Blood parameters remained within the normal range 
throughout the study. Roughness and scaling appeared to be the best parameters to 
establish clinical improvement. 
Table Π. Clinical effects of topical calcipotriol 
patient no. 
Effect on scaling 
1 
2 
3 
4 
5 
6 
Effect on roughness 
1 
2 
3 
4 
5 
6 
Effect on erythema 
1 
2 
3 
4 
5 
6 
vehicle 
start 
2 
3 
3 
2 
3 
2 
2 
3 
3 
2 
3 
2 
2 
3 
3 
2 
3 
2 
end 
2 
2 
3 
1 
3 
2 
2 
2 
3 
1 
3 
2 
0 
0 
2 
0 
1 
2 
calcipotriol 
start 
2 
3 
3 
2 
3 
3 
2 
3 
3 
2 
3 
3 
0 
0 
2 
0 
1 
2 
end 
3 
2 
0 
0 
2 
0 
I 
2 
0, absent; 1, slight; 2, moderate; 3, severe 
DISCUSSION 
This study is the first to demonstrate a substantial improvement of lamellar and 
epidermolytic ichthyoses with topical calcipotriol therapy. No clinical side-effects or 
laboratory anomalies were found in our study, in particular, there was no rise in serum 
calcium. 
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Fig. 1 a. NEARLI patient with the typical phenotype consisting of large brown scales covering the 
trunk, before treatment, b. After treatment, the calcipotriol-treated right side has improved markedly, 
whereas only slight improvement has occurred on the ointment base-treated left side. 
Fig. 2 a.The same patient as in Figure 1. After treatment, a significant unilateral improvement was 
observed in favour of the calcipotriol-treated right leg. b. Some improvement was also noted on the 
ointment base-treated left leg. 
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Fig. 3 EARLI patient after treatment. Substantial improvement is seen on the calcipotriol-treated left 
side. The scaling on the ointment base-treated right side consists of characteristic fine scales, and is 
comparable with the pretreatment state. 
Topical la,25-dihydroxyvitamin D3 and systemic 1 a-hydroxyvitamin D3 have been 
reported to be ineffective in the treatment of ADIV and XRI [10,15]. In these studies the 
concentration of la,25-dihydroxyvitamin D3 was 0.1 μg/g, and the oral dose of la-
hydroxyvitamin D3 was 1 μg per day. 
Calcipotriol is a safe and useful therapeutic agent, which exerts its effect by suppression 
of increased proliferation, and stimulation of terminal differentiation of the epidermis. 
Frost et al. described increased proliferative activity of the epidermis in lamellar and 
epidermolytic ichthyoses. ADIV and XRI, however, were characterized by normal 
proliferative activity [16,17]. Recent investigations, using flow cytometry, have 
confirmed these data. Analysis of the lamellar ichthyoses, which are a heterogeneous 
group, revealed a pronounced increase in proliferative activity in EARLI, whereas 
NEARLI exhibited only moderate epidermal hyperproliferation. Furthermore, the Comèl-
Netherton syndrome showed also a high degree of hyperproliferation. It is attractive to 
speculate that these differences in epidermal cell proliferation rate might explain the 
different clinical responses to treatment with vitamin D3. The lack of improvement in 
ichthyosis bullosa of Siemens might be explained by the pronounced lichenified 
hyperkeratosis, which may prevent adequate penetration of calcipotriol. 
We conclude that calcipotriol appears to be a useful new approach to the treatment of 
lamellar ichthyoses, bullous ichthyotic erythroderma of Brocq, and possibly the Comèl-
Netherton syndrome. However, treatment of large areas of ichthyotic skin will require 
substantial amounts of calcipotriol ointment, and this constitutes a limiting factor in this 
approach to the therapy of ichthyoses. The potential risk of adverse biochemical effects 
could be lessened by using smaller quantities weekly, or by limiting the application 
frequency to three times a week. If quantities of calcipotriol > 120 g weekly are used, it 
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is essential to monitor serum calcium and 24-h urinary calcium excretion. The latter is a 
more sensitive parameter than the serum level [18]. 
Future studies are required in order to obtain additional information on the use o f 
calcipotriol in the treatment of ichthyoses, and to assess the clinical efficacy of 
calcipotriol in the treatment of other hyperproliferative epidermal diseases. 
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SUMMARY 
Two patients with Sjögren-Larsson syndrome were treated with calcipotriol in ointment 
and the ointment base only for 12 weeks, using a double-blind bilaterally paired 
comparative study. Unilateral improvement was observed in both patients in favour of 
the calcipotriol-treated side. The present case is the first demonstration of a substantial 
clinical effect of calcipotriol in the Sjögren-Larsson syndrome. 
INTRODUCTION 
The Sjögren-Larsson syndrome (SLS) is a rare, autosomal recessively inherited disorder 
with an estimated incidence of 1:200.000. Characterizing features of this neuroectodermal 
genodermatosis are ichthyosis and neurologic manifestations, while a number of 
associated symptoms may be present. The outstanding clinical feature of ichthyosis in 
SLS is the congenital, yellowish to dark brown, keratotic lichenification of the skin. 
Signs of the neurologic manifestations, i.e. pathologic reflexes, muscular hypertonia, 
spastic di- or tetraplegia and mental retardation, usually emerge between 4 and 30 
months of age and are stationary after puberty [1]. High-field magnetic resonance 
imaging may reveal atrophic changes of the cerebral motor area, extrapyramidal system, 
corpus callosum and spinal cord [2]. SLS may be associated with a variety of other 
anomalies. The presence of glistening dots on the macular region of the retina is 
regarded as pathognomonic, although not present in all patients. These dots are due to 
focal microglia degeneration and lead to impaired central vision [3,4]. Amblyopia may 
further reduce visual acuity [5]. Hyperkeratosis of palms and soles as well as joint 
hyperextensibility have been reported in association with the SLS [6]. Biochemically, a 
deficiency of the fatty aldehyde dehydrogenase component [7] of the fatty alcohol: 
NAD+ oxidoreductase complex has been established in cultured fibroblasts and 
leucocytes [8.9], while a partial reduction has been reported in obligate carriers [10]. 
Using a histochemical technique, a deficiency of fatty alcohol: NAD+ oxidoreductase 
activity in epidermis and jejunal mucosa has been demonstrated [11]. 
This enzyme deficiency may constitute the biochemical link between the skin and 
neurologic symptoms, for fatty alcohol: NAO+ oxidoreductase deficiency causes 
accumulation of fatty alcohols in keratinocytes and neurons. The fatty alcohols are 
subsequently incorporated into lipids essential for normal cell membrane functions. 
Recently, however, 2 patients with the typical clinical features of SLS have been 
reported with normal fatty alcohol: NAD+ oxidoreductase activity, possibly suggesting 
that SLS is a heterogeneous disease [12,13]. Vitamin D3 (dihydroxycholecalciferol) 
causes a dose-dependent decrease in proliferation and an increase in differentiation of 
human cultured keratinocytes [14]. Clinical data indicate that externally applied vitamin 
D3 is effective in alleviating psoriasis, where proliferative activity of the epidermis is 
greatly increased [15]. This study was part of a large multicentre study [16] and was 
intended to be an illustration of the effect of calcipotriol in SLS. 
S3 
Fig. 1 Pathognomonic glistening dots in the macular region of patient I. 
Fig. 2 Patient II. Both elbows equally covered with ichthyosis before treatment. 
Fig. 3 Same patient as in figure 2. Results after 12 weeks of treatment. The ichthyosis at the 
calcipotriol treated right side has almost completely disappeared. The ointment base treated left side is 
still covered with ichthyosis similar to the pretreatment observations. 
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PATIENTS AND METHODS 
Patients 
Sionce the age of 10 months, a 35-year-old man had shown an ichthyosis with a yellow 
to brownish lichenified appearance, particularly pronounced on the flexural surfaces and 
on the lower abdomen. In childhood a spastic diplegia, impaired vision and photophobia 
became manifest. His 38-year-old sister had a similar skin condition, though less 
extensive, without neurologic or ophthalmologic complaints. Funduscopic examination 
revealed a brightened macular region of the retina in both patients. Pathognomonic small 
glistening dots were observed only in patient I (Fig. 1). Histologic findings consisted of 
orthokeratosis, focal parakeratosis, acanthosis and focal papillomatosis of the epidermis. 
To confirm the clinical diagnosis, a biochemical assay was carried out, measuring the 
fatty aldehyde dehydrogenase component of fatty alcohol :NAD+ oxidoreductase in 
cultured fibroblasts. The assay was carried out as described by Rizzo and Craft [7] using 
hexadecanal as substrate. Fatty aldehyde dehydrogenase values were respectively 496 and 
1486 pmol/min/mg protein (normal range 3320-4850) in patients I and II, respectively, 
and confirmed the clinical diagnosis. 
Methods 
The 2 patients were treated with topical calcipotriol after informed consent had been 
obtained. Topical (urea 10%) as well as systemic treatment (acitretin 10 mg daily) was 
stopped 2 and 10 weeks, respectively, before the treatment was started. To make sure 
that any effect of previous topical therapy disappeared, the patients only used an 
emollient (Locobase) as required, in the pretreatment wash-out period of 2 weeks. Using 
a double-blind, bilaterally paired comparative approach, the patients received calcipotriol 
ointment (50 μ ^ ) on one side of the body and the vehicle only on the opposite side. 
The ointments were applied thinly and evenly, twice daily, for a period of 12 weeks. A 
maximum amount of 120 g ointment per week was dispensed for each side of the body. 
The patients were instructed to wash their hands after application, to avoid inadvertent 
spread to other body areas. Blood samples for haematological and biochemical analysis 
were taken 2 weeks before the start of the study and at weeks 2 and 12 of the treatment 
phase. Clinical efficacy was established by measuring the extent of roughness, using a 4-
point scale. 
RESULTS 
At the end of the study, a half-side reduction, in favour of the calcipotriol-treated side, 
was observed in both patients (Fig. 2, 3). No improvement was observed at the ointment-
base-treated side. Apart from some discomfort at both sides due to the fatty base, no 
unilateral side- effects were reported. Blood parameters remained in the normal range 
during the study. In particular, there was no rise in serum calcium. Roughness appeared 
to be the best parameter to establish clinical improvement of the ichthyosis, characterized 
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by keratotic lichenification, in SLS. Erythema and scaling, however, were absent in both 
patients at the start of the study, and remained so till the study was completed. 
DISCUSSION 
This is the first demonstration of a therapeutic effect of topical calcipotriol in the SLS. 
In the present study, no clinical side-effects or laboratory abnormalities were found. 
Previous reports on topical treatment with la,25-dihydroxyvitamin D3 as well as 
systemic treatment with Ια-hydroxyvitamin D3 of autosomal dominant ichthyosis 
vulgaris (ADIV) and X-linked recessive ichthyosis (XRI), showed an ineffectiveness of 
vitamin D3 [17,18]. 
Frost [19] established hyperprol i feration to be a contributing factor in the pathogenesis of 
lamellar ichthyosis and epidermolytic hyperkeratosis, but not in ADIV and XRI, using 
autoradiographic techniques with tritiated thymidine which is incorporated into cells in 
the period of DNA synthesis. Jagell and Liden [20] demonstrated the DNA synthesis of 
epidermal cells in SLS to be 2.7 times greater than normal, using the same technique. 
Therefore, the ichthyosis in SLS is characterized by hyperproliferation, whereas ADIV 
and XRI represent normoproliferative ichthyoses, possibly explaining the differences in 
clinical efficacy of the treatment with vitamin D3 analogues. 
Apart from symptomatic therapies improving skin manifestations, a substitutional 
treatment has been proposed, in order to correct the basic lipid disorder underlying both 
dermatologie and neurologic symptoms [21,22]. 
An interesting speculation is the possible amelioration of the neurologic symptoms by 
supplementation of dopamine agonists, since severely reduced dopamine concentrations 
have been found in the putamen and, to a lesser extent, in the substantia nigra and other 
striatal regions, suggesting a specific mono-aminergic dysfunction in patients with SLS 
[23]. 
Further research remains to be done, in order to offer the patient with SLS a 
substitutional treatment, ameliorating both skin and neurologic symptoms. At the moment 
though, symptomatic treatment of the skin manifestations remains important. Topical 
calcipotriol constitutes a new and promising approach in alleviating the ichthyosis in 
SLS. 
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Chapter 4 
Flow-cytometric investigation of epidermal cell 
characteristics in monogenic disorders of keratinization 
and their modulation by topical calcipotriol treatment 
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SUMMARY 
A flow-cytometric study was performed in monogenic disorders of keratinization, to 
assess DNA distribution as well as the expression of keratins and involucrin. In addition, 
the changes in expression of these markers under influence of calcipotriol treatment were 
investigated. 
Proliferation, measured by the percentage of epidermal cells in SG2M- phase of the cell 
cycle, was increased in Darier's disease, lamellar ichthyosis, congenital bullous ichthyotic 
erythroderma of Brocq and the Comel-Netherton syndrome, whereas normal proliferation 
was found in autosomal dominant ichthyosis vulgaris, X-linked recessive ichthyosis, 
keratosis pilaris, ichthyosis bullosa of Siemens and the Sjögren-Larsson syndrome. 
Keratin 6 was enhanced in erythrodermic lamellar ichthyosis, congenital bullous 
ichthyotic erythroderma of Brocq and the Comel-Netherton syndrome, showing also 
reduction of keratin 10. Involucrin was only slightly reduced in erythrodermic lamellar 
ichthyosis, congenital bullous ichthyotic erythroderma of Brocq and the Comel-Netherton 
syndrome, compared to the pronounced reduction in all other skin disorders studied. 
Calcipotriol was found to enhance differentiation in Darier's disease, erythrodermic 
lamellar ichthyosis, and congenital bullous ichthyotic erythroderma of Brocq. Only 
Darier's disease did not show clinical improvement. 
In conclusion, flow cytometry provides a useful method for quantification of epidermal 
cell characteristics in monogenic disorders of keratinization. Further studies need to be 
performed to establish its usefulness as a diagnostic and prognostic tool. 
INTRODUCTION 
One of the changes of normal, terminally differentiating keratinocytes is the specific 
expression of keratin intermediate filaments. Several methods for detection of these 
intermediate filament proteins are available. Two-dimensional Polyacrylamide gel 
electrophoresis is most often used to characterize keratin proteins biochemically (1,2). 
This method allows specific detection of the whole repertoire of keratins present in a 
tissue specimen, though the localization of the keratins is lost. Immunohistochemical 
methods using monoclonal antibodies recognizing single or sets of related keratins have 
the advantage that topographical information is maintained (3-5). A limitation of this 
approach is that only qualitative or semi-quantitative information can be obtained. Flow-
cytometric analysis of intermediate filament proteins in single cell suspensions of 
epidermal cells allows rapid simultaneous quantification of two or more characteristics 
per individual cell, with high reproducibility and statistical accuracy (6). 
Immunohistochemical and flow-cytometric approaches have been used to determine the 
epidermal cell characteristics in normal and psoriatic skin and to evaluate the effects of 
therapies on proliferation and differentiation in psoriasis (7-9). Little information is 
available on epidermal cell kinetics in monogenic disorders of keratinization. Some 
immunohistochemical studies have been performed with the monoclonal antibody Ki-67, 
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recognizing a proliferation-associated nuclear antigen (7). However, no quantitative data 
are available on epidermal cell characteristics in monogenic disorders of keratinization, 
using a flow-cytometric approach. 
The vitamin D3 analogues calcipotriol and calcitriol (la25-dihydroxyvitamin D3) have 
been shown to inhibit cell proliferation (10-12) and induce terminal differentiation 
(10,13-15) in cultured human keratinocytes. Immunohistochemical evaluation of 
treatment of psoriatic plaques with calcipotriol has revealed a rapid decrease of the 
number of proliferating cells, measured as Кі-67-positive nuclei, after 2 weeks, resulting 
in a total decrease of 48% after 12 weeks. Ks8.12-binding revealing keratin 16 
expression has shown a tendency to diminish after 4-12 weeks of treatment (8). Flow-
cytometric analysis has shown a decrease in DNA-content and a reduction of Ks8.12-
binding in psoriasis, after 6 weeks of treatment with calcipotriol (9). 
The aim of the present investigation was to assess, using a flow-cytometric approach, 
DNA distribution, as well as the expression of intermediate filament proteins and 
involucrin, markers for epidermal proliferation and differentiation, in order to 
characterize epidermal cell characteristics in Darter's disease, keratosis pilaris (KP), 
autosomal dominant ichthyosis vulgaris (ADIV), X-linked recessive ichthyosis (XRI), and 
congenital ichthyoses. Furthermore, the changes in expression of these keratins under 
influence of calcipotriol treatment were analyzed using flow cytometry. 
PATIENTS AND METHODS 
Patients 
Twenty-five patients (3 ADIV, 5 XRI, 5 Darier, 3 KP, 9 congenital ichthyosis) 
participated in the study. The group of congenital ichthyoses consisted of 1 
erythrodermic lamellar ichthyosis (ELI), 2 non-erythrodermic lamellar ichthyosis (NELI), 
1 ichthyosis bullosa of Siemens (Siemens), 2 congenital bullous ichthyotic erythroderma 
of Brocq (Brocq), 1 Comel-Netherton syndrome (CNS), and 2 patients with the Sjögren-
Larsson syndrome (SLS). A superficial skin sample, about 0.2 mm thick and 3 mm in 
diameter, was removed from a representative area from each side with a razor blade in 
conjunction with a metal guard, from all patients before treatment. Similar samples were 
taken from eleven healthy volunteers. Eighteen patients (2 ADIV, 5 XRI, 3 Darier, 3 KP, 
1 ELI, 2 NELI, 1 Siemens and 1 Brocq) completed a double-blind bilaterally paired 
comparative treatment period of 12 weeks with calcipotriol ointment 50 μβ/g and the 
ointment vehicle only. At week 12, similar biopsies were taken from both sides. All 25 
patients were recruited from the centre in Nijmegen. Twenty-four of them (except for 
one ADIV) constituted a subgroup, participating in a multicenter study from which the 
clinical results have been published before (16). For practical reasons only skin samples 
obtained from patients treated at the centre of dermatology in Nijmegen were analyzed 
using flow cytometry. 
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Monoclonal antibodies 
- AF 124 (National Cancer Institute, Bethesda, Maryland, USA)(17) to assess keratin б, 
which is expressed in hyperproliferative epidermis. 
- RKSE60 (Department of Pathology, University Hospital Maastricht, Netherlands)(18) 
to assess keratin 10 expression, present in differentiated epidermis. 
- Anti- involucrin (Biomedical Technologies, Ine, Stoughton, USA)(19) to assess 
involucrin expression, a marker for terminal differentiation. 
- 6B10 (Eurodiagnostics, Apeldoorn, Netherlands)(20) to assess keratin 4, which is 
expressed following treatment with retinoids. 
- 1C7 (Eurodiagnostics, Apeldoorn, Netherlands)(20) to assess keratin 13, which is also 
expressed following retinoid treatment. 
Analytical procedures 
Cell suspensions were prepared using a trypsinization procedure in order to dissociate 
biopsy specimens into single cells. The biopsy specimen was washed in phosphate-
buffered saline (PBS) and incubated with the dermal site downward in 1 ml of PBS 
containing 1% trypsin (DIFCO, Detroit, Mich.) and 0.3% dithioerythritol (Sigma, St. 
Louis, Mo.) at 37°C for 20 min. Subsequently, the specimen was fixed in 500 μΐ ice-cold 
70% ethanol and dissociated by sonification (Sonifier B-12, Branson Sonic Power, 
Danbury, Coun.) for 5 s at 70W. This resulted in a cell suspension containing only 
epidermal cells, for dermis and stratum corneum remained intact and floated on the 
surface. 
Aliquots of these ethanol-fixed cell suspensions were immunostained with the 
monoclonal antibodies anti-involucrin, 6B10, 1C7, RKSE60 and AFI24. As second 
antibody, goat anti-mouse IgG conjugated with fluorescein isothiocyanate (FITC) (GAM-
FITC; Tago, Burlingame, U.S.A.) was used for all stainings, except for detection of 
AF124 which required a FITC-conjugated swine anti-rabbit IgG (SAR-FITC; Dakopatts, 
Copenhagen, Denmark). These antibodies were added in a 1:25 dilution for 30 min at 
room temperature. After the two incubation steps, the cells were washed twice and 
resuspended in 200 μΐ PBS, pH 7.8, containing propidium iodide (PI) 40 mg/1 
(Calbiochem, San Diego, U.S.A.). Afterwards the cell suspensions were incubated for 15 
min with 50μ1 RNAse (lmg/ml in PBS) (Sigma, St. Louis, U.S.A.) at room temperature 
and filtered in order to remove clumps; fluorescence was measured using an Ortho 50H 
flow cytometer (Ortho Instruments, Westwood, U.S.A.). Both FITC and PI were excited 
with a 5W argon laser (164-05, Spectra Physics, Mountain View, U.S.A.) tuned at 488 
nm, and emission was recorded at 515-530 nm (FITC) and >630 nm (PI). The data were 
stored and analyzed with a Digital PDP 11/34 computer (Digital Equipment, Gal way. 
Republic of Ireland). Green fluorescence derived from FITC indicated staining with the 
primary antibodies. Red fluorescence derived from PI was used to establish the DNA 
content per cell, allowing a differentiation between the cells in the consecutive phases off 
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the cell cycle. The cells with elevated DNA content reflected the cells in the SG2M 
phase of the cell cycle. Therefore, the percentage of cells in SG2M phase was measured 
as a marker of proliferation. 
RESULTS 
Epidermal cell characteristics in monogenic disorders of keratinization 
Flow-cytometric measurements of cell suspensions obtained in the various monogenic 
disorders of keratinization are summarized in Table I. 
The SG2M values have been measured for each of the monoclonal antibodies, resulting 
in a total amount of five SG2M values in each sample. In the tables, the mean values are 
shown ± S.E.M. As most disorders are extremely rare, the number of patients in the 
various groups was too low to perform statistical analysis. To allow a comparison 
between the flow-cytometric data before calcipotriol treatment found in the various skin 
disorders, alterations more than one standard deviation from the mean values in the 
normal control group were taken into consideration. 
The percentage of cells in the SG2M phase of the cell cycle was elevated in Darier, ELI, 
NELI, Brocq, and CNS. Values comparative to normal were observed in ADIV, XRI, 
KP, Siemens, and the SLS. Keratin 6 revealed an increase in ELI, Brocq, and CNS. A 
reduction of keratin 10 was observed in CNS. A reduction, less than one standard 
deviation from the normal controls, was noticed in Darier, ELI, NELI, Siemens, and 
SLS. Involucrin was diminished in all monogenic disorders of keratinization studied. 
ELI, Brocq, and CNS exhibited only a reduction of involucrin expression of more than 
one standard deviation, whereas a reduction of more than three standard deviations was 
observed in the other dermatoses. The percentage of cells containing keratins 4 and 13 
was low in all subgroups. 
Modulation of epidermal cell characteristics by calcipotriol treatment 
To allow a comparison between the flow-cytometric changes by calcipotriol treatment, 
alterations of the nett calcipotriol effect of more than one standard deviation from the 
mean pretreatment values were taken into consideration. 
Changes in epidermal cell characteristics in the monogenic disorders of keratinization, 
after treatment with calcipotriol, compared to its vehicle, are summarized in Table II. 
An increase in involucrin expression in favour of the calcipotriol treated side was 
observed in Darier, ELI, and Brocq. 
Alteration of keratin 10 expression paralleled the changes observed in involucrin 
expression. Again, a unilateral increase in favour of the calcipotriol treated side was 
observed exclusively in Darier, ELI and Brocq. Keratin 6 expression in ADIV, KP and 
Siemens was reduced by calcipotriol, while an elevation was noticed in Darier, ELI and 
Brocq. 
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Modulation of keratins 4 and 13 was rather inconsistent: keratins 4 and 13 were both 
upregulated by calcipotriol in ADIV and Darier. In KP both were downregulated. 
Contradictory modification was observed in ELI, NELI, and Siemens. In Brocq only 
keratin 4 was modified upward, whereas in XRI only keratin 13 was regulated 
downward. 
Only moderate modulation was observed in the percentage of cells in SG2M phase. An 
increase was observed in ADIV, ELI and NELI, whereas a decrease was found in KP, 
Siemens and Brocq. 
DISCUSSION 
In the present study, information on epidermal cell kinetics of monogenic disorders of 
keratinization was obtained, using a fiow-cytometric approach. Furthermore, the 
influence of calcipotriol on proliferation and differentiation was analysed using flow 
cytometry. 
Proliferation, measured by the percentage of cells in SG2M phase of the cell cycle, 
revealed a hyperproliferative state of the epidermis in Darier, ELI, NELI, Brocq and 
CNS, whereas proliferation was comparative to normal in ADIV, XRI, KP, Siemens and 
SLS. In 1966, Frost et al. (21) established hyperproliferation to be a contributing factor 
in the pathogenesis of lamellar ichthyosis, epidermolytic hyperkeratosis and Darier's 
disease, but not in ADIV and XRI, using autoradiographic technics with tritiated 
thymidine which is incorporated into cells in the period of DNA synthesis (22). Jagell 
and Liden demonstrated DNA synthesis of epidermal cells in SLS to be 2.7 times greater 
than normal, using the same technique (23). Our fiow-cytometric data are in accordance 
with these previous observations, except for Siemens and SLS. This discrepancy may be 
explained by the fact that both Siemens and SLS are clinically characterized by 
prominent lichenification, implicating that relatively more superficial than basal 
epidermal cell layers may be obtained, using a 0.2 mm thick razor blade. Another marker 
for proliferation, AF124 staining keratin 6, was elevated in ELI, Brocq and CNS. 
Information on differentiation was obtained by the percentage of cells, positive for 
keratin 10, which is a marker for early differentiating keratinocytes. Keratin 10 was 
reduced more than one standard deviation compared to the normal controls only in CNS. 
However, all skin disorders characterized by hyperproliferation (as demonstrated with the 
SG2M values described previously) showed a reduced staining pattern for keratin 10, 
with the exception of Brocq, which is another ichthyosis subtype, clinically characterized 
by prominent lichenification. These data are in accordance with clonal analysis, growth 
kinetics, and cell cycle studies of normal human keratinocytes cultured in serum-free 
medium, which show that if keratinocyte proliferation is promoted, differentiation is 
inhibited (24). 
Involucrin is one of the substrates for the formation of comified envelopes and is 
synthesized in normal epidermis in the granular cell layer, implying that this protein is a 
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marker of late-stage differentiation. However, in hyperproliferative skin disorders such as 
benign neoplasms, malignant tumours, psoriasis, and DLE, involucrin is synthesized 
much earlier (25,26). Our study demonstrated diminished involucrin expression in all 
skin disorders studied. However, ELI, Brocq and CNS, all characterized by elevated 
keratin 6 expression and hyperproliferation, exhibited a more pronounced staining of 
anti-involucrin, compared to the other dermatoses studied. 
Concerning the influence of calcipotriol on epidermal cell kinetics, we observed 
induction of differentiation, indicated by keratin 10 expression, as well as induction of 
terminal differentiation, indicated by involucrin expression, in Darier, ELI and Brocq, 
which is in accordance with previous studies on calcipotriol in psoriasis (27). 
Nevertheless, the expected reduction in proliferation, as was observed previously in 
psoriasis, was lacking in our study. 
Keratins 4 and 13, which are expressed following treatment with retinoids (28), are 
normally found in fetal, but not in adult epidermis. Modulation after treatment with 
calcipotriol revealed no consistent findings. 
Comparing the fiow-cytometric data with the clinical data revealed a good correlation in 
KP and Siemens, which were unresponsive to calcipotriol, and in ELI and Brocq, which 
improved substantially. This in contrast to NELI, XR1 and ADIV, in which some clinical 
improvement was observed, whereas the flow cytometry remained unchanged. Finally, it 
is of interest that Darier was characterized by fiow-cytometric changes, although clinical 
improvement was not observed. It is attractive to speculate that Darier's disease might be 
responsive to calcipotriol when used at a lower and less irritating concentration. 
We conclude that flow cytometry provides a useful method for establishing epidermal 
cell kinetics of monogenic disorders of keratinization. Further studies are required to find 
out to what extent quantification of cell cycle kinetics and markers of keratinization is 
useful as a diagnostic and prognostic tool. 
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SUMMARY 
Liarozole, a novel imidazole derivative, inhibits the cytochrome P450-dependent 4-
hydroxylation of retinole acid, resulting in increased tissue levels of retinoic acid. Twelve 
male patients with ichthyosis were given oral Liarozole 150 mg twice daily in an open 
study for twelve weeks. Immunohistochemical parameters of inflammation, epidermal 
proliferation and differentiation were assessed before and after treatment. Extent and 
severity of the skjn lesions was markedly reduced in all patients. Clinical side effects 
were reminiscent of those with synthetic retinoids. No relevant changes were found in 
the haematological, urinary and biochemical parameters. Immunohistochemical 
assessment showed a statistically significant induction of keratin 4 after liarozole 
treatment in 10/12 patients. In 2 of these patients keratin 13 was induced. 
This open study showed that oral liarozole treatment was efficacious and well tolerated 
in the treatment of different types of ichthyosis. The immunohistochemical results 
suggest a retinoid mechanism as mode of action. 
INTRODUCTION 
Retinoids (vitamin Α-acid derivatives) are important compounds that control proliferation 
and differentiation of epithelial tissues in mammals M . Accordingly, systemic treatment 
with retinoids has yielded good results in the treatment of disorders of keratinization such 
as ichthyosis. However, their toxicity and teratogenicity limit their use to severely 
affected patients *"'. Therefore a search for new drugs with a broader toxic-therapeutic 
window is indicated. Liarozole, a novel imidazole derivative, inhibits the cytochrome 
P450-dependent 4-hydroxylation of retinoic acid which is the physiological breakdown of 
all-trans-retinoic acid. In rats, liarozole increased the concentration of retinoic acid in 
plasma and tissue '. Liarozole also inhibits several cytochrome P450-dependent steps in 
steroid biosynthesis - mainly the conversion of androgens to estrogens (aromatase), 
progestins to androgens (17-hydroxylase, 17 -20-lyase) and of 11-deoxycorticosterone to 
corticosterone (11-hydroxylase) l0. Administration of 150 mg liarozole bidaily for 10 
days to male volunteers showed neither reduction in Cortisol levels, nor on the Cortisol 
surge after ACTH stimulation ". Apart from a transient decrease of testosterone levels no 
changes of the levels of this hormone were observed. Furthermore, no abnormalities were 
observed in Cortisol, cholesterol and testosterone levels in psoriasis patients, treated with 
doses ranging from 75 to 150 mg bidaily 12. One open trial with liarozole 75 mg bid to 
150 mg bid in severe plaque psoriasis showed a significant improvement in 77% of the 
patients '2. Evidence is accumulating that liarozole will provide a broad efficacy-side 
effect window. However final conclusions await further comparative studies. The aim of 
the present study was to investigate the effectiveness and tolerability of oral liarozole in 
12 patients with hereditary ichthyoses. Additionally to get insight in the in vivo action of 
liarozole on these disorders, immunohistochemical parameters of inflammation, epidermal 
proliferation and differentiation were assessed before and after treatment. 
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PATIENTS AND METHODS 
In an open prospective study, 12 male patients suffering from various forms of 
ichthyosis were included: 5 patients with X- linked recessive ichthyosis (XRI), 4 patients 
with non erythrodermic lamellar ichthyosis (NELI), 1 patient with erythrodermic lamellar 
ichthyosis (ELI) and 2 patients with bullous congenital ichthyosiform erythroderma 
(BCIE). They were treated with oral liarozole (liarozole fumarate) 150 mg twice daily, 
for 12 weeks. Topical as well as systemical treatments were stopped respectively 2 and 
4 weeks before the start of the study. Patients were allowed to use bland emollients 
during the study except on the days of the visits. Only male patients, age 18 to 70 years, 
were included. XRI-patients had a documented steroidsulphatase deficiency, and sun 
exposure had to be avoided. Patients were examined before treatment, at week 0, 1, 2, 4, 
8, 12 during the treatment phase, and 4 and 8 weeks after discontinuation of therapy. The 
severity of involvement was rated using a 4 point scale for scaling, roughness, erythema, 
bullae and hyperpigmentation, as follows: 0 = absent, 1 = mild, 2 = moderate, 3 = 
severe. Scaling and roughness were recorded in all subgroups, erythema and bullae in 
ELI and BCIE, and hyperpigmentation only in XRI. The extent of involvement was 
expressed as the percentage of affected skin on arms, trunk and legs. An overall response 
to treatment was quantified by both the investigator and the patient, on a five-point scale: 
0 = deteriorated, 1 = unchanged, 2 = moderately improved, 3 = markedly improved, and 
4 = cleared. 
Haematological (haemoglobin, haematocrite, red blood count, white blood count, 
differentiation, platelet count), biochemical (Na, K, CI, Ca, Ρ, urea, kreatinin, albumin, 
protein, total bilirubin, cholesterol, triglycerides, alcalic phosphatase, ASAT, ALAT, 
GGT, glucose), and urinary analysis (specific gravity, pH, protein, glucose, urobilinogen, 
bilirubin, red blood count, white blood count) were performed at entry, and at each visit 
after initiation of the treatment. Statistical analysis was carried out using the Wilcoxon 
signed-rank test for paired data. 
In all 12 patients, punch biopsies were taken from representative skin lesions before and 
after treatment. The antibodies used to assess epidermal proliferation, keratinization, and 
epidermal and dermal inflammation are summarized in table I. Immunohistochemical 
procedures were carried out as described previously13. 
RESULTS 
Severity of skin involvement, assessed by the investigator, is presented in Figure 1. For 
the extent of involvement a comparative curve was observed. As expected, the extent and 
severity of the ichthyosis deteriorated during the wash-out phase and the severity even 
during the first week of treatment. Thereafter, a clear clinical improvement for both the 
extent and severity of the skin lesions was achieved. At the end of the treatment phase, 
an impressive clinical improvement was achieved in all patients (Figures 2,3). The extent 
of skin lesions was statistically significantly reduced for arms (pO.001), trunk (p=0.002) 
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and legs (pO.OOl). The degree of scaling and roughness, also significantly improved on 
the arms (pO.OOl), trunk (p=0.001) and legs (p=0.001). As hyperpigmentation, 
erythema, and bullae were only assessed in a few patients (respectively 5, 1, and 2), no 
statistics were carried out. Nevertheless, changes in hyperpigmentation were comparable 
with changes in roughness and scaling. Erythema was not remarkably influenced. For 
overall response, both the investigator and 11 patients assessed the treatment as a marked 
improvement. One patient reported a moderate improvement. In 6 patients after 
discontinuation of the treatment, the extent and severity of the lesions gradually 
worsened to reach pretreatment values after 8 weeks. The other six patients already 
required treatment after 4 weeks. Eleven patients experienced adverse events. The most 
frequently reported clinical side effects were dry lips (10 patients), itching (6 patients) 
and dry eyes (3 patients). These side effects were mild, not requiring discontinuation of 
treatment in any patient. Of the two patients who mentioned hair loss, one improved 
during treatment and the other patient improved upon discontinuation of treatment. One 
patient who was inflicted with BCIE developed multiple large bullae on a dose of ISO 
mg twice daily but these disappeared upon reduction of the dose to 1 SO mg daily. One 
patient with XRI developed urticaria after 2 weeks of treatment. After a temporary stop 
of 2 weeks the lesions did not reappear and no relapse occurred after gradual 
readministration of liarozole, first ISO mg daily for 2 weeks, followed by the initial dose 
of ISO mg bidaily. Dryness of the nose, headache, gastric pain, increased skin tension, 
burning skin sensation, dizziness, enhanced sweating, candidiasis and undefined erythema 
were each observed in one occasion. 
Haematological, biochemical and urinary parameters, measured at week 12, were not 
significantly influenced by liarozole, compared with the pretrial visit. 
Table I. Specificity and sources of the antibodies. 
Antibody 
Proliferation 
Ki-67 
Keratiniztion 
Ks8.12 
RKSE60 
6B10 
1C7 
Inflammation 
Anti-elastase 
Til 
WT14 
OKT6 
specificity 
nuclear antigen 
Keratin 13 and 16 
Keratin 10 
Keratin 4 
Keratin 13 
Elastase (polymorphonuclear 
leucocytes) 
CD2 (T-lymphocytes) 
CD14 (monocytes, macrophages) 
CD la (Langerhans cells) 
source 
Dakopatts, Copenhagen, DU 
Sigma, St. Louis, USA 
Eurodiagnostics, Apeldoorn, NL 
Eurodiagnostics, Apeldoorn, NL 
Eurodiagnostics, Apeldoorn, NL 
Serotec, Oxford, UK 
Dakopatts, Copenhagen, DU 
Dept. Nephrology, Nijmegen, NL 
Ortho Diagnostics Systems, Raritan, USA 
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severity of scaling on the arms 
3.0 
2.5 
2.0 -
1.5 
1.0 
0.5 H 
0.0 
treatment phase (oral liarozole) follow-up phase 
pretrial 12 16 20 
duration (weeks) 
Fig 1. Clinical severity; severity of scaling on the arms worsens during the wash-out period and the 
first week of treatment. Afterwards a gradual improvement, reaching its maximum at week 12 is 
observed. Discontinuation of the treatment is followed by progressive worsening of this symptom to 
pretreatment values at week 8. Whereas all 12 patients were evaluated until week 16, only 6 of them 
were considered at week 20, because the others required treatment. For the severity of scaling on 
trunk and legs, as well as the severity of roughness and hyperpigmentation on arms, trunk and legs, a 
similar pattern is observed. *p<0.05 **p<0.005 ***p<0.001 
Fig 2 a. NELI-patient before treatment, displaying large brown-coloured scales, covering a substantial 
part of the body. b. After 12 weeks of treatment, a marked reduction of scaling is observed, resulting 
in a normal appearance. 
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Fig. 3 a. BCIE-patient 
before treatment, showing 
thick yellowish scales in 
the neck, on an erythe-
matous skin. 
b. At the end of the treat-
ment phase, a substantial 
reduction of scales is 
observed. Some erythema 
is still present. 
Table II. Modulation of expression of keratin 4, 13, and 16, in the various ichthyosis subgroups, 
under influence of liarozole therapy. 
parameter 
keratin 4 (6B10) 
unchanged 
increased 
keratin 13 (1C7) 
unchanged 
increased 
keratin 13/16 (Ks8.12) 
reduced 
unchanged 
increased 
XRI 
(n=5) 
1 
4 
5 
0 
0 
1 
4 
NELI 
(n=4) 
1 
3 
4 
0 
0 
3 
1 
ELI 
(n=l) 
0 
1 
0 
1 
1 
0 
0 
Brocq 
(n=2) 
0 
2 
1 
1 
0 
1 
1 
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The most obvious histochemical effect was seen for the expression of keratin 4 (Table 
II). While keratin 4 was absent at baseline, it was expressed in 10 out of the 12 patients 
after 12 weeks of treatment, independently of the type of ichthyosis. The induction of 
keratin 4 was statistically significant (p<0.05). Keratin 13 could not be detected at 
baseline, but was sporadically detected in 2 patients after 12 weeks of treatment. The 
expression of keratin 13 and 16 was variable: increased in 6 patients, reduced in one 
patient, and inconsistent in 5 patients. Treatment with liarozole did not change the 
baseline expression of keratin 10 which could be detected within the suprabasal 
compartment. Before treatment, the average number of actively cycling cells (mab Ki-67) 
was 88.9 per mm of section. After 12 weeks of treatment, this number was 86.6 
(pO.10). None of the inflammatory parameters did significantly change upon treatment. 
DISCUSSION 
Twelve patients with different types of ichthyosis, showed a statistically significant 
improvement in the extent and severity of the skin lesions after 12 weeks of treatment 
with liarozole. As anticipated clinical side effects were consistent with those experienced 
in hypervitaminosis A namely: mostly dry lips, dry eyes and itching. These effects were 
mild and did not necessitate discontinuation of the treatment. No significant changes 
were observed in the haematological, biochemical and urinary parameters. The present 
results suggest that liarozole provides a substantial clinical efficacy with limited side 
effects. 
The treatment of disorders of keratinization has been revolutionized by systemic retinoids 
'
4
. However, the margin between safety and efficacy is limited for these drugs. Based on 
12 patients, however, it is virtually impossible to conclude whether the therapeutic 
window between efficacy and side effects is broader for liarozole compared to acitretin. 
However, the present study suggests that liarozole is at least as effective, whereas the 
side effect profile is rather similar to that of acitretin. In particular the mucocutaneous 
side effects, occurring within the therapeutic dose-range is a characteristic for both 
treatments. Furthermore, dose dependent blistering occurs both during liarozole and 
acitretin treatment in BCIE 15. In our opinion double blind comparative study between 
liarozole and acitretin is warranted in patients with ichthyosis. The development of a 
topical liarozole formulation could help to broaden the margin between efficacy and side 
effects even more. 
Although the clinical response in various disorders of keratinization and the 
mucocutaneous side effects suggest that liarozole might work via a retinoid effect, further 
evidence for such an effect might be provided by immunohistochemical studies on the 
cellbiological effects during treatment. Immunohistochemical assessment of biopsies, 
revealed a statistically significant induction of the expression of keratin 4 in 10/12 
patients (p<0.05). In 2 patients keratin 13 was induced. Keratin 4 and 13 are keratins 
which are absent in normal adult human skin. Induction has been described after 
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treatment with topical retinoids , 6 · ' 7 . Therefore, the present results provide indirect 
evidence for the hypothesis that the pharmacological effects of liarozole could be 
mediated by enhanced levels of endogenous retinoic acid. However, further studies on 
retinoid levels in the skin and induction of expression of cellular retinoic acid binding 
protein II are required before this hypothesis can be proven. 
Theoretically, topical application of liarozole may be effective too. However, at the start 
of this study topical liarozole was not available. Furthermore, topical retinoids used in 
the past were characterized by a high irritancy potential " . Based on the good clinical 
results obtained with oral liarozole in this study, a topical liarozole formulation has been 
developed. Studies on topical liarozole in ichthyosis are currently ongoing. 
In conclusion, in this open study, treatment with liarozole was followed by a substantial 
clinical improvement in all patients with ichthyosis. Relevant laboratory side effects were 
absent. Subjective side effects were reminiscent of those observed with synthetic 
retinoids. The immunohistochemical results lend further support for a retinoid 
mechanism, although other modes of actions are not excluded. Additional controlled 
studies are required to confirm the efficacy and to determine the optimum dosage and 
safety profile of this new compound. 
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Chapter 6 
Topical liarozole treatment of hereditary ich thy oses: a 
double-blind, placebo-controlled left-right comparative 
clinical and immunohistochemical study. 
GPH Lucker 
AMC Heremans 
PJ Boeghcim 
PM Stcijlen 
Submitted. 

SUMMARY 
The novel imidazole derivative liarozole, inhibits the cytochrome P450-dependent 4-
hydroxylation of retinoic acid, increasing the tissue levels of endogeneous retinole acid. 
After a wash-out phase of 2-4 weeks, twelve male patients with ichthyosis were treated 
for 6 weeks, using a bilaterally paired double-blind approach with liarozole 5% cream. 
This was followed by an open phase of 4 weeks during which both sides were treated 
with liarozole cream. Immunohistochemical parameters of epidermal keratinization and 
inflammation were assessed before and after the double-blind treatment. At the end of 
the double-blind treatment, a significant unilateral improvement in extent and severity of 
skin lesions was observed in favour of the liarozole cream treated side. Clinical side 
effects were only minimal. No relevant changes were found in the haematological, 
biochemical, and urinary parameters. Plasma levels of liarozole could be detected in 10 
patients. Highest levels were observed in those with more inflammatory types of 
ichthyosis. However, except for one patient, these levels were apparently not 
therapeutical, as only the side treated with liarozole cream responded well to the 
treatment. On the other hand, decreased oestradiol levels were measured in some patients, 
which might have been due to a systemic effect of liarozole, but without correlation 
between oestradiol and liarozole levels. Finally, immunohistochemistry showed induction 
of keratin 4 in 3 patients and of keratin 13 in one patient at the end of the double blind 
treatment, again only on the side treated with liarozole cream. At the end of the open 
treatment, an inverted clinical effect was observed. Unilateral improvement in extent and 
severity was noticed in favour of the previously cream base treated side. Topical 
administration of liarozole 5% cream caused a definite amelioration in different types of 
ichthyosis, suggesting that therapeutical concentrations of retinoic acid may be achieved 
by an in situ inhibition of the endogeneous breakdown of this acid. The retinoid-like 
effect on the keratin pattern was only seen on the liarozole-treated side, further indicating 
a selective increase of retinoic acid in the target skin cells. 
INTRODUCTION 
The genetically determined ichthyoses require lifelong treatment. Whereas topical 
treatment is the therapy of first choice, most topical therapeutical modalities available, 
however, are insufficient as monotherapy in the treatment of severe ichthyosis subtypes. 
Retinoids (vitamin Α-acid derivatives) are important compounds that control proliferation 
and differentiation of epithelial tissues in mammals (1-4). Liarozole, a novel imidazole 
derivative, inhibits the cytochrome P450-dependent 4-hydroxylation of retinoic acid 
which is the physiological breakdown of all-trans-retinoic acid (5,6). In vitro 
pharmacological studies in cultured human breast cancer cells, teratocarcinoma cells, and 
keratinocytes, demonstrated a synergistic effect of liarozole and exogenously added 
retinoic acid (RA) (7,8). In-vivo keratinization and tumour models in rats and mice 
showed that orally administered liarozole (10-40 mg/kg/day) delays the plasma clearance 
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and enhances tissue levels of endogenous RA, and mimics the biochemical and 
morphological effects of RA on proliferation and differentiation of epithelial tissues 
(9,10). The presently available clinical data corroborate these in-vitro and in-vivo data on 
RA metabolism, as oral administration of liarozole proved efficacious in the treatment of 
psoriasis (11), and cancer patients receiving oral liarozole developed cutaneous signs of 
hypervitaminosis A (12). 
Besides inhibiting the 4-hydroxylation of RA, liarozole also inhibits cytochrome P450-
dependent steps in the biosynthetic pathways of testicular, ovarian and adrenal steroids, 
mainly the conversion of androgens to estrogens (aromatase), progestins to androgens 
(17-hydroxylase, 17-20-lyase) and of 11-deoxycorticosterone to corticosterone (11-
hydroxylase) (6). However, the effect on testicular and adrenal steroid biosynthesis may 
not be clinically relevant, as upon chronic administration of oral liarozole in human 
volunteers, recovery of plasma testosterone and Cortisol levels was achieved by 
hypopituitary compensation (13). In accordance, psoriasis patients receiving oral liarozole 
treatment did not reveal abnormalities in Cortisol and testosterone levels (14). 
Topical therapeutical modalities available in ichthyosis mainly consist of urea and lactic 
acid, aiming at rehydration and keratolysis of the comified cell layer. However, these 
ointments are of limited value as they are only effective in autosomal dominant 
ichthyosis vulgaris, whereas the more severe ichthyosis subtypes do not improve 
sufficiently. Recently, we demonstrated a good clinical improvement of lamellar and 
epidermolytic ichthyosis with topical calcipotriol (15). However, to prevent derangements 
in calcium metabolism, the maximum weekly amount has been limited to 100 grammes. 
This limitation constitutes a restriction for its use, as in these severe ichthyosis patients, a 
substantial part of the total body surface is affected. The use of topical retinoids has been 
limited because of irritative side effects (16). However, 13-cis-relinoic acid constitutes an 
exception to this rule, and might be useful in the topical treatment of ichthyosis (17). 
The present study was performed to investigate the effectiveness and tolerability of 
liarozole 5% cream in 12 patients with hereditary ichthyoses. Immunohistochemical 
parameters of epidermal differentiation and inflammation were assessed before and after 
treatment. 
PATIENTS AND METHODS 
In a randomized, double blind, placebo controlled, left-right comparative study, 12 
patients with a hereditary ichthyosis, were treated with topical liarozole (liarozole 
fumarate) 5% cream and the cream base only. The following ichthyoses could be 
distinguished: 6 patients with X-linked recessive ichthyosis (XRI), 4 with non 
erythrodermic lamellar ichthyosis (NELI), and 2 patients with congenital bullous 
ichthyotic erythroderma of Brocq (CBIE). After a wash-out phase (2-4 weeks) the lesions 
were treated at one side with liarozole 5% cream and at the contralateral side with the 
cream base only for a period of 6 weeks. In an open follow-up phase, both sides of the 
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body were treated with liarozole cream for 4 weeks. The creams were applied thinly and 
evenly, twice daily. Written informed consent was obtained after the nature of the 
procedures had been fully explained. XRI-patients had a documented steroidsulphatase 
deficiency, and sun exposure had to be avoided. Patients were examined before 
treatment, at week 0,2,4,6 of the double-blind treatment phase, and at the end of the 
open treatment. At each visit, severity and extent of the skin lesions was assessed by the 
investigator. The severity of involvement was rated using a 4 point scale for scaling, 
roughness, hyperpigmentation, erythema, and bullae, as follows: 0 = absent, 1 = mild , 2 
= moderate, 3 = severe. Scaling and roughness were recorded in all subgroups, 
hyperpigmentation only in XRI, erythema and bullae in CBIE. The extent of involvement 
was recorded for the left and right side of the upper and lower extremities separately and 
expressed in % of the surfaces of these body parts, going from 0 to 100%. An overall 
response to treatment was documented by the investigator and the patient at each visit for 
severity and extent of involvement, on a five-point scale: worse, unchanged, slightly 
improved, markedly improved, and cleared. 
Haematological, biochemical, urinary, and endocrinological examinations assessing 
Cortisol, testosterone, oestradiol, and luteinizing hormone, were performed at week 0, 6 
and 10. Plasma samples for drug level analysis were taken at week 6 and 10 of the 
treatment. At the start and the end of the double-blind treatment phase, a photographic 
documentation was done under standardized conditions. Statistical analysis was 
performed using the Wilcoxon signed-rank test for paired data. 
Biopsies from representative skin lesions were taken, one at the start and one from each 
side at the end of the double-blind treatment phase. The biopsies were snap frozen in 
liquid nitrogen and stored at -80°C until processing. Slices of 4 μηι were cut and fixed in 
acetone for 10 minutes. Staining to assess epidermal keratinization, and epidermal and 
dermal inflammation, was done, using the following antibodies: 
Keratinization 
Ks8.12 (Sigma, St Louis, USA): directed against keratin 13 and 16. Keratin 13 is a fetal 
cytokeratin, not present in adult human skin, induced after retinoid treatment. Keratin 16 
is expressed by hyperproliferative keratinocytes. 
RKSE60 (gift of F. Ramaekers, Dept. of Medicine, Pathology, University Hospital 
Maastricht): binding keratin 10, expressed in differentiated epidermis. 
6B10 (Eurodiagnostics, Apeldoorn, Netherlands): directed against keratin 4. Keratin 4 is 
another cytokeratin, not present in adult human skin, induced after retinoid treatment. 
1C7 (Eurodiagnostics, Apeldoorn, Netherlands): binding keratin 13. 
Inflammation 
Anti-elastase (Serotec, Oxford, England): staining leucocyte elastase, present in 
polymorphonuclear leucocytes. 
Tl 1 (Dakpopatts, Copenhagen, Denmark): staining CD2, present on T-lymphocytes. 
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WT14 (Dept of Medicine, Nephrology, University Hospital Nijmegen): directed against 
CD 14, present on monocytes and macrophages. 
OKT6 (Ortho Diagnostic Systems, Raritan, USA): staining CD la, present on Langerhans 
cells. 
An indirect alkalic phosphatase technique was used for staining with the antibodies Ki-67 
and anti-elastase. Slides were incubated for 60 minutes with the primary antibodies. After 
washing in phosphate buffer saline (PBS) the slides were incubated with a solution of 
rabbit-anti-mouse-immunoglobulin conjugated with alkalic phosphatase for 30 minutes. 
After washing in PBS, slides were stained with fast red, counterstained with Mayer's 
haematein and mounted in glycerin gelatin. 
Staining with Ks8.12, RKSE60, 6B10, 1C7, Ti l , OKT6 and WT14, was carried out 
using an indirect peroxidase technique. Slides were incubated for 60 minutes with the 
primary antibody. After washing in PBS, the slides were incubated with a solution of 
rabbit-anti-mouse-immunoglobulin conjugated with peroxidase for 30 minutes. After 
washing in PBS, the peroxidase label was visualized by incubation with 3.3 
diaminobenzidintetrahydrochloride (DAB) solution as a substrate. Subsequently, they 
were incubated with CuS04 for 5 minutes, counterstained with Mayer's haematein, 
dehydrated and mounted in permount. The whole procedure was performed at room 
temperature. 
Presence in the epidermis and dermis of the stained structures was assessed using a semi-
quantitative scale: 
Epidermis: 0= no staining; 1= sporadic staining; 2= minimal staining; 3= moderate 
staining; 4= moderate-pronounced staining; 5= pronounced staining; 6= whole epidermis 
stained. 
Dermis: 0= no presence; 1= sporadically present; 2= 1-25% of infiltrate cells stained; 3= 
26-50% of infiltrate cells stained; 4= 51-75% of infiltrate cells stained; 5= 76-99% of 
infiltrate cells stained; 6= 100% of infiltrate stained. 
RESULTS 
Extent and severity of skin involvement, assessed by the investigator, are summarized in 
Table I, and Figure 1, 2, and 3. 
Wash-out phase. During the wash-out phase, the extent and severity of the lesions 
hardly changed. 
Double-blind treatment phase. At the start of the double-blind treatment phase, the 
extent of skin lesions on the upper extremities was 87%. At the end of this phase, the 
extent was reduced to 44 % at the liarozole treated side (p=0.001) and 69% at the 
placebo treated side (p<0.005). The difference in reduction between both sides was 
statistically significant in favour of the liarozole treated side (p<0.005). The severity of 
scaling and roughness was strongly reduced at the liarozole treated side (scaling 
p=0.0005; roughness p=0.0005), but not at the placebo treated side. Also in this respect, 
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analysis of the difference between both sides revealed that liarozole was superior to 
placebo (scaling p=0.0005; roughness p=0.0005). 
Follow-up phase. After 4 weeks of bilateral treatment with liarozole, a considerable 
reduction of the extent of skin lesions (-24%) was found at the previously placebo treated 
arms (p<0.01), whereas only a moderate reduction (-11%) was found at the contralateral 
side (p<0.1). Analysis of the difference in shifts between both sides, displayed an 
improvement in favour of the previously placebo treated side (p<0.05). With regard to 
severity, the previously placebo treated arms showed a reduction of scaling (p<0.005) 
and roughness (p<0.005), which was absent at the contralateral side. Comparing both 
sides, again revealed improvement in favour of the previously placebo treated side 
(scaling p<0.005; roughness p<0.005). 
As shown in Table I, the development of extent and severity of lesions on the legs in 
both double-blind treatment and follow-up phase, parallel the shifts described for the 
arms. 
Table I. Extent and severity of skin lesions. Statistical testing on the difference in the change 
between treatment sides, compared to baseline values: * pá0.05 *· psO.Ol •** p^O.001. The 
asterisks are placed in the column corresponding to the side of the body where the improvement was 
statistically significantly better. 
extent of lesions on arms (%) 
week 0 
week 6 
week 10 
extent of lesions on legs (%) 
week 0 
week 6 
week 10 
severity of scaling on arras 
week 0 
week 6 
week 10 
severity of roughness on arms 
week 0 
week 6 
week 10 
severity of scaling on legs 
week 0 
week 6 
week 10 
severity of roughness on legs 
week 0 
week 6 
week 10 
liarozole placebo 
side side 
86% 86% 
44%·· 69% 
33% 45%·· 
87% 87% 
57%·* 74% 
48% 58%· 
2 50 2.50 
1 08·*· 2.33 
1.00 1.36** 
2.50 2.50 
1.0B*** 2.33 
1.00 1 36** 
2 67 2.67 
1.50*« 2.33 
1.45 1.82 
2 67 2 67 
1.50** 2.33 
1.45 1.82 
87 
severity ol scaling on the arms 
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Fig. 1 The severity of skin lesions shows definite improvement in favour of the harozole treated side 
during the double-blind treatment phase, whereas a reversed effect is observed during the open 
treatment phase. 
extent ol lesions on the arms (in percentages) 
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Fig. 2 In the double-blind treatment phase, reduction of skin lesions on the arms is considerable (86 
to 44%) at the Harozole treated side, whereas improvement is only modest at the cream base treated 
side (86 to 69%). 
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Fig. 3 
a. NELI patient before treatment, exhibiting 
large brown scales covering a substantial part 
of the skin surface. 
b. NELI patient at the end of the double-
blind treatment, showing marked improve­
ment at the liarozole treated left side, 
whereas improvement at the cream-base 
treated right side is only small. 
с After 6 weeks double-blind and 4 weeks 
open liarozole treatment, improvement is 
marked on both sides. At the previously 
cream-base treated right side, minimal scaling 
is still visible. 
Adverse experiences, were mentioned by 6 patients, and are summarized in Table II. In 5 
patients, they are probably liarozole related, since they were present only at the liarozole 
treated side. Two patients stopped treatment because of adverse experiences. One patient 
stopped at the end of the double-blind treatment phase because of erythematous itching 
papules at the liarozole treated side, probably due to liarozole. Another patient stopped 
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treatment during the follow-up phase after 8 weeks of treatment because of contact 
eczema, which started already during the wash-out phase, and therefore probably related 
to the cream-base. No significant changes of haematological, biochemical, and urinary 
parameters were found. Endocrinological examinations revealed after 0, 6, and 10 weeks 
of treatment, a reduction in the plasma oestradiol concentration. No relevant changes 
were found in all other hormones tested (Cortisol, testosterone, LH). Drug plasma 
concentrations of liarozole could be measured in 10 patients after 6 and 10 weeks of 
treatment and varied strongly (Figure 4). No correlation could be established between the 
liarozole and oestradiol plasma concentrations. The plasma concentration seems to be 
related to the type of ichthyosis. The highest concentrations were found in patients with 
NELI, the lowest in patients with XRI. Only the patient with the highest plasma 
concentration showed a marked improvement at the placebo treated side during the 
double-blind phase. This was the only patient who had completely cleared arms at the 
end of the follow-up phase. 
Table II. Per trial phase, the side of the body (liarozole treated or placebo treated) of the adverse 
experience is mentioned. (A) dose reduction, (B) temporary stop, treatment continuation, permanent 
stop, (C) temporary stop, (D) dose reduction, (E) permanent stop. 
Table II: Survey of adverse experiences. 
pat. 
no. 
1 
2 
Э 
4 
5 
9 
Adverse experience 
ITCH ON TRUNK 
DRY LIPS 
- ITCH 
- ERYTHEMATOUS PAPULES ON ARM 
- ITCHING ERYTHEMATOUS PAPULES/ LEG 
BILATERAL CONTACT ECZEMA ON 
NATES, UPPER LEGS AND ABDOMEN 
ITCH ON TRUNK 
PARESTHESIA AFTER APPLICATION 
OF CREAM 
wash-out 
phase 
placebo (C) 
double-blind 
phase 
liarozole (A) 
liarozole (B) 
placebo + 
liarozole (D) 
liarozole 
liarozole 
open 
phase 
liarozole 
liarozole 
liarozole (E) 
Per trial phase, the side of the body (liarozole-treated or placebo-treated) of the AE is 
mentioned. 
(A) dose reduction 
(B) temporary stop, treatment continuation/ permanent stop 
(C) temporary stop 
(D) dose reduction 
(E) permanent stop 
Staining for keratin 4 and 13 was absent at baseline. After 6 weeks of treatment, a slight 
induction of keratin 4 was found in 3 patients (1 NELI, 2 CBIE) patients, and an 
induction of keratin 13 in one CBIE patient. Expression was only found at the liarozole 
treated side. Treatment with liarozole did not change the baseline expression of keratin 
10 which could be detected within the suprabasal compartment. None of the 
inflammatory parameters did significantly change upon treatment. 
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Fig. 4 A remarkable difference is observed in liarozole plasma concentrations, measured after 6 and 
10 weeks of treatment. Concentrations appear rather high in NELI, moderate in CB1E, and low in 
XRI. 
DISCUSSION 
In this double-blind, placebo-controlled trial, it has been demonstrated that liarozole 5% 
cream is effective in various forms of ichthyosis (XRI, NELI, CBIE). After 4 and 6 
weeks of treatment, the extent of the lesions and the severity of scaling was statistically 
significantly more reduced at the liarozole-treated side than at the placebo-treated side. 
This liarozole-induced improvement was robust, so statistically significant differences 
with placebo were already obtained in a small trial with 12 patients. The effectiveness of 
liarozole was also evident in the follow-up phase, were both sides of the body were 
treated with liarozole. In the follow-up phase, the largest improvement was found at the 
previously placebo-treated side, reflecting a catching-up effect. Overall, the spectrum of 
side effects of topical liarozole is similar or milder to that of calcipotriol or topical 
retinoids. Nevertheless, two patients discontinued treatment because of side effects. In 
one case, side effects were related to the cream base rather than to liarozole. Liarozole is 
known to be an inhibitor of estrogen biosynthesis. In this trial a reduction of the plasma 
estradiol concentration was found after topical administration of liarozole. However, the 
amount of estradiol reduction was not related to the plasma concentration of liarozole. 
Liarozole is clinically effective by its inhibition of the cytochrome P450- dependent 
break-down of endogenous retinole acid. Consequently, liarozole increases tissue levels 
of retinole acid. Topical liarozole induces the fetal keratins 4 and 13 at the liarozole 
treated side only. This induction is probably a consequence of the increase in the amount 
of endogenous retinole acid, for induction of keratins has also been found after topical 
administration of retinoids (18,19). 
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In this trial we discovered that administration of liarozole cream resulted in rather high 
plasma concentrations in patients with NELI or CBIE, but less in patient with XRI. 
Between these groups no significant differences were found in the amount of liarozole 
used, so the differences in plasma concentrations might be explained by skin differences, 
resulting in differences in the absorption of liarozole. NELI and CBIE represent 
hyperproliferative ichthyosis subtypes (20). Consequently, the demand for nutrients and 
therefore dermal blood supply, are probably higher compared to subtypes characterized 
by normal proliferation, such as XRI. This might explain the differences in liarozole 
absorption. The highest plasma concentrations measured after topical administration 
could be clinically relevant: the strongest improvement at the placebo-treated side was 
found in the patient with the highest plasma level of liarozole. This NELI patient had 
levels comparative to the peak plasma levels found in healthy volunteers after a single 
oral dose administration of 37.5 mg. 
In conclusion, liarozole 5% cream is effective in the treatment of various ichthyosis 
subtypes. The clinical improvement is probably achieved by a local inhibition of the 
endogenous breakdown of retinoic acid. Consequently the concentration of retinole acid 
is elevated specifically in the target epidermal cells, minimalizing the risk of systemic 
effects, as illustrated by the good tolerance in this trial. Liarozole plasma concentrations 
could be measured indicating systemic resorption of liarozole. However, as consistent 
clinical improvement and biochemical induction of keratins were only observed at the 
liarozole treated side, circulating retinoic acid must be low or absent. Plasma liarozole 
levels might exert hormonal effects, as the oestradiol levels were decreased in some 
patients. These however were not correlated with the liarozole plasma concentrations, and 
patients did not experience hormonal side effects. These were also lacking during oral 
liarozole treatment of ichthyosis (21) and psoriasis (11). 
Therefore, liarozole 5% cream represents a new concept which is of interest as it might 
represent a clinical effective and safe therapeutical option without systemic retinoic acid 
effects. As a certain degree of systemic resorption of liarozole is present, future studies 
remain to be performed to establish safety parameters. 
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Chapter 7 
Topical treatment of Darier's disease with 13-cis-
retinoic acid. A clinical and immunohistochemical 
study. 
GPH Lucker 
PCM van de Kerkhof 
FACM Castelijns 
PM Steijlen 
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SUMMARY 
In a prospective, double-blind, left-right comparative study, a cream containing 13-cis-
retinoic acid 0.1% (13-cis-RA) and its cream base were applied on a test patch of skin 
during a period varying between 3 and 10 weeks in 7 patients with Darier's disease. A 
half-side reduction of papules was observed in 4 patients. The treatment had no effect on 
scaling and increased erythema in 2 patients. Clinical improvement of papules was 
statistically significant, whereas scaling and erythema did not change significantly. Side 
effects due to the study medication were only minimal and easily controlled by reduction 
of the application frequency. Biopsies for immunohistochemical examination were taken 
from representative skin lesions, one before and one from each side after treatment. 
Keratins 4 and 13, were induced by the treatment with topical 13-cis-RA in 3 and 2 
patients respectively. 
In conclusion, topical 13-cis-RA 0.1% cream is a well-tolerated therapy for Darier's 
disease. Induction of keratins 4 and 13 seems to offer an immunohistochemical tool for 
the investigation of the mode of action of 13-cis-RA. 
INTRODUCTION 
Darier's disease is an autosomal dominant monogenic disorder of keratinization, 
characterized by changes in epidermal differentiation and increased proliferation. Oral 
application of retinoids is very effective in alleviating Darier's disease (1). Because of 
the risk of systemic side effects, topical application would be preferable. Beneficial 
effects of topical treatment with all-trans-retinoic acid in disorders of keratinization, have 
been documented (2-6). Irritation of the skin, however, has limited its use to the 
treatment of acne. Compared to the intolerable tenderness caused by treatment with all-
trans-retinoic acid, irritation induced by treatment with 13-cis-RA is negligible. Recently, 
good clinical results were observed in Darier's disease with 13-cis-RA 0.1% (7,8,9). The 
aim of the present study was to evaluate the clinical efficacy of prolonged topical 
application of 13-cis-RA 0.1% in 7 patients with Darier's disease. Furthermore, 
immunohistochemical assessment was made of parameters of proliferation, keratinization, 
and inflammation, using monoclonal antibodies. 
PATIENTS AND METHODS 
Patients 
Seven patients with Darier's disease were treated with topical 13-cis-retinoic acid after 
informed consent was obtained. Details regarding sex, age, duration of treatment, reason 
for discontinuation, and side effects are summarized in Table I. Topical as well as 
systemic treatment was stopped respectively 2 and 4 weeks before the study medication 
was started. In every patient two comparative and representative test areas of 10x10 cm 
were selected. In this prospective, double-blind, left-right comparative study, a cream 
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containing 13-cis-RA in 0.1% concentration and the cream base only (Hofmann-la 
Roche, Basel, Switzerland) were applied during a period varying between 3 and 10 
weeks. Patients were instructed to apply the creams thinly and evenly twice daily. In case 
of intolerable irritation, they were advised to reduce the application frequency. Papules, 
scaling, and erythema were scored using a 4 point scale, in order to establish clinical 
efficacy. Statistical analysis was carried out using the Wilcoxon signed-rank test for 
paired data. 
Table I. Patient details and tolerability to 13-cis-RA 
patient 
1 
2 
3 
4 
5 
6 
7 
sex 
F 
F 
M 
M 
M 
F 
M 
age 
43 
52 
20 
19 
28 
49 
21 
duration of 
treatment 
(weeks) 
10 
3 
10 
10 
8 
6 
10 
reason for 
discontinuation of 
trial medication 
end of study 
worsening of Darier 
end of study 
end of study 
worsening of Darier 
clearance of skin 
lesions at the cream-
base treated side 
end of study 
side effects 
13-cis-RA 
side 
burning, itching 
irritation 
none 
itching 
itching 
none 
none 
side effects 
cream base 
side 
none 
irritation 
none 
none 
irritation 
none 
none 
Analytical procedures 
Biopsies from representative skin lesions within the test areas were taken, one at the start 
and one from each area at the end of treatment. To assess epidermal proliferation, 
keratinization and epidermal and dermal inflammation, the slides were stained using the 
monoclonal antibodies summarized in Table II. Staining procedures were carried out as 
described previously (10). 
RESULTS 
Clinical response 
Patient details and side effects of the treatment with 13-cis-RA and the cream base are 
summarized in Table I. Table III provides the efficacy results for the individual patients. 
At the end of the study, a half-side reduction of papules was observed in 4 out of 7 
patients in favour of the 13-cis-RA treated side (patient 1, 3, 4, and 7). Patient 5 
demonstrated a clear half side effect in favour of the 13-cis-RA treated side after 4 
weeks, followed by a relapse of the disease on both sides, requiring systemic treatment 
with acitretin. Patient 2 did not show a half side effect. She was withdrawn from the 
study because of a severe relapse requiring systemic treatment with acitretin. Half-side 
improvement of scaling in favour of the 13-cis-RA treated side, was only observed in 
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patient 3. Patient 6 displayed a remarkable improvement of both induration and scaling at 
the cream-base treated side, whereas improvement was only moderate at the 13-cis-RA 
treated side. In 2 of the 4 responders, worsening of erythema was observed on the 13-cis-
RA treated side. The reduction of papules at the 13-cis-RA treated side compared to the 
cream base side was statistically significant (p<0.05). The slight increase of erythema 
was not statistically significant 
As side effects, burning and itching were reported in 1 and 3 patients respectively. These 
were not severe and diminished by reducing the treatment frequency. 
A considerable interindividual variation concerning the duration of treatment necessary 
for reduction of skin lesions was noticed. Of the 4 responders, 2 did not improve until 
the second month of treatment. In one of the 2 patients responding in the first month, 
further improvement was achieved by continuing the treatment. 
Table II. Antibodies used in the study 
Monoclonal 
antibody 
6B10 
1C7 
2D7 
RCK102 
RCK107 
LL002 
RCK105 
Cam5.2 
M20 
LE4.I 
RGE53 
RCK106 
CK 18.2 
2C8 
LP2K 
RCK108 
Ks8.12 
RKSE60 
КІ67 
LEU 14 
OKT6 
WT14 
Til 
anti-elastase 
Antigen 
cytokeratin 4 
cytokeratin 13 
cytokeratin 13 
cytokeratin S (and 8) 
cytokeratin 14 
cytokeratin 14 
cytokeratin 7 
cytokeratin 8 
cytokeratin 8 
cytokeratin 8 
cytokeratin 18 
cytokeratin 18 
cytokeratin 18 
cytokeratin 18 
cytokeratin 19 
cytokeratin 19 
cytokeratin 13 and 16 
cytokeratin 10 
nuclear antigen 
CD22 
CD1A 
CD14 
CD2 
elastase 
Location of antigen 
foetal skin and stratifying, non-cornifying 
(suprabasal) cells 
basal cells 
simple epithelial cells 
foetal skin and hyperproliferative keratinocytes 
stratifying, comifying suprabasal cells 
cycling cells 
B-lymphocytes 
Langerhans cells 
macophages and monocytes 
T-lymphocytes 
polymorphonuclear leucocytes 
Histological findings 
The markers for keratin staining patterns did not show consistent changes, except for the 
monoclonal antibodies 6B10 and 1C7, staining keratin 4 and 13. Whereas staining was 
absent before treatment, staining for keratin 4 and 13 (mab 1C7) was observed in 3 
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(patient 1, 3, and 4) and 2 (patient 1 and 2) patients respectively, after treatment (Fig. 1). 
Staining was only found at the 13-cis-RA treated side. The average number of cycling 
cells per millimetre epidermis is shown in Table IV. No changes were found for the 
investigated parameters of inflammation. 
Table III. Clinical effects of topical 13-cis-RA 
Patient no. 
Effect on induration 
1 
2 
3 
4 
5 
6 
7 
Effect on scaling 
1 
2 
3 
4 
5 
6 
7 
Effect on erythema 
1 
2 
3 
4 
5 
6 
7 
start 
3 
2 
2 
3 
2 
3 
2 
1 
1 
I 
0 
1 
3 
0 
1 
2 
0 
0 
0 
2 
0 
Vehicle 
4wlcs 
2 
* 
2 
3 
2 
1 
2 
0 
* 
1 
0 
1 
0 
0 
1 
* 
0 
0 
1 
2 
0 
end 
3 
3 
2 
3 
2 
0 
2 
0 
1 
1 
0 
2 
0 
0 
1 
2 
0 
0 
2 
1 
0 
start 
3 
2 
2 
3 
2 
3 
2 
1 
1 
1 
0 
1 
3 
0 
1 
2 
0 
0 
0 
2 
0 
13-cis-RA 
4wks 
2 
* 
2 
1 
0 
2 
2 
0 
* 
1 
0 
I 
2 
0 
2 
* 
0 
1 
2 
1 
0 
end 
1 
3 
1 
1 
2 
2 
1 
0 
1 
0 
0 
1 
1 
0 
2 
2 
0 
1 
2 
1 
0 
Patient withdrawn from the study because of a severe relapse. 
Table Г . Expression of Ki-67 positive cells 
patient 
1 
2 
3 
4 
5 
6 
7 
average 
before treatment 
99 
56 
166 
90 
140 
238 
81 
124 
13-cis-RA side 
174 
180 
141 
122 
152 
115 
147 
162 
cream-base treated side 
95 
244 
103 
225 
332 
57 
240 
185 
100 
ι — * 
' · f - » Y * 
Fig. 1 Staining pattern of the monoclonal antibody 6B10, indicating keratin 4, in patient 3 at the 13-
cis-RA treatedside, after treatment. 
DISCUSSION 
Seven patients with Darier's disease were treated in a prospective, double-blind, 
bilaterally paired study, with a cream containing 13-cis-retinoic acid 0.1% and its cream-
base only, for a period varying between 3 and 10 weeks. A statistically significant 
reduction of papules was observed. Irritation was minimal and could be controlled easily 
by reduction of the application frequency. Elongation of the treatment beyond the first 
month caused further improvement of the clinical results. Immunohistochemical 
assessment, revealed staining of keratin 4 in 3 and keratin 13 in 2 patients, at the 13-cis-
RA treated side only. No induction was observed at baseline. Compared to baseline, Ki-
67 was elevated after treatment at both sides. Nevertheless, the average number of Ki-67 
positive cells at the 13-cis-RA treated side was lower than that at the cream-base treated 
side. 
The good clinical results are in accordance with previous observations (7,8,9). Increasing 
the length of the treatment period from 4 to 10 weeks, improved the response to topical 
retinoids. Those patients not responding to topical 13-cis-RA, and requiring additional 
treatment, improved on systemic retinoids, indicating that oral acitretin is more effective. 
As keratin 4 was induced in 3/4 responders and keratin 13 in 1 responder and 1 non-
responder, induction seems to offer an immunohistochemical tool for the investigation of 
the mode of action of 13-cis-RA, as suggested previously (8). The increase of the 
number of cycling cells after treatment showed great interindividual differences without a 
clear correlation with the clinical results, and therefore remains difficult to explain. 
However, the tendency for proliferation to be lower at the 13-cis-RA treated side, 
compared to the cream-base treated side, might be explained by the normalizing effect of 
retinoids on deregulated proliferation (11). 
Topical treatment with retinoids may be improved by raising the concentration to 0.2% 
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(11) or even 0.3% (12). Addition of UVA-blocking agents may prevent conversion of 
isotretinoin to tretinoin (13), and therefore reduce local irritation, so the concentration of 
13-cis-RA can be raised even more. Application of retinoids under plastic occlusion have 
been reported to induce remissions, persisting for about 3 months at the treated areas 
(4,5). The choice of the cream base is essential, for retinoid absorption is highly vehicle 
dependent. The penetration through stratum comeum and hence bioavailability of topical 
retinoids, is greatest when the drug is administered in isopropyl alcohol, followed by 
mineral oil, diisopropyl adipate and polyethylene glycol (14). Other retinoids may be 
more effective as a topical treatment for Darier's disease. With respect to interference 
with epidermal differentiation, arotinoids are the most potential retinoids, followed by 
etetrinate, tetrazol-retinamides and isotretinoin/tretinoin (IS). 
It has been shown that topical application of the retinoids isotretinoin and acitretin can 
produce dermal concentrations in excess of those produced by therapeutical oral doses of 
these drugs (14). Therefore it is attractive to speculate that topical treatment with 
retinoids constitutes a promising approach in the treatment of Darier's disease. 
At the moment, however, oral retinoids seem to be more potent in the treatment of 
Darier's disease than the topical retinoids available. Nevertheless, topical 13-cis-RA 0.1% 
offers a new and well-tolerated alternative for systemic retinoid treatment in Darier's 
disease. Optimalisation of bioavailability and development of new topical retinoids are 
worthwhile. 
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Palmoplantar keratodermas 
Part 2 

Introduction 
As has been elucidated in the general introduction, the development of the nosology of 
HPPK's has not yet been completed so far. New reports of cases which do not fit in the 
existing nosology require a critical reappraisal of the classification. The absence or 
presence of associated clinical conditions, not fitting in the available descriptions, and 
therefore warranting extension of the previous nosology, are illustrated in chapters 1 and 
2 of this part of the thesis. Chapter 3 demonstrates the simultaneous presence of two 
previously considered unrelated HPPK's, enabling a simplification of the present 
nosology. For day to day praxis, misdiagnosis of HPPK's may have a serious long-term 
impact on the quality of life of a patient. In chapter 4 the consequences of a 
misdiagnosis of a patient suffering from Olmsted's disease as acrodermatitis enteropatica 
who has been treated with zinc suppletion for years, illustrate such. Chapter 5 further 
illustrates that classifying the individual patient with a HPPK properly is not an 
academical exercise, but of practical relevance for good patient management. In this 
patient unfortunately, the correct diagnosis HPPK of Huriez was just made after she had 
developed 3 squamous cell carcinomas of the affected skin, which might have been 
prevented by a correct diagnosis in an earlier stage. Concerning therapeutical options, 
systemic retinoids might be effective for several HPPK's. Nevertheless, HPPK's exhibit 
distinct disease specificity concerning the sensitivity to retinoids (1). Good results have 
been reported in HPPK Greither (2), Papillon-Lefevre (1, 3-5), mal de Meleda (1,6-8), 
Vohwinkel (9-11), and pachyonychia congenita (12,13). Mild improvement has been 
noticed in PPK varians Wachters (1), whereas variable results have been achieved in 
HPPK Unna-Thost (1) and the Olmsted's syndrome (14-17). In case of epidermolytic 
hyperkeratosis, retinoid treatment usually leads to severe skin erosions and consequently 
intolerable tenderness of the palmoplanar skin (18,19). Therefore, the search for 
alternatives for systemic retinoids is important, particularly in HPPK's poorly responding 
to retinoid treatment such as Vomer's disease. Chapter 4 introduces an alternative 
therapeutical method which proved to be successful in alleviating the pain in a case with 
HPPK of Olmsted, poorly responding to retinoids. In chapter 6 a topical treatment is 
described in HPPK of Vomer, which might offer an alternative to retinoid treatment. 
Classification should be comprehensive, but simple. Classification should on one hand 
define separate diseases in a genetic sense, but on the other hand provide the 
dermatologist with leads to the management of care. Finally, in chapter 7 a new approach 
to the nosology of palmoplanar keratodermas is provided. 
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Chapter 1 
Pachyonychia congenita in the absence of other 
syndrome abnormalities. 
A Chang 
GPH Lucker 
PCM van de Kerkhof 
PM Steijlen 
J Am Acad Dermatol 1994;30:1017-1018 

INTRODUCTION 
Pachyonychia congenita was first described by Jadassohn and Lewandowski [1] in 1906. 
Nail changes that affect all nails symmetrically are the hallmark of the disease. The base 
of the nails appears to be normal but the free edge is raised by a thick, subungual 
hyperkeratosis. The lateral borders often angulate toward the center. Associated 
symptoms include palmoplantar hyperkeratosis, follicular keratosis, xerodermia, 
palmoplantar hyperhidrosis, and blisters on the soles of the feet. Leukokeratosis of the 
tongue and buccal mucosa, corneal abnormalities, and malformations of the teeth have 
also been described [2]. On the basis of the presence and prevalence of associated 
symptoms, numerous subdivisions of pachyonychia congenita have been suggested [3-5]. 
Both autosomal dominant and autosomal recessive [6] forms have been described, 
reflecting heterogeneity. 
We describe a Moroccan family with nail deformities in the abscence of other syndrome 
abnormalities, which demonstrates that the coexistence of associated symptoms is not an 
absolute prerequisite for the diagnosis of pachyonychia congenita. 
L D O O Ó Ù 
I I I ! 
I I (__) male, female, unaffected 
^ | ^ P male, female, affected 
Fig. 1 Pedigree of family manifesting a monosymptomatic form of pachyonychia congenita. Circle, 
Female; square, male; shaded symbols, affected; open symbols, unaffected. 
CASE REPORT 
Several members of a family had nail deformities that had been present since the first 
months of life. Affected members were the grandmother, the father, and his four sons, 
ages 73, 51, 21, 19, 16, and 13 years, respectively. The mother and four other siblings 
were not affected (Fig. 1). There was no history of consanguinity. In the affected persons 
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all nails of hands and feet showed symmetric thickening and hardening, with yellow-
brown discoloration, subungual hyperkeratosis, and upward growth of the distal nail with 
hypercurvature (Fig. 2). On further examination, the affected persons had no deformities 
of the skin, hair, mucous membranes, eyes, or teeth. To exclude onychomycosis, nail 
cultures were examined for the presence of fungi. All cultures were negative. 
No treatment was given because the patients' complaints were of a cosmetic nature only. 
Fig. 2 Fingernail shows thickened nail plate, subungual hyperkeratosis, and upward growth of the 
distal nail with hypercurvature. 
DISCUSSION 
The nail changes of all five affected family members consisted of symmetric thickening, 
subungual hyperkeratosis, and upward growth of the distal nail with angulation of the 
lateral borders toward the center. All nails were equally affected. The nail changes had 
been present since the first months of life. The pedigree is consistent with an autosomal 
dominant mode of inheritance. 
In the differential diagnosis, congenital onychogryphosis and pachyonychia congenita 
must be considered. Congenital onychogryphosis is a hereditary nail disorder with an 
autosomal dominant mode of inheritance. Associated features are lacking. 
Onychogryphosis appears in adolescence, affects predominantly the thumb and large 
toenails, and lacks massive subungual hyperkeratosis; the nails curve downward at the 
free margin [7]. Pachyonychia congenita is characterized by nail changes similar to those 
of our patients; all nails are symmetrically affected, and the condition appears within the 
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first months of life. Furthermore, the coexistence of associated features is characteristic 
of the disease. 
The nail deformities present in our patients are characteristic of pachyonychia congenita, 
although the associated findings of the syndrome are lacking. Therefore the family 
appears to represent a monosymptomatic form of pachyonychia congenita. In thse 
patients the same gene is probably affected as in other cases of autosomal dominant 
pachyonychia congenita; however, it may represent a different allele, resulting in a 
milder phenotype. 
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SUMMARY 
Pachyonychia congenita is a distinct hereditary disorder of keratinization, in which 
dystrophy of all nails is associated with palmoplantar keratoderma and other 
hyperkeratoses. Recently a late-onset type has been reported. We report a second family 
with late-onset pachyonychia congenita, showing a remarkable clinical heterogeneity. 
Furthermore, one patient demonstrated a number of associated hyperkeratoses not 
previously recognized. Acitretin proved useful in the treatment of this late-onset form of 
pachyonychia congenita. 
INTRODUCTION 
Pachyonychia congenita has been described by Muller in 1904 [1] and Wilson in 1905 
[2]. Jadassohn and Lewandowski reported in 1906 on the association with palmoplantar 
keratoderma and other ectodermal defects [3]. Since then, the presence of associated 
features has been considered essential for the diagnosis. Based on the prevalence of the 
associated symptoms, several classifications have been proposed [4-7]. We recently 
described a monosymptomatic form of the disease, lacking the associated anomalies of 
the syndrome [8]. Both autosomal dominant and autosomal recessive [9] modes of 
inheritance have been described, reflecting genetic heterogeneity. Dystrophy of all nails 
is the main feature of the syndrome and usually presents within the first months of life. 
Recently five patients were observed with the onset of the characteristic nail changes 
during the second and third decades of life [10]. The term pachyonychia congenita tarda 
was proposed to describe this subset of pachyonychia congenita, characterized by 
palmoplantar keratoderma, hyperhidrosis and oral leucokeratosis associated with the nail 
lesions. No other hyperkeratoses were found to be associated. 
We have observed a second family with the late-onset type of pachyonychia congenita, 
exhibiting remarkable phenotypic heterogeneity. Combined topical keratolytic and oral 
retinoid treatment was started in one family member with a number of associated 
hyperkeratoses. 
CASE REPORT 
A 45-year-old man presented with a hyperkeratotic skin disorder localized to the nails, 
palms, soles, knees, lower legs, face and scalp. The dermatosis had started at the age of 
44 and had progressed rapidly. Painful plantar keratoderma prevented him from walking. 
On examination, all nails were dystrophic (Fig. 1). The free edges were raised by thick 
subungual hyperkeratosis with angulation of the lateral borders towards the centre. All 
nails appeared to be affected equally. In addition, a diffuse, thick, warty palmoplantar 
keratoderma was present (Figs 2 and 3). Nummular hyperkeratoses were observed at the 
knees, and similar lesions were noticed at the forehead and the scalp. The lower legs 
were covered by large brown scales, mimicking lamellar ichthyosis. 
Family history revealed that his brother and father had similar, although less pronounced 
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nail changes (Fig 4), which had started in, respectively, the third and fourth decades of 
age. Neither had additional hyperkeratoses. 
Fig. 1 Characteristic dystrophic changes, affecting all nails symmetrically. At the dorsum of the right 
hand, two verrucous hyperkeratotic plaques are visible, extending from the palmar skin to the dorsal 
surfaces. 
Fig. 2 The plantar skin is diffusely covered by Fig. 3 Verrucous hyperkeratotic plaques at the 
a thick, warty hyperkeratosis, causing painful palmar surfaces. 
fissures. 
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Fig. 4 Nail changes observed in the patient's father, less pronounced though similar to those 
presented in Figure 1. 
Histopathological examination of a biopsy taken from the palmar skin revealed 
hyperkeratosis and acanthosis, consistent with palmoplanar keratoderma. Mycological 
culture and microscopic examination of the subungual hyperkeratosis proved negative. 
To remove the hyperkeratoses, topical treatment was given with salicylic acid 20% in 
petrolatum, resulting in a significant improvement within three weeks. Subsequently, oral 
retinoid treatment was started with acitretin 35 mg daily, to prevent new hyperkeratoses 
from developing. After 2.5 weeks of therapy, a further reduction of hyperkeratoses was 
observed (Fig. 5) and the daily dosage of acitretin was reduced to 20 mg for the next 6 
weeks, with continued improvement. Because of elevated liver enzymes, the daily dosage 
was further reduced to 10 mg for 4 weeks and eventually stopped, resulting in a relapse 
of the hyperkeratoses. The nail changes, however, responded poorly to the retinoid 
therapy. 
DISCUSSION 
The present communication reports a second family with pachyonychia congenita tarda. 
The characteristic nail changes, which had started in the third and fourth decades of life, 
were observed in all three affected family members. The patient described exhibited, in 
addition, a diffuse, incapacitating palmoplanar keratoderma, ichthyosiform scaling on 
both legs and nummular hyperkeratoses at the knees, face and scalp, which appeared 
simultaneously with the nail dystrophy. Associated dyskeratoses were absent in his two 
affected family members. 
In classical pachyonychia congenita, however, hyperkeratotic skin lesions, such as 
palmoplanar keratoderma, follicular keratosis, verrucosities over knees, elbows, buttocks 
and popliteal area, and oral leucokeratosis, have been well documented to be variably 
associated [11]. The range of associated hyperkeratoses and the variable expression we 
observed in our case with the late-onset variant of pachyonychia congenita are, therefore, 
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similar to pachyonychia congenita. Nevertheless, some additional hyperkeratoses we 
observed, including nummular hyperkeratoses on the face and scalp, as well as the 
ichthyosiform scaling on both legs, have not been described previously and are therefore 
new to the syndrome. 
Fig. 5 Palmar skin after 3 weeks of 
local keratolytic and 2.5 weeks of 
acitretin treatment. 
The inheritance pattern of our pedigree is highly suggestive of an autosomal dominant 
mode of inheritance, and therefore consistent with the other family with pachyonychia 
congenita tarda described [10]. 
There are no reports available at the moment on the therapy of pachyonychia congenita 
tarda. In classical pachyonychia congenita, retinoids have been reported to be effective in 
alleviating the palmoplantar keratoderma, the subungual hyperkeratosis [12], the keratotic 
patches on the knees and the leucokeratotic lesions in the mouth [13]. One of our cases 
demonstrates acitretin to be effective in preventing new hyperkeratoses from developing 
in the late-onset type. Simple local keratolytic measures proved useful in reducing the 
hyperkeratoses. 
We conclude that both the classical and late-onset variant of pachyonychia congenita are 
characterized by heterogeneity in expression of a number of associated hyperkeratoses. It 
seems rational to distinguish pachyonychia congenita tarda from pachyonychia congenita 
by the differences in age of onset. Retinoids constitute a promising approach to the 
treatment of the hyperkeratoses in both variants. 
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ZUSAMMENFASSUNG 
Keratosis palmoplantaris (KPP) varians und KFP punctata werden bisher als 
unterschiedliche Formen der kongenitalen Palmoplantarkeratosen aufgefaßt. Die Keratosis 
punctata der Palmarfurchen, durch stecknadelkopfgroße Hyperkeratosen innerhalb der 
palmaren Falten charakterisiert, ist als eigenständige Erscheinungsform einer KPP 
beschrieben worden. Wir berichten über einen 31jährigen Mann mit sowohl 
inselförmigen als auch erbsengroßen Hyperkeratosen an den Fußsohlen sowie 
stecknadelkopfgroßen Hyperkeratosen in den Palmarfurchen. Aufgrund der Koexistenz 
dieser kongenitalen Hautveränderungen kann man sich die Frage stellen ob KPP varians 
und KPP punctata wirklich eigenständige Entitäten sind oder variable Manifestationen ein 
und desselben Gendefekts darstellen. 
EINLEITUNG 
Verhornungsstörungen der Handteller und Fußsohlen stellen ein dermatologisches 
Leitsymptom für zahlreiche erbliche und nichterbliche Krankheitsbilder dar. Aufgrund 
morphologischer, histologischer und genetischer Kriterien können die hereditären 
Palmoplantarkeratosen im engeren Sinne klassifiziert werden, wobei gesetzmäßig 
auftretende assoziierte Symptome für eine weitere Differenzierung herangezogen werden 
[5]. Inselförmige Palmoplantarkeratosen ohne assoziierte Symptome werden als 
"Keratosis palmoplantaris varians" bezeichnet, wobei jedoch auch streifenförmige Formen 
einbezogen werden [6]. Histologisch läßt sich hiervon die klinisch ähnliche Keratosis 
palmoplantaris nummularis unterscheiden, da diese durch eine epidermolytische 
Hyperkeratose kennzeichnet ist [7]. Punktförmige Palmoplantarkeratosen ohne assoziierte 
Symptome werden in Keratosis palmoplantaris punctata [2], Akrokeratoelastoidose [3] 
und fokale akrale Hyperkeratose [1] unterteilt. Die Keratosis punctata der Palmarfurchen 
[8], als Variante der Keratosis palmoplantaris punctata beschrieben, ist durch kleine 
Hyperkeratosen in den Palmarfurchen charakterisiert. 
Berichtet wird über einen 31jährigen Patienten, der sich mit insel- und punktförmigen 
Hyperkeratosen an den Fußsohlen und vereinzelten punktförmigen Hyperkeratosen in den 
Beugefalten der Handflächen vorstellte. Ein zusammentreffen dieser bisher als 
eigenständig geltenden Entitäten ist, soweit uns bekannt, bislang noch nicht beschrieben 
worden. 
FALLBERICHT 
Ein 31jähriger Mann stellte sich mit schmerzhaften, symmetrischen Hyperkeratosen an 
den Fußsohlen vor. Bei der klinischen Untersuchung wurden sowohl inselförmige als 
auch erbsgroße Hyperkeratosen an beiden Fußsohlen beobachtet (Abb. 1). 
Stecknadelkopfgroße hyperkeratotische Papeln waren in den Beugefalten der Handflächen 
lokalisiert (Abb. 2). Assoziierte Symptome fehlten. 
Die Hyperkeratosen hatten sich erstmalig im Alter von 14 Jahren entwickelt. Nach 
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Exzision einiger Hyperkeratosen an den Fußsohlen zum Zwecke der Schmerzlinderung, 
traten innerhalb von 3 Wochen Rezidive auf. 
Bei der Mutter des Patienten bestanden ähnliche Hautveränderungen. 
Die histologische Untersuchung einer Biopsie von der Fußsohle ergab eine ausgeprägte 
Hyperkeratose mit Parakeratose und Akanthose. Es bestand keine epidermolytische 
Hyperkeratose. 
Die hämatologischen Laborbefunde waren normal. 
Eine Therapie mit 30%iger Salizylvaseline führte zu einer Linderung der Hyperkeratosen. 
Abb 1. Grosse inselförmige und erb-
sengroße Hyperkeratosen an den Fuß-
sohlen. Zustand nach zweiwöchiger 
keratolytischer Behandlung. 
Abb 2. Stecknadelkopfgroße Hyper-
keratosen in den Palmarfurchen. 
126 
BESPRECHUNG 
Die große klinisch-morphologische Vielfalt der hereditären Palmoplantarkeratosen, die 
uneinheitliche Nomenklatur und die Vielzahl kasuistischer Mitteilungen erschweren die 
Klassifikation. In den letzten Jahrzehnten sind nicht nur neue Typen beschrieben, sondern 
auch zuvor als eigenständig geltenden Typen zusammengefügt worden. So hat Küster 
nachgewiesen, daß die Keratosis palmoplantaris diffusa (Unna-Thost) histologisch durch 
epidermolytische Hyperkeratose charakterisiert und mit der Keratosis palmoplantaris cum 
degeneratione granulosa (Vomer) offenbar identisch ist [4]. Wachters' Untersuchungen 
haben ergeben daß die Keratosis palmoplantaris linearis-striata (Brünauer-Fuhs) und die 
Keratosis palmoplantaris areata (Siemens) unterschiedliche Manifestationen ein und 
derselben Genodermatose darstellen, und somit keine eigenständigen Krankheitsbilder 
sind [6]. 
Aufgrund unserer kasuistischer Mitteilung stellt sich die Frage ob KPP punctata und KPP 
varians eigenständige Entitäten sind. In diesem Fall würde unserer Patient an zwei 
verschiedenen Genodermatosen leiden. Wahrscheinlicher ist aber, daß es sich um einen 
einzigen Genotyp mit variabler phänotypischer Ausprägung handelt. 
Man könnte annehmen, daß die KPP punctata und die KPP varians wahrscheinlich keine 
unabhängigen Krankheitsbilder, sondern variable klinische Erscheinungsforme einer 
einzigen Genodermatose darstellen. 
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INTRODUCTION 
In 1927, Olmsted [1] described a congenital palmoplantar keratoderma characterized by 
sharply marginated, diffuse, warty hyperkeratosis of the palms and soles, leading to 
flexura! deformities and spontaneous amputation of two terminal phalanges. A 
pronounced subungual and circumungual hyperkeratosis also occurs, curving the nails 
laterally and anterioposteriorly. Hyperkeratotic plaques parallel to the mucocutaneous 
junction of the lower lip and at the angles of the mouth are also present. Similar lesions 
occur around the umbilicus and the anus. 
To date eight cases have been reported [1-8]. Transmission from mother to son has been 
observed [3,7], which suggests an autosomal dominant mode of inheritance. Local 
measures such as repeated prolonged soaking of the affected parts in warm water 
followed by mechanical removal of the thickened epidermis [1], full thickness excision 
of the palmar skin, followed by skin grafting [7] as well as oral etretinate [8] have been 
reported to be effective in single cases. 
We describe a patient with the typical characteristics of the syndrome, who was treated 
with full thickness excision of the palmar and plantar skin, followed by skin grafting. 
CASE REPORT 
A 33-year-old man had a hyperkeratotic disorder, which appeared on the palmoplantar 
skin when he was 3 months old. The palmoplantar keratoderma gradually progressed to a 
thick, warty hyperkeratosis, diffusely covering the palms and soles, and leading to 
painful flexion contractures of the fingers and toes. A family history of similar lesions 
was lacking. The skin disorder had previously been diagnosed as acrodermatitis 
enteropathica, although the plasma zinc concentration was normal. Treatment with oral 
zinc sulfate for several years did not cause significant improvement. Strict relief of 
external factors resulted in a much slower development of new lesions, although this 
could not prevent hyperkeratoses from developing. Hyperkeratosis gradually recurred 
focally, necessitating surgical removal and transplantation annually. 
In addition to the palmar and plantar hyperkeratoses (Fig. 1), examination revealed 
prominent nail dystrophy and perioral, perinasal (Fig. 2), and perianal hyperkeratoses. A 
universal alopecia was also present. 
Histopathological examination of the palmar skin displayed massive hyperkeratosis and a 
reduced to absent granular cell layer. In the thickened horny layer, many cells showed 
parakeratosis and perinuclear edema. 
Because the flexion contractures were extremely painful, a full-thickness excision of the 
palmar skin, followed by skin grafting plus arthrolysis and arthrodesis of the finger 
joints, were performed, before referral to our clinic. Although the joint contractures 
failed to improve, a substantial relief of pain was achieved, and the plantar skin was 
similarly treated. In addition, amputation of the toes was performed at the patient's 
request, to achieve optimal pain reduction. Because the patient noted a striking relation 
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between trauma and exacerbation of the hyperkeratosis, he decided to avoid pressure on 
the soles, by using a wheelchair or creeping. Subsequently, hyperkeratoses developed on 
both knees. After referral to our dermatology department, treatment with the oral retinoid 
acitretin was proposed to prevent new hyperkeratoses from developing. However, this 
option was rejected by the patient because his pain was limited and he feared possible 
side effects. 
Fig. 1 Before treatment, warty hyper-
keratosis diffusely covers palmar sites of 
both hands and fingers. Keratoderma does 
not involve dorsal surfaces. Painful 
flexion contractures are prominent. Most 
fingernails are dystrophic. 
Fig. 2 Hyperkeratotic plaques beneath 
lower lip and in nasolabial fold. 
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DISCUSSION 
We have described a patient with typical Olmsted syndrome who also had universal 
alopecia and hyperkeratotic plaques on both knees. A striking relation was noted between 
trauma and the hyperkeratoses. In the differential diagnosis, Clouston's syndrome, 
acrodermatitis enteropathica, keratoderma mutilans of Vohwinkel, mal de Meleda, and 
pachyonychia congenita have to be considered. Clouston's syndrome is characterized by 
alopecia and a nonmutilating palmoplantar keratoderma. This can usually be 
differentiated easily from Olmsted syndrome by the absence of periorificial keratoses. 
Acrodermatitis enteropathica mimics Olmsted syndrome and is caused by zinc deficiency. 
Our patient had been misdiagnosed as such and treated for years with zinc. Probably 
other cases have been similarly misdiagnosed. 
Oral retinoids have proved effective in the treatment of several palmoplantar 
keratodermas [9], such as mutilating mal de Meleda [10] and palmoplantar keratoderma 
of Vohwinkel [11-13], but some failed to respond. One patient with Olmsted syndrome 
rapidly improved with etretinate, 0.5 mg/kg/day [8]. However, another patient failed to 
improve with etretinate, 1 mg/kg/day [7]. For the nonresponding patient, full-thickness 
excision followed by skin grafting, is an alternative to alleviate the pain. 
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INTRODUCTION 
In 1963, Huriez et al. described an autosomal dominantly inherited syndrome, 
characterized by a diffuse palmoplanar keratoderma with sclerodactyly and nail changes, 
in two families resident in the north of France (1-3). The palmoplantar keratoderma 
consists of a discrete, sometimes lamellated hyperkeratosis with atrophy, diffusely 
covering especially the palmar skin. The plantar skin usually displays less severe 
involvement Atrophic plaques may be found on the dorsa of the hands and fingers. 
Obligatorily associated features are sclerodactyly and nail changes. The sclerodactyly 
strongly resembles sclerodermia, although the genetic inheritance, absence of systemic 
symptoms, lack of vasomotor phenomena, appearance of the initial symptoms at birth or 
in early childhood, and absence of progression during adulthood, enable a differentiation. 
Nail changes consist of aplasia, ridging and clubbing. Hypohidrosis is associated in half 
of the cases. The disease usually starts at birth or during early childhood and persists 
unchanged throughout adult life. The distinctive feature of this syndrome is the risk of 
the development of squamous cell carcinoma on the affected skin, which may occur as 
early as the third or fourth decade. Until now, seven families (1-8) and one case report 
(9) have been published. We describe another familial case affected with the Huriez 
syndrome. 
CASE REPORT 
A 34-year old woman presented with a palmoplantar keratoderma, focally involving the 
dorsal surfaces, that had appeared at the age of 1 year. At the age of 31, four 
hyperkeratotic nodules and plaques had developed progressively on the affected skin at 
the dorsal side of the left hand. After surgical removal, histopathological examination 
revealed squamous cell carcinoma in three of them. 
Similar, though less pronounced palmoplantar hyperkeratosis, had appeared shortly after 
birth in her son. A family history of similar lesions was lacking. The maternal family 
history revealed that ancestors had lived in the north of France. 
Examination of the mother revealed thin hyperkeratoses with erythema and atrophy on 
the palmoplantar skin, with small areas of normal skin in between (Fig. 1). The palmar 
lesions were restricted to the palms, and did not spread to the dorsal skin. In addition, 
irregular areas with similar lesions were observed at the dorsal skin of the hands. The 
dorsal skin of the feet displayed no abnormalities. All fingers of both hands revealed a 
marked sclerosis of the skin (Fig. 2). Most fingernails showed longitudinal ridging. 
Examination of her son revealed palmar erythema with slight hyperkeratotic 
desquamation. Erythematous, slightly hyperkeratotic plaques were observed on the dorsal 
skin overlying the finger joints of the hands (Fig. 3). Sclerodactyly prevented full 
extension of the fingers. 
Histopathological examination of the palmar skin of the mother displayed hyperkeratosis, 
acanthosis and papillomatosis. Epidermolytic hyperkeratosis was absent. 
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Therapy was started with calcipotriol ointment once daily on the right palmar and plantar 
skin. After 5 weeks of therapy, no beneficial effect was observed. The application 
frequency of calcipotriol was doubled. In addition, oral acitretin treatment was started 
with a daily dose of 25mg. Mucocutaneous retinoid side effects were observed though 
not severe, and well tolerated. After 2 months of treatment, a slight reduction of the 
hyperkeratosis was observed. A left-right difference was absent. 
Fig. 1 Palmar skin of the mother, 
showing a diffuse, thin hyperkeratosis 
with erythema and atrophy. Dermato-
glyphic patterns are lost. Extension of 
the fingers is limited due to sclero-
dactyly. 
Fig. 2 Sclerosis of the skin of all fingers. The fingernails display ridging. 
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Fig. 3 Atrophic, erythematous, slightly 
keratotic plaques covering the dorsal 
skin of the finger joints in the son. 
DISCUSSION 
We have described a mother and son with the Huriez syndrome. Mother developed three 
squamous cell carcinomas in the affected dorsal skin of the left hand. 
Until now seven families and one solitary case have been described, including the 
original description by Huriez (1-9). Malignant degeneration of the affected skin was 
observed in 11/86 affected family members (average 13%). Four of them had died from 
metastasis of their cutaneous malignancy. This unusually high mortality rate of 5% might 
be explained by the frequently low grade of differentiation. As several affected family 
members described were often young, the lifetime risk is probably even higher. Hamm et 
al. found a virtual absence of epidermal Langerhans cells in the involved skin only. The 
resulting diminution of recognition and presentation of tumour-associated antigens, might 
contribute to the proneness to malignant degeneration (8). 
Yesudian et al. described a family with palmoplantar keratoderma clinically identical to 
that observed in the Huriez syndrome. In 3/22 tylotic family members squamous cell 
carcinomas were found in the affected skin, and one of these died of squamous cell 
carcinoma of the oesophagus (10). A similar association with internal malignancies has 
not been described in other patients. Malignant degeneration of the tylotic skin has also 
been observed in the Schöpf-Schulz-Passarge syndrome, which can be differentiated 
easily from the Huriez syndrome (11). No other palmoplantar keratodermas are known to 
be associated with the development of squamous cell carcinomas of the affected skin. 
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The enhanced risk of development of squamous cell carcinoma on the affected skin at 
young age, in the syndrome of Huriez, underlines the statement that the accurate 
specification and diagnosis of an individual patient presenting with a hereditary 
palmoplantar keratoderma is not an academical exercise but important for individual 
patient management to offer optimal treatment and follow-up in those at risk of skin 
cancer. As we described recently, specific morphology and distribution of the 
hyperkeratosis, the inheritance pattern and the presence or absence of associated features, 
are the most important features enabling a rapid classication. Additional criteria are the 
presence of skin lesions on areas other than the palms and soles, the age of onset of the 
keratoderma, the severity of the disease process and the histological findings (12). 
Concerning treatment of the Huriez syndrome, almost no data are available. Retinoids 
have been used succesfully in several other palmoplantar keratodermas (13-17). 
Furthermore, there is ongoing evidence that retinoids are effective as profylaxis against 
the development of neoplasias of the skin (18,19). Until now, only one patient with the 
Huriez syndrome has been treated with retinoids for 5 years. This patient did not develop 
any further squamous cell carcinomata in this period (20). 
In conclusion, patients with the Huriez syndrome should be regarded at risk for the 
development of squamous cell carcinomas on the affected skin. Therefore, regular 
follow-up and explicite patient instruction are a prerequisite. Treatment with retinoids 
might be considered. 
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INTRODUCTION 
Hereditary epidermolytic palmoplanar keratoderma (HEPPK) is a genodermatosis with 
an autosomal dominant mode of inheritance, which was first described by Vomer in 
1901 [1]. The clinical features and mode of transmission are similar to those of 
palmoplanar keratoderma (PPK) diffusa circumscripta of Unna-Thost. The dermatosis 
usually appears in the first weeks of life as a palmoplanar erythema which subsequently 
becomes covered by thick hyperkeratosis. The hyperkeratosis starts at the margins of the 
palms and soles, extends towards the centre, and finally covers the whole surface with a 
uniformly thick horny layer. In addition, hyperkeratotic lesions may develop on the dorsa 
of the joints of the fingers and toes [2], and on the dorsa of the hands [3], but the 
borders of the affected areas on the palms and soles are sharply demarcated, and there is 
no transgression to the dorsal surfaces. In the early stages of the disorder, a violaceous 
border is present, but this usually resolves after several years. Hyperhidrosis may be 
present, but is not a constant feature. Blisters may occur on the affected areas, and may 
suggest the diagnosis [2,4-6]. Histological examination reveals the features of 
epidermolytic hyperkeratosis, and distinguishes HEPPK of Vomer from PPK diffusa 
circumscripta of Unna-Thost. 
Treatment with aromatic retinoids reduces the hyperkeratosis and increases the tactile 
sensitivity [2], but pronounced sensitivity and vulnerability of the skin on the 
palmoplanar surfaces, resulting in discomfort and even erosions, may necessitate 
discontinuation of the treatment. We report the clinical efficacy of topical calcipotriol 
treatment in a patient with HEPPK of Vomer. 
Fig. 1 Before therapy an evenly thick, 
yellowish hyperkeratosis is visible 
covering diffusely the palmar skin. 
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CASE REPORT 
A 38-year-old man presented with hyperkeratosis of the palms and soles, which had been 
present since he was 4 weeks old. On examination, there was diffuse, thick, yellowish 
hyperkeratosis confined to the palms and soles, with a shrply defined margin (Fig. 1). 
Erythema was not evident at the borders of the affected areas. The dorsa of the hands 
and feet were not involved. There were no areas of hyperkeratosis elsewhere on the 
body, and his hair, teeth, and mucous membranes were normal. He complained of 
significant hyperhidrosis, which had diminished with increasing age. He found that 
walking barefoot was uncomfortable, as was heavy manual work. Blisters had never been 
present. 
His family history revealed that nine individuals in four consecutive generations had 
suffered from the same dermatosis, which is consistent with an autosomal dominant 
mode of inheritance. 
Histology of a biopsy specimen from the palmar skin revealed orthokeratotic 
hyperkeratosi, focal parakeratosis, a prominent granular cell layer, and acanthosis. In the 
thickened stratum granulosum, keratohyalin granules appeared clumped, the cells 
displayed numerous vacuoles, and cell walls were ruptured (Fig. 2). These findings are 
consistent with epidermolytic hyperkeratosis. 
Fig. 2 Clumpy keratohyalin granules, 
numerous vacuoles and ruptured cell 
walls in the granular cell layer, 
(hematoxylin-eosin, x400) 
Using a bilaterally paired comparative approach, calcipotriol 50 μg/g and urea 40mg/g, 
both in an ointment base, were applied twice daily to the right and left hands, 
respectively. Within a month of starting treatment there was focal reduction of 
hyperkeratosis on the right hand (Fig. 3). Improvement of tactile sense was marked. As a 
result of increased tactile sensitivity, the application frequency was reduced to once 
daily 3 times a week, after 4 weeks of treatment. Clinical evaluation at 3 months 
revealed a remarkable unilateral improvement in favour of the calcipotriol-treated side 
(Fig. 4 a and b). 
Despite the fact that the increased sensitivity could be maintained at an acceptable level 
by reduction of the application frequency, the patient discontinued treatment after 4 
months, because he considered the pretreatment state was preferable to the marked 
sensitivity of the skin which accompanied a reduction in the degree of hyperkeratosis. 
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Fig. 3 Intermediate stage, 4 weeks 
after onset of treatment with calcipo-
triol. A patchy red reduction of hyper-
keratosis is seen at the calcipotriol 
treated hand. 
Fig. 4 Clinical results after 3 months of treatment, a. Hyperkeratosis has almost completely 
disappeared at the calcipotriol treated right hand. b. The left hand still shows a diffuse hyperkeratosis 
comparatible with the pre-treatment observations. 
DISCUSSION 
As far as we are aware, this case represents the first report of a beneficial response of 
HEPPK of Vomer to treatment with topical calcipotriol. 
Until recently PPK diffusa circumscripta Unna-Thost was believed to be the most 
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frequent type of hereditary PPK, whereas HEPPK of Vomer was considered to be a rare 
disorder. Hamm et al. [7], reviewed a group of 21 patients with diffuse PPK and found 
the features of epidermolytic hyperkeratosis in 12 of them, confirming the diagnosis of 
HEPPK. None of the patients was classified as PPK of Unna-Thost. Reinvestigation of 
the family originally seen by Thost also revealed the features of epidermolytic 
hyperkeratosis [8]. The true frequency of HEPPK is therefore probably underestimated, 
and possibly this dermatosis may represent the most frequent type of hereditary PPK. 
Treatment options for HEPPK are limited. Systemic retinoids produce disabling 
tenderness of the skin, and topical treatments are of modest value. Our case demonstrates 
that calcipotriol (50 μg/g) ointment may be effective in the treatment of HEPPK. The 
increased sensitivity of palms and soles which accompanies the reduction in 
hyperkeratosis can be controlled by adjusting the application frequency, and topical 
calcipotriol may therefore be a promising approach to the treatment of HEPPK of 
Vomer. 
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SUMMARY 
The palmoplanar keratoses (PPKs) comprise a heterogeneous group of disorders of 
keratinization, which can be subdivided into hereditary and acquired forms. Many authors 
have attempted to classify the hereditary forms [1-5], and most classifications have been 
based on the morphology, distribution, associated symptoms and mode of inheritance. 
Subsequently, many new forms have been recognized, and what were previously 
considered to be distinct types have been shown to be variants of a single type, both of 
which limit the usefulness of previous classifications. Hence, we propose a new, updated 
classification, which enables accurate diagnosis of these disorders. 
INTRODUCTION 
The disorders known as palmoplantar keratoses (PPKs) comprise a number of different 
clinical entities, and there are both hereditary and acquired forms. Hereditary forms may 
be localized primarily to the hands and feet or be associated with more generalized skin 
diseases, such as autosomal dominant ichthyosis vulgaris, bullous ichthyosiform 
erythroderma, lamellar ichthyosis and erythrokeratoderma. Classification of the hereditary 
PPKs localized primarily to the hands and feet is difficult, because of inter- and 
intraindividual variations, differences in nomenclature, and the large number of reported 
cases. In recent years, a number of new forms have been described, and forms which 
were previously considered to be distinct have been shown to be variants of the same 
type of keratoderma. Based on the available data, we propose an updated classification 
(Table I). The most important features in the classification of PPKs are the specific 
morphology and distribution of the hyperkeratosis, the presence or absence of associated 
features, and the inheritance pattern. Additional criteria are the presence of skin lesions 
on areas other than the palms and soles, the age at onset of the keratoderma, the severity 
of the disease process, and the histopathological findings. 
DIFFUSE HEREDITARY PPKs WITHOUT ASSOCIATED FEATURES 
PPK diffusa circumscripta Unna-Thost 
Diffuse PPK Unna-Thost [6,7] usually presents in the first month of life, and is evident by the age of 
2 in the majority of cases. An even, very thick, diffuse hyperkeratosis covers the palms and soles, 
starting at the margins and extending to the centre. Initially, the margins show a violaceous border, 
which usually disappears after several years. There is no spread on to the extensor surfaces. Aberrant 
keratotic lesions may appear on the dorsa on the hands and feet, and the knees and elbows. Marked 
hyperhidrosis is usual. The nails may be thickened. Histologically, PPK Unna-Thost is said to show 
non-specific changes, but there are no case reports in the literature confirming such histological 
findings. Until recently, diffuse PPK Unna-Thost was generally believed to be the most frequent type 
of hereditary PPK. Clinically, the disease is identical to PPK VOrner, which is characterized 
histologically by epidermolytic hyperkeratosis. In a number of cases clinically thought to have PPK 
Unna-Thost, the histological features were those of epidermolytic hyperkeratosis [8]. Reinvestigation 
of the family originally seen by Thost also revealed the histological features of epidermolytic 
hyperkeratosis [9]. Hence, there is doubt about the existence of PPK Unna-Thost as a separate entity. 
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Table I. Hereditary palmoplanar keratoses 
Diffuse 
Nummular/Linear 
Papular 
Inheritance 
AD 
AR 
AD 
AR 
AD 
AR 
No associated features 
Unna-Thost 
Greither 
Vomer 
Sybert 
Mal de Meleda 
Gamborg Nielsen 
Nagashima 
Acrai keratoderma 
Wachters 
PPK nummularis 
Davies-Colley 
Acrokeratoelastoidosis 
Focal aerai hyperkeratosis 
Associated features 
Vohwinkel 
Howel-Evans 
Huriez 
Clouston 
PPK and sensorineural deafness 
Olmsted 
Papillon-Lefèvre 
Bureau-Barrière-Thomas 
Richner-Hanhart 
Pachyonychia congenita 
Focal palmoplanar and oral 
mucosa hyperkeratosis syndrome 
Pachyonychia congenita 
Jakac-Wolf 
Hanhart 
Schöpf-Schulz-Passarge 
Fig. 1 PPK transgrediens et progrediens 
Greither, showing diffuse hyperkeratosis 
covering the heel and the region of the Achilles 
tendon. Spreading to the dorsal surfaces is 
similar to mal de Meleda, shown in figure 4 
and 5. 
Fig. 2 PPK cum degeneratione granulosa 
Vomer, exhibiting thick hyperkeratosis 
covering diffusely the palms. The characteristic 
histopathological picture is shown in figure 3. 
152 
PPK transgrediens et progrediens Greither (Fig. 1) 
PPK Greither is a diffuse PPK which extends on to the dorsa of the hands and feet 
(transgrediens), has a violaceous border, and is associated with hyperhidrosis [10-14]. 
Additional hyperkeratotic lesions can be seen on the knees and elbows, and in the region 
of the Achilles tendon. Worsening of the keratosis is seen during childhood, followed by 
a static phase after puberty, and finally a tendency to improve in the fifth decade. It 
differs from the Unna-Thost variety by extending to the dorsal surfaces, and from mal de 
Meleda by its dominant inheritance and variable intrafamilial expression. Solitary cases 
must be differentiated from erythrokeratodermas. 
PPK cum degeneratione granulosa Vomer (Figs 2, 3 and 4) 
The clinical features and the mode of transmission of PPK Vomer [15] are the same as 
those of PPK Unna-Thost. It differs from the latter in that epidermolytic hyperkeratosis 
is a histological feature of PPK Vomer. To date, at least 33 families with this disorder 
and 11 sporadic cases have been reported [16]. Epidermolytic hyperkeratosis also occurs 
in several other skin conditions, such as bullous congenital ichthyosiform erythroderma 
Brocq, ichthyosis bullosa Siemens, and some linear epidermal naevi. PPK nummularis is 
another PPK characterized by epidermolytic hyperkeratosis [17]. In this disorder, the 
involvement is not diffuse, but mainly confined to the pressure points. Within the group 
of diffuse hereditary PPKs, however, PPK Vomer is so far considered to be the only 
type showing this distinctive histological feature. Consequently, a correct classification of 
diffuse PPK is impossible without histological examination. PPK Vomer appears to be 
the most frequent type of hereditary PPK [8]. 
Fig. 3 Same patient as in figure 2. 
Additional hyperkeratotic plaques are 
present at the dorsal surfaces of the 
proximal ¡nterphalangeal joints. 
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Fig. 4 Hyperkeratosis, hypergranulosis and acanthosis. The granular cell layer displays numerous 
clumpy keratohyalin granules, vacuoles and ruptured cell walls, consistent with epidermolytic 
hyperkeratosis (hematoxylin-eosin, x400). 
PPK of Sybert 
In 1988, Sybert described a family with a palmoplanar keratoderma which started with 
erythema and scaling of the palms and soles in the first year of life [18]. The 
palmoplantar lesions eventually progressed to a severe diffuse hyperkeratosis, causing 
deformities and spontaneous amputation of the digits. In childhood, additional lesions 
developed in the natal cleft and groins. With increasing age, hyperkeratoses developed on 
the elbows, knees, dorsa of the hands and feet, posterior aspects of the forearms and 
anterior aspects of the legs. The pedigree was consistent with an autosomal dominant 
mode of inheritance. This diffuse, transgrediens, mutilating PPK has to be differentiated 
from mal de Meleda, PPK of Gamborg Nielsen and PPK of Greither. The clinical 
features resemble those found in mal de Meleda which, however, is an autosomal 
recessive disorder. PPK of Gamborg Nielsen shows less extension on to dorsal surfaces, 
fewer additional hyperkeratoses, and is recessively inherited. The severity and extent of 
involvement are much greater than in PPK of Greither. 
Mal de Meleda (Keratosis extremitatum hereditaria transgrediens et progrediens) 
(Figs 5 and 6) 
This very rare disorder has, as a result of inbreeding, an endemic prevalence on the 
adriatic island of Mljet [19-21]. It is characterized by a diffuse, thick hyperkeratosis with 
a prominent erythematous border. The thick hyperkeratosis may lead to flexion 
contractures. The disease has its onset in early infancy, and follows a progressive course, 
with extention on to the dorsal surfaces of hands and feet. Constricting bands 
surrounding the digits are typical [22], and occasionally result in spontaneous amputation 
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[23]. Concomitant lesions can be found on other sites, especially the elbows and knees 
[24]. Perioral erythema and hyperkeratosis may be present [25], resembling the clinical 
features of Olmsted syndrome. Hyperhidrosis of the affected parts, with maceration of 
the hyperkeratotic masses and consequent production of a rancid odour, is pronounced. 
Nailchanges (koilonychia, nail thickening, subungual hyperkeratosis) are usually present. 
The disease has to be differentiated from PPK transgrediens et progrediens Greither and 
PPK of Sybert, both of which have a dominant mode of inheritance, and from PPK of 
Gamborg Nielsen. 
Fig. 5 Mal de Meleda displaying a diffuse Fig. 6 Same patient as in figure 5. The dorsal 
hyperkeratosis with a prominent erythematous surfaces are covered by hyperkeratosis, extend-
rim, spreading to the dorsal surfaces as shown ing from the plantar surfaces. The hyperkera-
in figure 6. tosis is surrounded by a border of erythema. 
PPK Gamborg Nielsen 
Gamborg Nielsen delineated a severe form of PPK, represented by six patients in two 
families, who lived in the northernmost county of Sweden [26]. This type of PPK was 
characterized by a very thick hyperkeratosis, distinctly demarcated from normal skin. The 
dorsal aspects of the finger joints were covered by hyperkeratotic plaques. A violaceous 
margin was present in four patients. One patient demonstrated extension of the 
keratoderma on to the dorsa of the hands. Another featured mutilating changes due to 
constricting bands surrounding the fingers [27]. Apart from knuckle pads on the dorsa of 
the fingers, there were no additional hyperkeratoses. The pedigree in both families was 
consistent with an autosomal recessive mode of inheritance. The disease has to be 
differentiated from PPK of Sybert, PPK of Greither, and from mal de Meleda. PPK 
Sybert exhibits more extension on to dorsal surfaces, and distant keratoses, and is 
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inherited as an autosomal dominant trait. Compared with mal de Meleda, the Gamborg 
Nielsen type displays less severe hyperkeratoses, no nail deformities, and no distant 
keratoses, except for the knuckle pads. Similar, although less severe, cases have been 
described in the Japanese literature as the "Nagashima type" [28]. 
Acrai keratoderma 
Three siblings have been reported who displayed a keratoderma characterized by diffuse 
and striate hyperkeratosis of the palms and soles, hyperkeratotic plaques on the dorsa of 
the hands and toes, and linear hyperkeratotic lesions over the Achilles tendons, ankles, 
elbows and knees. In one individual, the right fifth toe was missing, and a constricting 
band completely encircled the base of the left fifth toe. Histology showed dyskeratotic 
changes without epidermolytic hyperkeratosis. Clinically, the keratoderma can be 
distinguished from PPK mutilans by the presence of striate hyperkeratosis on the palmar 
surface of the fingers, the absence of starfish-shaped hyperkeratosis, and the lack of a 
violaceous border surrounding the palmoplantar keratoderma. In addition, the pedigree 
suggests an autosomal recessive inheritance pattern. The typical clinical features enable a 
distinction to be made between aerai keratoderma and mal de Meleda [29]. 
DIFFUSE HEREDITARY PPK'S WITH ASSOCIATED FEATURES 
PPK mutilans Vohwinkel 
PPK Vohwinkel is a diffuse PPK with a honeycombed hyperkeratosis, a violaceous 
border, and hyperhidrosis [30-37]. It presents in infancy, and is characterized by 
strangulating fibrous bands leading to progressive constriction and eventual spontaneous 
amputation of the digits. In addition, patients may have distinctive keratotic lesions on 
the elbows and knees, as well as the dorsa of the hands and feet, with a peculiar, linear 
and starfish-shaped configuration. In one patient, grossly mutilating keratoderma was 
accompanied by keratosis of the groins and perianal skin [38]. A number of associated 
features have been noted to occur sporadically: alopecia [35,38], high-tone acoustic 
impairment [35,37], deafness [33], spastic paraplegia, myopathy [37], ichthyosiform 
dermatoses [31,32,39], and nail anomalies. Constriction bands on digits may occasionally 
occur in mal de Meleda, pachyonychia congenita, aerai keratoderma, the Olmsted 
syndrome and PPK of Sybert 
Carcinoma of the oesophagus with keratosis palmaris et plantaris (Howel-Evans) 
Howel-Evans et al. reported the association of palmoplantar keratoderma with carcinoma 
of the oesophagus [40]. In their study of two Liverpool families, oesophageal carcinoma 
occurred in 18 of 48 tylotic family members, but in only one of 87 non-tylotic members. 
The age of onset of the palmoplantar hyperkeratosis was between 5 and 15 years, and the 
average age of onset of the oesophageal carcinoma 43 years. Yesudian et al. described a 
pedigree with tylosis in 22 members of a family spanning over 5 generations [41]. Of 
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those affected, three of the fourth generation tylotics developed squamous carcinoma of 
the tylotic skin, and one of these died from carcinoma of the oesophagus. Palmoplantar 
keratosis was present at birth. Skin cancer developed in the second decade of life. It is 
possible that there is a genetic association between the state of the oesophagus and the 
palmoplantar keratoderma which predisposes both sites to the development of squamous 
carcinoma. Acquired PPK, beginning late in life and apparently not genetically 
determined, has also been described in association with internal malignancy [42-46]. 
PPK with sclerodactyly (Huriez syndrome) 
The disorder described first by Huriez et al [47-49] is characterized by sclerodactyly, 
diffuse keratoderma of the palms and soles, nail anomalies (aplasia, ridging and 
clubbing) and possible malignant degeneration of the affected skin. Associated 
hypohidrosis is common. Another two familial cases have been reported [50,51]. The 
disease is present at birth, or appears in the first years of life, and persists unchanged 
throughout adult life. Sclerodactyly, not associated with Raynaud's phenomenon, is the 
most prominent feature of the syndrome. In some severe PPKs there is a suggestion of 
sclerosis, but in the Huriez syndrome the sclerotic changes are disproportionately greater. 
Squamous cell carcinomas often develop in the atrophic skin, as early as the third to 
fourth decades of life. The Huriez syndrome can be distinguished from scleroderma by 
its onset at birth, absence of systemic signs and symptoms, lack of vasomotor 
phenomena, and lack of progression during adulthood. 
Hidrotic ectodermal dysplasia (Clouston syndrome) 
Hidrotic ectodermal dysplasia, first described by Clouston in 1928, is characterized by 
dystrophy of the nails, defects of the hair, and palmoplantar keratosis [52-55]. There is 
sparsity of the hair of the scalp, face, eyebrows, eyelashes, axillae and genitalia, varies in 
severity from mild thinning to complete baldness [56]. In some cases, alopecia appears 
maximally soon after birth, although in the majority hair loss is gradual, less severe, and 
only occurs after puberty. Hyperkeratosis of the palms and soles has a papillomatous 
appearance, with multiple small fissures, and generally increases in severity with age. 
Skin thickening has also been reported on the knuckles, knees and elbows [56]. 
Biochemically, a depletion of hair matrix protein, related to a disruption of disulphide 
bond formation in the keratin of the integumentary system, may account for the clinical 
features in hair and skin [57]. Sensorineural deafness [58,59], Polydactyly, syndactyly, 
finger clubbing, mental retardation, dwarfism [60], photophobia [57], and strabismus 
[61], may be associated. 
PPK and sensorineural deafness 
Recently, Sharland et al. [62] described a new syndrome of diffuse palmoplantar 
hyperkeratosis invariably associated with a slowly progressive, bilateral, high-frequency, 
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cochlear hearing loss. The onset of deafness in infancy and early childhood precedes the 
skin changes, and thereafter both progress slowly with age. The two abnormalities never 
appeared as isolated defects in the family described. A combination of sensorineural 
hearing loss and palmoplantar keratosis has been recognized previously [63,64]. A 
variable relationship between the inheritance of skin lesions and acoustic impairment has 
been reported in the Olmsted syndrome [65], and PPK mutilans Vohwinkel [35]. The 
Clouston syndrome also includes other ectodermal defects [52]. 
Mutilating palmoplantar keratoderma with periorificial keratotic plaques (Olmsted 
syndrome) 
Including the original description by Olmsted [65], there are five well documented cases 
of this syndrome [65-68]. The syndrome consists of congenital, diffuse, sharply 
marginated keratoderma of the palms and soles, with flexion deformities of the digits, 
leading to constriction or spontaneous amputation, periorificial keratoses, and 
onychodystrophy. Perianal involvement has been reported in four cases [38, 65-67]. 
Leukokeratosis was present in two cases [66,67], and in one patient the groins and inner 
thighs, ears and anterior neck, were all involved by the age of 2 years. This patient also 
had universal alopecia, absence of a premolar tooth, joint hypermobility and, at the age 
of 20, linear hyperkeratotic streaks in the anticubital fossae and on the flexor aspects of 
the forearms [67]. Recently, a case has been reported with a congenital non-mutilating 
PPK and nail dystrophy, who developed progressive perioral and perineal keratoderma 
and, in addition, bilateral corneal epithelial dysplasia, leading to severe corneal scarring 
and impairment of vision [69]. The principal genetic syndromes to be excluded in the 
differential diagnosis include hidrotic ectodermal dysplasia of the Clouston type, 
pachyonychia congenita, mal de Meleda, and PPK of Vohwinkel. The condition mimics 
acrodermatitis enteropathica, which can be excluded by determination of the plasma zinc 
level. 
Palmoplantar keratoderma with periodontitis (Papillon-Lefèvre syndrome) 
The Papillon-Lefèvre syndrome (PLS) is characterized by a diffuse transgrediens 
palmoplantar keratosis and premature loss of both the deciduous and permanent teeth 
[70]. In addition to the palmoplantar hyperkeratosis, many PLS patients have scaly 
erythematous lesions over the knees, elbows, and interphalangeal joints, not uncommonly 
misdiagnosed as psoriasis [71]. Redness and thickening of the palms and soles usually 
appear in the first years of life, at the time of eruption of the deciduous teeth. A 
spontaneous improvement parallels the resolution of gingival inflammation after the loss 
of the permanent teeth. Associated hyperhidrosis causes an unpleasant odour [72]. An 
increased susceptibility to infections has been observed in about 20% of PLS patients 
[73]. The skin is reported to be the most common site affected by infections; internal 
organs are less frequently involved [74]. Disorders of leucocyte function might account 
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for the prominent gingival and cutaneous infections. Some investigators have 
demonstrated disturbances in both polymorphonuclear leucocyte motility and bactericidal 
functions [75-77] or in bactericidal functions alone [78-80], whereas others have not 
found any defects in leucocyte function [81,82]. The precise underlying mechanism 
responsible for susceptibility to infections in PLS patients, however, remains to be 
determined. Histopathological changes are non-specific. Electron microscopic features 
include lipid-like vacuoles in the corneocytes and granulocytes, a reduction in 
tonofilaments, and irregular keratohyalin granules. A syndrome combining the features of 
PLS with flat feet, onychogryphosis, arachnodactyly and acro-osteolysis, has been 
described in one family by several authors [83-85]. PLS has to be distinguished from the 
Schöpf-Schulz-Passarge syndrome. 
PPK with clubbing of the fingers and toes and skeletal deformity (Bureau, Barrière, 
Thomas) 
In 1959, Bureau, Barrière and Thomas described four members of one family who 
presented with a diffuse, symmetrical, non-transgrediens palmoplantar keratosis, clubbing 
of the fingers and toes, and skeletal changes consisting of bone hypertrophy and thinning 
of the cortex of long bones [86,87]. Hedstrand et al. reported two sisters with 
consanguineous parents, who developed palmoplantar keratoderma in childhood, clubbing 
of fingers and toes, and unusual skeletal changes in the terminal phalanges. X-rays 
showed a peculiar deformity of the terminal phalanges. The distal ends appeared splayed, 
and showed marginal effects suggesting atrophy [88]. In both of these families the PPK 
was accompanied by marked hyperhidrosis. Recently, a patient was described with PPK, 
drumstick-fingers, hypotrichosis, hypohidrosis and dental dysplasia [89]. 
Fig. 7 PPK varians of Wachters, displaying characteristic nummular hyperkeratotic plaques, mainly 
confined to the pressure points. 
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Keratosis palmoplantaris varians Wachters (Fig. 7) 
Originally, distinct subtypes were described by Fuhs [90], Briinauer [91], and Siemens 
[92], because of the diversity of clinical features. All of these variants, however, should 
be considered as one dermatosis, for which Wachters introduced the term 'keratosis 
palmoplantaris varians' [93]. A characteristic feature is the great inter- and intra-familial 
variability. The palmar keratoses have either a nummular, linear, membranaceous, 
fissured or periungual configuration. The keratoses on the soles always have a nummular 
appearance, and are localized on the pressure points [92,93]. Woolly hair has been 
described as an associated feature in one family [94]. Nevertheless, because of the 
absence of associated features in other families [90-93,95,96] PPK varians Wachters is 
classified in the group of nummular-linear PPKs without associated features. 
Keratosis palmoplantaris nummularis ('hereditary painful callosities') (Fig. 8) 
Nummular keratotic lesions, almost exclusively located on the plantar pressure points, 
with pain as the major complaint, are characteristic of this disease, and have been 
reported in 34 patients in 14 families [97-103]. The lesions usually appear when an 
affected child begins to walk. They progress slowly, and are often accompanied by pain. 
The palms may also be involved after mechanical trauma. Lesions in areas other than the 
palms and soles have been observed in only two patients [101,102]. The major 
histological feature, in nearly all patients, is local epidermolytic hyperkeratosis [102]. 
This disorder differs from PPK Vomer in that in the Vomer type of palmoplantar 
keratosis there is diffuse palmoplantar epidermolytic hyperkeratosis. 
Fig. 8 
PPK nummularis. Confluent nummular 
hyperkeratosis displaying epidermolytic 
hyperkeratosis as shown in figure 3 in 
a focal pattern. 
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Tyrosinaemia type II (Richner-Hanhart syndrome) 
Tyrosinaemia type II is a rare disorder of tyrosine metabolism, characterized clinically by 
focal, painful, palmoplantar keratoses, bilateral pseudoherpetic corneal ulceration and 
mental retardation [104-107]. The typical cutaneous changes of tyrosinaemia type II 
consist of painful, circumscribed, hyperkeratotic plaques on the palms and soles. 
Occasionally, aberrant hyperkeratotic lesions are present in areas such as the elbows and 
knees, or even the tongue [108]. Hyperhidrosis of the palms and soles is frequently 
associated [109-111]. Mild herpetiform corneal erosions and dendritic ulcers develop 
within the first months of life, and may lead to corneal scarring and glaucoma [112]. 
Skin lesions usually occur when eye lesions have developed, although the skin lesions 
may be present without eye lesions [113]. Deficiency of the enzyme tyrosine 
aminotransferase, which leads to increased serum levels of tyrosine and phenolic acid 
metabolites of tyrosine, is the biochemical basis for tyrosinaemia type II [108,114,115]. 
Histologically, eosinophilic cytoplasmic inclusions are present in the Malpighian layer of 
a thickened epidermis [109]. 
Fig. 9 
Pachyonychia congenita, exhibiting 
severe naildystrophy, a diffuse warty 
palmoplantar keratosis and nummular 
keratoses on the dorsal surfaces. 
Pachyonychia congenita (Fig. 9) 
Pachyonychia congenita was originally described by Muller in 1904 [116] and Wilson in 
1905 [117], although the association with palmoplantar keratoderma and other ectodermal 
defects was first reported by Jadassohn and Lewandowski [118]. It is characterized by 
discoloration and thickening of the nails, usually beginning within the first month of life. 
The thickening is the result of subungual hyperkeratosis, with an upward angulation of 
the distal part of the nail plate, whereas the lateral borders are often incurved. Dystrophy 
of all the nails, and dyskeratotic skin lesions are necessary to establish the diagnosis. 
Several subdivisions have been proposed [119-121]. A retrospective study of 
pachyonychia congenita, performed by Feinstein et al. [122], revealed 168 reported cases. 
Based on the main features found in this survey, the following classification was 
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proposed: type I (56% of cases), hyperkeratosis of nails, palmoplanar keratosis, follicular 
keratosis and oral leucokeratosis; type II (25% of cases), clinical findings of type I, plus 
bullae of palms and soles, palmar and plantar Hyperhidrosis, natal or neonatal teeth, and 
steatocystoma multiplex; type III (12% of cases), clinical findings of types I and II, plus 
angular cheilosis, corneal dyskeratosis and cataracts; type IV (7% of cases), clinical 
findings of types I, II and III, plus laryngeal lesions, hoarseness, mental retardation, hair 
anomalies and alopecia [122]. However, we recently demonstrated that the presence of 
other abnormalities is not an absolute prerequisite for the diagnosis [123]. Histopathology 
of the bullae, which are quite a common manifestation, did not reveal any features of 
epidermolytic hyperkeratosis [120]. An autosomal recessive form of the disorder has 
been described [124], and recently late onset pachyonychia congenita has been reported 
[125]. 
Focal palmoplanar and oral mucosa hyperkeratosis syndrome 
The combination of PPK and hyperkeratosis of the oral mucosa was first described by 
Fred et al. [126]. Raphael et al. described this combination of clinical features in a 
family in which there were four affected individuals [127]. There have since been reports 
of kindreds in which several generations were affected [128-130]. The syndrome is 
characterized by hyperkeratosis of the palms, soles and oral mucosa. The hyperkeratosis 
is especially marked on the weight-bearing areas of the soles, areas of the palms exposed 
to pressure, and the labial attached gingiva. In addition to the attached gingiva, 
hyperkeratotic lesions develop in areas of the oral mucosa subjected to friction and 
irritation. The hyperkeratosis, which has a symmetrical distribution, appears in early 
childhood or around puberty, and the lesions increase in severity with age. However, the 
severity varies between individuals, and among affected members of the same family. 
Subungual and circumungual hyperkeratosis may be an associated feature [130]. The 
syndrome has to be differentiated from others which feature hyperkeratosis of the palms 
and soles, and oral mucosal lesions, such as PPK Howel-Evans and pachyonychia 
congenita. 
Keratosis palmoplantaris papillomatosa et verrucosa 
In 1975, Jakac and Wolf described a clinically distinct keratoderma in four members of 
one family. This disorder has its onset between 2 and 6 years of age, and is characterized 
by a verrucous-papillomatous appearance [131]. The PPK, which has a violaceous 
border, and is nummular at onset, subsequently extends to cover the entire surface of the 
palms and soles, but does not extend beyond the palmar and plantar surfaces. The skin of 
the fingers and toes is atrophic, and the digits develop flexion contractures. Aberrant 
keratotic lesions may be present on the knees, lower arms and buttocks. Profuse 
hyperhidrosis, which is a constant accompanying feature of the disease, and the 
pronounced papillomatosis, predispose to secondary infection, and this may lead to 
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periostitis and osteomyelitis. Although spontaneous remissions have been described, the 
overall clinical course is progressive. In one of the patients, gingivitis and periodontitis 
resulted in premature loss of teeth. 
PAPULAR HEREDITARY PPKs WITHOUT ASSOCIATED FEATURES 
Keratosis palmoplantaris punctata (Davies-Colley, Buschke, Fischer, Brauer) (Figs 
10 and 11) 
The clinical presentation of numerous tiny keratotic papules, strictly limited to the volar 
aspects of the hands and feet, has been designated porokeratosis punctata palmaris et 
plantaris [132,133], palmoplanar keratosis acuminata [134], and punctate porokeratotic 
keratoderma [135,136], and these numerous apellations have led to much confusion. 
Lesions usually first develop between the second and fourth decades, with the age of 
onset ranging from 12 to 70 years. The papular keratoses progress slowly, and remain 
asymptomatic. Despite great interfamilial clinical variation, there is uniform expression 
within an affected family. Localized forms limited to the palmar creases have been 
described [137]. Most of the patients do not have any associated features, but spastic 
paralysis [138], ankylosing spondylitis [139], and facial sebaceous hyperplasia [134], 
have been reported in association with PPK punctata. In addition, a coincidental [140], 
and a possible familial [141], association with gastrointestinal malignancy have been 
discussed. Histologic examination reveals a compact column of parakeratosis resembling 
that of a cornoid lamella, but without evidence of dyskeratosis or hydropic degeneration 
in the epidermis, differentiating the condition from porokeratosis [126,142] a distinction 
which is important because of the malignant potential of porokeratosis [143]. 
Fig. 10 Classical PPK punctata with multiple Fig. 11 PPK punctata of the palmar creases, 
keratotic papules covering the soles. This rare variant of PPK punctata demonstrates 
small keratotic papules confined to the creases. 
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Acrokeratoelastoidosis 
In 1952, Costa described a clinical entity which he called acrokeratoelastoidosis 
[144,145]. Clinically, the disease is characterized by small, yellowish, round to oval 
keratotic papules, mainly confined to the margins of the palms and soles. The keratotic 
papules may become confluent in the centre of the palms and soles, to produce a diffuse 
keratoderma. The process begins in adolescence or adult life. The number of papules 
gradually increases over several years. Local hyperhidrosis is present. Histologically, the 
disease is characterized by elastorrhexis [144,145]. It must be differentiated histologically 
from focal aerai hyperkeratosis, and clinically from degenerative collagenous plaques of 
the hands [146], a separate acquired condition, which occurs in an older age group on the 
sun-exposed parts of the hands. 
Focal aerai hyperkeratosis (Fig. 12) 
This dermatosis is clinically similar to, but histologically different from 
acrokeratoelastoidosis [147]. It appears to be a focal disorder of keratinization, which has 
an insidious onset in childhood, reaches a maximum in early life, and causes only 
cosmetic embarrassment. With the exception of one Arab patient, all reported individuals 
have been of Negroid racial origin. In addition to the typical papules along the borders of 
hands and feet, hyperkeratotic papules may be present over the interphalangeal joints of 
the fingers and toes, and on the heels. On histological examination, there is no 
elastorrhexis, and this distinguishes the disease from acrokeratoelastoidosis. 
\ 
Fig. 12 
Focal aerai hyperkeratosis displaying a 
similar picture as acrokeratoelastoido-
sis, showing yellowish papules mainly 
confined to the thenar region of the 
palm. 
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Keratosis palmoplantaris with lipomata 
In 1947, Hanhart reported a family in which six members in three consecutive 
generations co-expressed palmoplantar keratosis with lipomata [104]. The keratosis is 
limited to the palms, soles and volar surfaces of the fingers and toes, and consists of 
multiple papular keratotic lesions. Its onset is from the third decade of life onwards. The 
number of lipomata varies from solitary lesions to multiple lipomata in a generalized 
distribution. However, five members of the same family expressed only palmoplantar 
keratosis, suggesting a coincidence of two unrelated anomalies in the "affected" 
members. 
Syndrome of cystic eyelids, palmoplantar keratosis, hypodontia and hypotrichosis 
(Schöpf-Schulz-Passarge syndrome) 
Schöpf et al. reported two sisters with a syndrome of cystic eyelids, hypodontia, 
hypotrichosis and palmoplantar keratosis [148]. A similar grouping of ectodermal defects 
was reported by Burket et al. in a man who was a sporadic case [149]. Unique in this 
individual were multiple facial tumours of the follicular infundibulum (Mehregan and 
Butler) [150]. Happle et al. described the development of squamous cell carcinomata in 
association with this syndrome [151]. The Papillon-Lefevre syndrome can be easily 
distinguished from this disorder. Periodontitis, which is an integral part of the PLS, was 
not a feature of the reported cases of the Schöpf syndrome, and eyelid cysts have not 
been described in the PLS. 
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SUMMARY, DISCUSSION AND CONCLUSIONS 
At the end of the general introduction we defined two major objectives: 
(i) The development of new therapeutical approaches for patients with ichthyosis and 
Darier's disease, 
(ii) The development of a nosology for palmoplantar keratodermas and the exploration 
of new treatments. 
Here we will integrate the observations described in this thesis with the existing 
protocols and we will construct an updated approach which will be applicable for office 
dermatology. 
L The development of a treatment program for patients with ichthvoses and Parier's 
disease. 
The efficacy and limitation of the treatment of disorders of keratinization with topical 
moisturizing creams and/ or the systemic retinoid acitretin has been summarized in the 
general introduction. The side effects of acitretin and the limited efficacy of moisturizing 
creams require the development of new treatments for patients suffering from ichthyoses 
and Darier's disease. The topical retinoid 13-cis-retinoic acid (13-cis-RA), the vitamin 
D3 analogue calcipotriol and the cytochrome P-450 inhibitor liarozole proved to be 
challenging new approaches. 
1.1. Comparative efficacy analysis 
The efficacy of various treatments in various disorders is presented in Table I. 
Acitretin, as systemic treatment, is effective in almost all disorders of keratinization. 
However, in patients with Darier's disease, erythrodermic lamellar ichthyosis and bullous 
ichthyosis, low-dose acitretin treatment is required as these disorders are characterized by 
acitretin induced aggravation. Acitretin still remains to be the golden standard with which 
new candidate drugs have to be compared and contrasted. 
This thesis presents various alternatives for acitretin treatment. 
Autosomal dominant ichthyosis vulgaris (ADIV), a disorder not severe enough to 
accept the side effects of systemic retinoids, in general responds well to topical 
moisturizing creams. ADIV did not improve unilaterally during topical treatment with 
13-cis-retinoic acid (13-cis-RA) (part 1, chapter 1). X-linked recessive ichthyosis (XRI) 
usually only mildly improving with topical moisturizing creams, responds well to 
systemic acitretin. In this disorder topical 13-cis-RA, topical liarozole, and oral liarozole, 
also proved to be effective (part 1, chapters 1, 5, 6). In contrast, XRI did not improve on 
calcipotriol (own observations). The isolated congenital ichthyoses non-erythrodermic 
lamellar ichthyosis (NELI), erythrodermic lamellar ichthyosis (ELI), ichthyosis 
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bullosa Siemens (IBS), congenital bullous ichthyotic erythroderma (CBIE) and the 
associated congenital ichthyosis SjSgren-Larsson syndrome (SLS) demonstrated 
excellent responsiveness to oral acitretin, which so far was supposed to be the only 
effective treatment available. In this thesis, topical 13-cis-RA, topical calcipotriol, topical 
liarozole and oral liarozole revealed effective alternatives in the treatment of isolated 
congenital ichthyoses (part 1, chapters 1, 2, 5, 6). Whereas 13-cis-RA, topical and oral 
liarozole proved effective in the treatment of isolated congenital ichthyoses and XRI, 
calcipotriol had a more selective indication spectrum showing impressive improvement in 
some isolated congenital ichthyoses without a significant effect on XRI. However, a 
recent report suggesting that calcipotriol might be effective in ADIV and XRI, is at 
variance with our own observations (1); on the other hand recent reports on the failure of 
treatment of ADIV and XRI with calcitriol, suggest that both conditions are vitamin D3 
resistant (2,3). Furthermore, a selective indication spectrum was observed in the 
calcipotriol treatment of associated congenital ichthyoses, revealing a good improvement 
in SLS, whereas Comel-Netherton syndrome (CNS) did not improve. Darier's disease, 
which is a classical indication for oral acitretin, proved to respond well to 13-cis-RA 
treatment, though a great interindividual variation was observed. Calcipotriol, however, 
did not constitute an alternative treatment for Darier's disease. In recent literature, the 
efficacy of 13-cis-RA in non erythrodermic lamellar ichthyosis (NELI) and Darier's 
disease has been reconfirmed (4,5). 
1.2 Comparative side effect analysis 
AH-trans-retinoic acid has been shown to have some therapeutical effect in disorders of 
keratinization. However, irritation of the skin seriously limits the application of all-trans-
retinoic acid. An important improvement was the development of 13-cis-Retinoic Acid 
(13-cis-RA) formulations which proved to be far less irritative (part 1, chapters 1 and 
7). However, 33% of the patients with ichthyoses and 43% of the patients with Darier's 
disease experienced some mild irritation of the skin which could be attributed to 13-cis-
RA. In these patients the irritation could easily be controlled by reducing the application 
frequency. Therefore, 13-cis-RA can be regarded as a well tolerated topical treatment. 
Topical calcipotriol (part 1, chapters 2 and 3), was tolerated very well in patients 
inflicted with ichthyosis. Apart from some discomfort on both sides, attributable to the 
fatty ointment base, no unilateral side effects were reported. However, in Darier's disease 
pronounced irritation of the skin and aggravation of the disease were observed. Another 
drawback is that the maximal amount of calcipotriol ointment which is permitted to be 
applied per week is 100 gr. A major breakthrough in the topical treatment of ichthyoses 
is liarozole (part 1, chapter 6). Liarozole associated side effects (pruritus and irritation of 
the skin) were found in 42% of the patients, but did not constitute a major problem, with 
exception of 1 patient who experienced unacceptable irritation of the liarozole treated 
skin, and discontinued treatment. One patient prematurely stopped, because of adverse 
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effects equally at verum and placebo treated sides, which already started in the wash-out 
phase. In this patient it is likely that these adverse events were not due to the medication. 
Although we do not have data on a comparative study it is our impression that the use of 
cakipotriol, 13-cis-RA, and topical liarozole is associated with irritation of the skin, 
which in some patients may require discontinuation of treatment. Systemic treatment with 
liarozole (part 1, chapter 5) had a profile of side effects comparable with systemic 
acitretin treatment. As topical treatment with liarozole resulted in plasma liarozole levels 
substantially below the levels reached during systemic treatment, which implies that the 
topical application has far lower systemic availability in the treatment of disorders of 
keratinization. The fact that reduction of the daily dose in one patient from 300 to 150 
mg. did not aggravate clinical symptoms suggests that the optimum daily dose of 
liarozole might be lower than 300 mg. Present studies with topical liarozole treatment, 
show that the application frequency of liarozole required for maintainance of clinical 
improvement, is considerably lower than the twice daily application used in our study 
(part 1, chapter 6). Alternatively it is attractive to speculate that the optimum 
concentration of topical liarozole might be lower than 5%. To minimalize side effects 
with oral and topical liarozole treatment, dose finding studies are indicated to establish 
the optimum treatment dose in ichthyoses. 
1.3 Comparative cytometric analyses 
Visual assessment of therapeutical efficacy of treatments in disorders of keratinization 
might be confused by the moisturizing capacity of topical treatment. The assessment of 
changes at the cellular level in vivo during treatment provides further information on 
therapeutic effects at the level of epidermal proliferation and differentiation and dermal 
inflammation. A selective action of retinoids is the induction of the keratins 4 and 13. In 
adult epidermis these keratins are normally not present. Therefore, the induction of 
keratins 4 and 13 during treatment, might be used to assess to what extent a treatment 
might have had a retinoid-mechanism as mode of action. 
Treatment with 13-cis-RA (part 1, chapters 1 and 7) resulted in the induction of keratin 4 
and 13 in patients with ichthyoses and Darier's disease. Furthermore, in patients with 
ichthyoses (part 1, chapter 1) induction of keratin 8 expression was observed after 
treatment with 13-cis-RA. Topical and systemic liarozole also induced keratins 4 and 13 
(part 1, chapters 5 and 6) in parallel to the induction of these keratins by 13-cis-RA. In 
contrast, calcipotriol did not induce the expression of these keratins (part 1, chapter 4). 
From these observations we may conclude that 13-cis-RA and liarozole most likely exert 
their mode of action by a retinoid mechanism, in contrast to calcipotriol. However, this 
cell biological effect was not correlated with the clinical improvement. Therefore, the 
expression of these keratins can not be used as "technology assessment" for a "retinoid 
effect" in the individual patient. 
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Characterization of epidermal growth and differentiation was carried out using a panel of 
antibodies (part 1, chapters 1, 4-7). Although the treatments described in the chapters did 
improve the clinical aspects of the disorders of keratinization, no consistent pattern of 
modulation of these markers was observed. We conclude that the epidermal growth 
characteristics (Keratin 6, 16, Ki-67 binding and % SG2M phase), the differentiation 
characteristics (involucrin, keratin 10) and the inflammation markers (polymorphonuclear 
leucocytes, T-lymphocytes, B-lymphocytes, monocytes, macrophages and Langerhans 
cells) did not provide a method to precise the effect of the treatment in disorders of 
keratinization. However, an important limitation of the present methodology used for the 
flow cytometric assessment, might have been the biopsy method: razor blade biopsies. 
The collection of the material using this approach might not consistently have comprised 
the whole epidermis. Recently a method was developed to prepare pure epidermal cell 
suspension from punch biopsies. Further studies are required before we can refute the 
above mentioned parameters as useful in the assessment of cell biological effects during 
treatment of monogenic disorders of keratinization. 
1.4 The therapeutical approach for today and tomorrow 
Today, the treatment of autosomal dominant ichthyosis vulgaris (ADIV) consists of 
topical moisturizing creams. The topical retinoid 13-cis-RA is available in several 
European countries. In the Netherlands, topical 13-cis-RA is not available so far. Patients 
with X-linked recessive ichthyosis (XRI) can be treated with 13-cis-retinoic acid (13-cis-
RA). The isolated congenital ichthyoses non-erythrodermic lamellar ichthyosis (NELI), 
erythrodermic lamellar ichthyosis (ELI), and congenital bullous ichthyotic erythroderma 
(CBIE) may be treated first with 13-cis-RA or calcipotriol. The treatment of choice in 
the associated congenital ichthyosis Sjögren-Larsson syndrome (SLS) is calcipotriol. In 
Darier's disease treatment with 13-cis-RA might be tried. With respect to calcipotriol it 
is important to realise that the maximum quantity of ointment, used per week, should not 
exceed 100 gr. With respect to topical 13-cis-RA no such upper limit can be given. 
However, a restrictive attitude is indicated for females at child bearing ages. Calcipotriol 
and 13-cis-RA are not indicated in females during pregnancy especially not in the first 
trimester. As 13-cis-RA or calcipotriol do not provide a treatment for the whole skin 
surface, these compounds may offer an elective treatment for the more severely involved 
or cosmetically disturbing areas. In case of an inefficient result of these treatments, 
systemic treatment with oral acitretin is the "ultimum refugium". Guidelines for the use 
of acitretin have been given in the thesis of van Dooren-Greebe. 
Tomorrow, it is feasible that the treatment of monogenic disorders of keratinization will 
have been revolutionized by topical liarozole and as the next step systemic liarozole. In 
general, this compound proved to be well tolerated and very effective both as a topical 
and systemic treatment. Therefore, the future for patients with monogenic disorders of 
keratinization seems to be bright. 
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2. The management of palmoplanar keratodermas 
2.1 The development of the nosology of hereditary palmoplanar keratodermas 
In part 2 chapter 7 an updated classification is proposed offering the general 
dermatologist guidelines to classify the individual patient. As can be deducted from 
Table II, a patient visiting the dermatological department for the first time, can be 
classified in one of the 3 major groups "diffuse", "nummular/linear" or "papular" 
immediately, based on the clinical presentation. Subsequently, the mode of inheritance, 
palmoplanar hallmarks, histopathological examination, keratoses on distinct sites, and 
associated features provide additional information, eventually leading to the correct 
diagnosis. 
2.2 The therapeutical approach 
It has been reported by various groups that acitretin is highly effective in palmoplanar 
keratodermas. However, in patients having palmoplanar keratoderma with epidermolytic 
hyperkeratosis, acitretin aggravates the condition. As has been described in part 2 chapter 
6, calcipotriol proved to fill this niche within the therapeutic management, as this 
compound proved to be effective in Vomers disease. Therefore, following histological 
classification of palmoplanar keratoderma, a treatment with acitretin or calcipotriol may 
be initiated. Based on the excellent results observed in the treatment of ichthyoses, it is 
attractive to speculate that liarozole might offer a new approach in the treatment of 
palmoplanar keratodermas. 
The nosology and treatment of disorders of keratinization has changed by developments 
in molecular genetics and skin pharmacology. Further development of the nosology and 
new therapeutical principles will be realised probably before the end of this century. 
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Dankwoord 
Op deze plaats zou ik eenieder willen bedanken die heeft bijgedragen aan het tot stand 
komen van dit proefschrift Dit betekent automatisch dat ik alle medewerkers van zowel 
de polikliniek, kliniek, alsook het laboratorium bedank voor de prettige sfeer van deze 
afdeling, welke tot een ideale ambiance leidt voor zowel het uitoefenen van klinische als 
wetenschappelijke activiteiten, in dit proefschrift onlosmakelijk met elkaar verbonden. 
Dit brengt mij vanzelf tot mijn promotor en hoofd van de afdeling, Prof.dr.dr. P.C.M, 
van de Kerkhof, wiens verdienste het is om een groot aantal individuele persoonlijk-
heden, tot een geheel te smeden, dat enerzijds eendrachtig samenwerkt, zonder dit 
anderzijds van zijn individuele creativiteiten te ontdoen. Peter, ik wil je bedanken voor 
jouw aanstekelijk enthousiasme en steun, waardoor deze promotie tot stand is gekomen. 
Hiermee bedoel ik niet alleen je practische adviezen en stimulerende rol teneinde de 
voortgang te bespoedigen, maar ook je begrip in die tijd dat mijn gezinsomstandigheden 
dusdanig waren dat een noodgedwongen tijdelijke temporisatie onvermijdelijk was. Het is 
mij vooral in die periode gebleken hoe waardevol bovengenoemde ambiance op de 
afdeling was, waarbij ik eigenlijk iedere medewerker persoonlijk zou moeten noemen. 
Uiteraard wil ik nog mijn co-promotor Dr. P.M. Steijlen noemen, welke ik in het 
bijzonder waardeer als mens, waarbij principes stevig overeind blijven en tesamen met 
een uitgebreide kennis aangaande de (geno)dermatologie, leiden tot een accurate 
individuele patiëntgerichte benadering. Dankzij jouw uitspraak dat een proefschrift niet te 
snel moet worden voltooid, maar moet "rijpen" heb je bijgedragen aan een relaxatie 
welke een promotie alleen maar ten goede kan komen. Aangaande dit laatste, hebben 
voor mijn gevoel, promotor en co-promotor tesamen de ideale combinatie gevormd voor 
de totstandkoming van dit proefschrift. Wat betreft het immunohistochemische deel van 
dit proefschrift wil ik Lia Schalkwijk en Monique Link, afdeling pathologie alhier 
bedanken voor hun fraaie en snelle kleuringen. Betreffende het flowcytometrische deel 
wil ik graag Emiel Suijkerbuijk alsook Ivonne van Vlijmen en Candida van Hooijdonk 
danken. Diny de Heus bedank ik voor haar waardevolle adviezen aangaande de secre-
tariële kant van deze dissertatie. Namens Janssen Pharmaceutica bedank ik Annie 
Heremans voor haar creatieve kwaliteiten waardoor liarozole beschikbaar is gekomen 
voor klinische trials binnen de dermatologie, Pierre Boegheim voor zijn prettige en 
structurele samenwerking, en Robert Wapenaar voor de statistische analyse van de 
liarozole studies. Uiteraard wil ik ook mijn ouders noemen welke mij een levensinstelling 
hebben meegegeven die niet alleen gericht is op mijzelf, maar die mij moreel verplicht 
ook open te staan voor anderen. Oprechte interesse vergemakkelijkt het verplaatsen in de 
ander en draagt zodoende bij tot een optimale patiëntenzorg. Last but not least wil ik 
mijn vrouw Els bedanken voor haar liefde jegens mij en Ceriel. Haar onbegrensde 
vertrouwen in iedereen leidt in deze tijd weliswaar soms tot frustratie, doch vormt een 
goede tegenbalans voor mijn soms te groot wantrouwen. Ceriel bedank ik voor zijn 
vrolijke aanwezigheid, welke in het voorbije jaar kortdurend twijfelachtig was en 
daarmee de bovenbeschreven temporisatie ten dele tot gevolg heeft gehad. 
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Curriculum Vitae 
De schrijver van dit proefschrift, werd op 20-06-1965 te Maastricht geboren. Na het 
behalen van het eindexamen Atheneum В in 1983 aan het Sint Maartenscollege te 
Maastricht startte hij met de opleiding Geneeskunde aan de Rijksuniversiteit Limburg, 
waar hij in 1989 het artsexamen behaalde. In de periode van 01-10-89 tot 30-09-90 was 
hij werkzaam op de afdeling dermatologie van het Academisch Ziekenhuis Maastricht 
waar hij histopathologic van de huid bestudeerde, en wetenschappelijk onderzoek 
verrichtte op het gebied van allergologie en proctologie. Van 01-10-90 tot 14-09-92 
vervulde hij een assistentschap dermatologie bij de maatschap Oostelijke Mijnstreek in 
het "De Wever Ziekenhuis" te Heerlen. Sinds 15-09-1992 is hij werkzaam op de afdeling 
dermatologie van het Academisch Ziekenhuis Nijmegen, waar hij onder leiding van 
Prof.dr.dr. P.C.M, van de Kerkhof en Dr. P.M. Steijlen werkte aan dit proefschrift. Sinds 
01-12-1993 is hij in opleiding tot dermatoloog te Nijmegen (opleider Prof.dr.dr. P.C.M, 
van de Kerkhof). Hij is getrouwd met Els Evers en is sedert 16-01-1995 de trotse vader 
van Ceriel. 
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STELLINGEN 
behorend bij het proefschrift 
"Ichthyosis, Dariers disease and Palmoplanar Keratodenma. 
New insights in classification and therapy." 
1. Classificatie van palmoplantaire keratodermieen is geen academische exercitie, doch 
van belang om de individuele patient adequaat te informeren omtrent het te 
verwachten beloop (progressie?, autoamputatie?), geassocieerde kenmerken 
(maligne degeneratie van de aangedane huid of de oesofagus?), en overerving. 
2. De adequate classificatie van een palmoplantaire keratodermie, bepaalt het te volgen 
beleid aangaande aanvullende diagnostiek, periodieke controle en therapie. 
3. Nauwkeurige observatie is elementair in de ontwikkeling van nieuwe geneesmiddelen. 
Liarozol, effectief in de behandeling van keratinisatiestoomissen, is als afgeleide van 
het antimycoticum ketoconazol, een goed voorbeeld hiervan. 
4. De liganden voor de "steroid receptor superfamily" zijn met een zekere ziekte-
specificiteit effectief bij de behandeling van monogene keratinizatiestoomissen. 
5. Daivonex is een effectieve locale behandeling voor lamellaire ichthyosis, congenitale 
bulleuze ichthyosiforme erythrodermie, en het syndroom van Sjögren-Larsson. 
6. Liarozol, een nieuwe endogene vitamine A afbraak remmer, is zowel in orale als in 
topische toedieningsvorm effectief in de behandeling van X-linked recessive 
ichthyosis, lamellaire ichthyosis, en congenitale bulleuze ichthyosiforme 
erythrodermie. 
7. 13-cis-retinoic acid is in locale toedieningsvorm minder irritatief dan all-trans-retinoic 
acid en daardoor geschikt als therapie voor ichthyosis. 
8. Geluk is relatief: gelukkig hij die ziet wat hij heeft; ongelukkig hij die ziet wat hij niet 
heeft. 
9. Vorm en inhoud zijn vaak omgekeerd evenredig aan elkaar. 
10. Evaluatie wordt soms verward met ego-massage. 
11. Functioneringsgesprekscursussen zijn een moderne vorm van verborgen 
werkloosheid. 
12. Tijd is geen snelweg tussen de wieg en het graf, maar ruimte om te parkeren in de 
zon. (Phil Bosmans) 


